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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. Amyloid 
precursor protein (APP) processing and the subsequent generation of amyloid β 
(Aβ) are central to the pathogenesis of AD, as soluble, oligomeric Aβ peptides are 
thought to be the toxic species driving disease progression. Flavonoids, a group of 
dietary polyphenols, have been shown to possess cognitive health benefits. 
Epidemiological evidence suggests they could play a role in risk reduction in 
dementia.  In vitro and in vivo reports suggest flavonoids can modulate APP 
metabolism and Aβ production, although the most effective compounds and the 
underlying mechanism of action remain unclear. This study identified select 
flavonoids that were able to reduce amyloidogenic processing in primary cortical 
neurons at physiologically relevant concentrations. An APP-Gal4 gene reporter 
assay was characterised for identification of modulators of APP processing in 
primary neurons. It was tested under physiological conditions, in a pro-oxidant 
environment or against pathological levels of Aβ production through introduction 
of a known familial AD (FAD) causing mutation of APP (K595N/M596L). Using this 
system, five flavonoids were identified that inhibited amyloidogenic APP processing 
at 100 nM, these were: fisetin, pelargonidin, sinensetin, (-) epicatechin and 
epigallocatechin. Due to known bioavailability, the catechin family were 
investigated further and epigallocatechin and (-) epicatechin were confirmed as 
potent (low nanomolar) inhibitors of amyloidogenic processing. Investigation into 
the mechanism of action by (-) epicatechin suggested it was likely through indirect 
BACE1 activity inhibition, independent of BACE1 expression. In addition to activity 
at APP processing (-) epicatechin also induced extracellular signal-regulated kinase 
(ERK) activation and transcriptional activity. Investigation of other lead flavonoids 
also identified fisetin as an inhibitor of ERK-dependent transcriptional activity. This 
study supports the hypothesis that flavonoids are modulators of APP processing 
and that they could offer a potential therapy for the prophylaxis of AD. 
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1.1 Alzheimer’s disease 
AD is the most common form of dementia and is the tenth biggest killer of people 
over the age of 65. The biggest risk factor for most AD cases is age: there is a 1 in 40 
chance of developing dementia at 65 rising to 1 in 3 at 90 years of age (Figure 1.1). 
Owing to the demographic trend towards an older population, the number of 
patients with AD is projected to increase from 24 million in 2005 to 81 million 
sufferers worldwide by 2040 (Ferri et al., 2005).  
Currently, AD costs the UK economy £23 billion annually and this is predicted to rise 
to £50 billion by 2038 (Alzheimer’s Research Trust report 2010). The reasons for this 
are multifactorial, however increases in informal care and social care are the major 
costs, direct medical costs are much lower due to the lack of treatments available 
(Wimo et al., 2013). A projected decrease in the proportion of informal care due to 
societal family structure changes means UK local authorities are predicted to need 
to increase home care hours by 91% by 2031 (Comas-Herrera et al., 2007). 
AD creates physical, mental and social challenges for the individual and their 
community and these are much harder to measure. Following diagnosis many 
patients take a fatalistic view and withdraw from society, not only excluding 
themselves from societal support, but also putting significant psychological, 
practical and economic burden on caregivers, often family members (Ferri et al., 
2005). 
Medical practitioners are still poorly informed as to the best health care to be 
prescribed to AD patients and many remain uncertain as to the clinical features of 
AD, resulting in missed opportunities for diagnoses. Currently it is estimated that 
half of AD sufferers have not received a diagnosis and that there is on average 24 
months between first symptoms and diagnosis(INSERM Collective Expertise Centre, 




Figure 1.1: Estimated incidence of dementia in the UK 




Once a diagnosis has been made patients can prepare for future decisions such as 
late stage care and also allows understanding from their community. Due to a lack 
of approved disease modifying drugs, even those patients that have received a 
diagnosis only receive symptomatic treatment for their condition; therefore there is 
a huge unmet medical need for therapies impacting on AD pathology. 
1.2 Pathology of AD 
 
AD was first described by its pathology over 100 years ago. In 1906, Alois Alzheimer 
described the case of a woman who had ‘peculiar’ dementia at 51 years old. He 
described how her cognitive and behavioural features correlated with the 
histological findings found on autopsy at death age 55, of ‘miliary foci’ and 
neurofibrillary changes in the cerebral cortex (English translation:(Alzheimer et al., 
1995)).  
1.2.1 Symptoms and pathology 
 
The clinical features of AD are progressive loss or decline in memory and cognitive 
function. These start with episodic memory loss and changes in attention, 
advancing to language dysfunction, long-term memory problems and at late stages 
AD patients are mute, non-ambulatory, doubly incontinent and unable to swallow.  
Diagnosis of AD is clinicopathological: the patient must present with insidious 
onset, a history of dementia, and cognitive deficits including amnesia, language 
deficits, visuospatial deficits or executive dysfunction; diagnosis can only be 
confirmed at autopsy (McKhann et al., 2011). As well as the cognitive symptoms of 
AD, there are also behavioural and psychological symptoms of dementia (BPSD) 
that often affect AD patients. These include depression, psychosis, anxiety and 
aberrant motor activity (Francis et al., 2010); these often cause significant problems 
in the care of AD patients, and are the leading cause of admittance of AD patients 
to residential social care. Symptoms progress over an average time course of 9-10 
25 
 
years, however it is thought the AD pathology begins 10-20 years prior to onset of 
the clinical symptoms (Holtzman et al., 2011).  
Gross visual examination of AD brain shows symmetrical, cerebral atrophy 
recognised by MRI, with histological lesions in the hippocampus, entorhinal cortex, 
amygdala and cerebral association cortices whilst sparing sensorimotor cortices 
(Selkoe and Podlisny, 2002). There are also expansions of the ventricular and sulcal 
cerebral spinal fluid (CSF) spaces (Ewers et al., 2011) (Figure 1.2(A)). Grey matter 
loss in patients with AD is 15% more than age matched controls and progresses at a 
rate of 3-4% per year (Thompson et al., 2003) affecting regions unaffected by age 
alone (Frisoni et al., 2008). This demonstrates that AD is not simply an acceleration 
of ageing. Progression of cortical atrophy is tightly associated with progressive 
cognitive decline, as demonstrated by the correlation between mini mental state 
examination (MMSE) performance, a global measure of cognition in AD, and grey 
matter integrity in the entorhinal and parietal cortices (Apostolova et al., 2006). 
More specific studies have correlated loss of particular cognitive functions to 
precise areas of cortical atrophy: atrophy in the anterior cingulate and 
supplementary motor cortices has been associated with apathy in AD patients and 
the degree of language impairment has been associated with atrophy of the left 
temporal and parietal cortices (Apostolova et al., 2007, Apostolova et al., 2008). 
1.2.2  Neuropathology 
 
The pathology of AD follows a stereotypical pathway through progression of the 
disease. In the early stages of AD, extracellular amyloid deposits occur in the limbic 
and associated cortices, with temporary, intermittent, alterations to hippocampal 
synaptic function (Selkoe, 2002). As the disease progresses, intracellular fibrillary 
tangles develop, initially in the lateral transentorhinal cortex, a critical component 
in episodic memory (Khan et al., 2014), and amyloid pathology spreads to the 
striatum and other subcortical regions. Towards end stages of AD there is gross 
neuronal loss, with all areas of the cortex affected including sensory and motor core 





Figure 1.2: Pathology of AD 
(A) Post-mortem brain sections from AD brain (left) and cognitive normal brain 
(right) indicated level of cortical atrophy in AD. (B) Photomicrograph using silver 
stain of amyloid plaque (surrounded by dotted white line), with dystrophic 
neurites (small arrow) and neurofibrillary tangle (NFT) (large arrow). (C) 
Immunohistochemical staining of AD brain using anti-Aβ antibody showing 
diffuse plaques (larger arrow), compact plaques (medium arrow) and cerebral 
amyloid angiopathy (small arrow). (D) Immunohistochemical staining of AD brain 
using anti-phospho tau antibody showing hyperphosphorylated tau accumulation 
in cell bodies (large arrow) and throughout the neuropil (small arrow). (E) 
Thioflavin-S stain shows β-pleated sheet secondary structure of amyloid plaques 




Cortical atrophy as described above, along with neurotransmitter dysfunction, 
extracellular Aβ deposition and intracellular tau aggregation are recognised as the 
hallmarks of AD, each with their own characteristic distribution and progression. 
Other neuropathological features associated with AD included neuropil threads, 
microglial activation, and congophilic amyloid angiopathy (Serrano-Pozo et al., 
2011). 
1.2.2.1 Neurotransmitter dysfunction 
 
Abnormalities in the cholinergic system were amongst the first pathological 
discoveries in AD brains and the subsequent cholinergic depletion hypothesis was 
the first theory proposed to explain the aetiology of AD (Bartus et al., 1982). Study 
of post mortem AD brains demonstrated loss of cholinergic neurons in the basal 
forebrain and loss of presynaptic markers of cholinergic neurons including choline 
acetyltransferase (ChAT), acetylcholine (Ach) and acetylcholinesterase (AChE) in the 
hippocampus and neocortex (Bartus et al., 1982, Whitehouse et al., 1982). These 
initial suggestions that deficits were due to  presynaptic components of cholinergic 
signalling was questioned following studies showing uncoupling of post-synaptic  
M1 G-protein signalling correlated well with dementia severity, suggesting a post-
synaptic cholinergic deficit (Tsang et al., 2006). This was supported by the 
disappointing cognitive benefits of AChE inhibitors (AChEIs) as breakdown of M1 
mediated intracellular signalling would not be significantly affected by increased 
levels of Ach in the synapse (Francis et al., 2010). 
The cholinergic system is not the only neurotransmitter system affected in AD: 
deficits in the serotonergic, glutamatergic and GABAergic systems also occur to 
varying degrees. Extensive serotonergic denervation in post mortem AD brain has 
been demonstrated although correlation with disease severity remains unclear 
(Chen et al., 2000). Decreased levels of 5HT1A receptors, a pyramidal cell specific 
subtype of serotonin receptor, has been correlated with MMSE scores suggesting 
deficits in the serotonergic system contribute to cognitive decline (Kepe et al., 
2006).The major loss of serotonergic neurons and associated cell shrinkage, occurs 
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in the dorsal raphe nucleus, which provides serotonergic projections to the 
hippocampus, an area severely affected in AD (Zweig et al., 1988, Aletrino et al., 
1992).  
Glutamatergic pyramidal neurons account for the majority of neuronal cells lost in 
the cerebral cortex and hippocampus in AD (Francis et al., 2010); the subunit 
specific dysfunction of N-Methyl-D-aspartic acid (NMDA) receptors in these brain 
regions suggests that this loss is not due to generalised cortical atrophy and that 
the glutamatergic system is targeted (Hynd et al., 2004). As well as neuronal loss, 
dysfunction of the glutamatergic system also contributes to disease progression. 
Impaired glutamate uptake at the nerve terminal leads to increased background 
‘noise’ at synapses. This causes post-synaptic membranes to become more 
frequently depolarised, affecting the ability of NMDA receptors (NMDAR)  to trigger 
long term potentiation (LTP) - a cellular signalling pathway that strengthens 
synapses and is strongly associated with learning and memory (Francis et al., 2010). 
Furthermore, excessive synaptic glutamate concentrations lead to excitotoxicity in 
the cell and ultimately neuronal cell death (Mattson, 2003).  
Preclinical and clinical studies show that neuronal loss and neurochemical 
alterations in different transmitter systems are the main factors underlying the 
cognitive and behavioural symptoms of AD. Loss of particular neuronal populations 
are strongly correlated with specific cognitive deficits, however the mechanisms 
and toxic species triggering this widespread cell death are less clear. 
1.2.2.2 Neurofibrillary tangles 
 
Neurofibrillary tangles (NFTs) are intraneuronal aggregates of hyperphosphorylated 
and mis-folded tau protein (Figure 1.2(D)). Human tau exists in the brain as six 
isoforms, generated by alternative splicing of its N-terminal domain and 
microtubule binding domain from a single gene transcript (Goedert et al., 1989). 
Tau is a major microtubule associating protein (MAP) in  neurons, acting to stabilise 
microtubules and increase microtubule rigidity (Dehmelt and Halpain, 2005). The 
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protein is unstructured and hydrophilic and in healthy individuals is found primarily 
in the axonal cytosol (Mandelkow and Mandelkow, 2012). 
Phosphorylation of tau tends to weaken microtubule affinity (Illenberger et al., 
1998, Mandelkow et al., 2004). Dissociation from microtubules alters the β-sheet 
structural content of tau, making it prone to self-association and polymerisation to 
form the paired helical filaments that are present in NFTs (Hanger et al., 1992) 
(Figure 1.2(E)). The pattern of NFT appearance in AD progression is stereotypical 
and distinguished into six stages according to the pathological severity (Braak and 
Braak, 1991). The amount and distribution of NFTs closely correlate to the level and 
sequence of brain atrophy and associated cognitive decline in AD (Braak and Braak, 
1991, Johnson et al., 2012, Khan et al., 2014). They start in the lateral 
transentorhinal cortex (episodic memory), followed by the prefrontal cortex 
(executive function), parietal cortex (apraxias), and occipitoparietal cortex 
(visuospatial deficits), although whether NFT formation is a requirement for 
neuronal death in AD is still controversial. 
1.2.2.3 Amyloid plaques 
 
Amyloid plaques are proteinaceous extracellular deposits resulting from abnormal 
accumulation of Aβ, a physiological product of APP metabolism. The plaques have a 
central deposit of Aβ (the core), intimately surrounded by dystrophic neurites and 
activated microglia and astrocytes (Selkoe, 1991b) (Figure 1.2(B)). Within the 
plaques, Aβ exists in insoluble forms including fibrils and oligomers with a 
predominantly β- sheet structure. Although Aβ can be released as a 38-42 amino 
acid peptide, Aβ42 is the predominant form in plaques due to its increased rate of 
fibrillisation and its increased hydrophobicity. The ratio of Aβ42 to the less 
hydrophobic Aβ40 product is now thought to be the driver of fibrillisation, perhaps 
due to the ability of Aβ40 to sequester  Aβ42 and facilitate its clearance (Kumar-Singh 
et al., 2006). The Aβ content of the brain is not restricted to that deposited in the 
characteristic plaques. A large proportion of it is in ‘diffuse’ structures which do not 
have β- sheet structure or associated dystrophic neurites; instead the Aβ exists as 
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granular structures or as fine filaments. Despite this, it is the dense-core plaques 
that are associated with the synaptic and neuronal loss characteristic of AD (Selkoe 
and Podlisny, 2002, Serrano-Pozo et al., 2011). In addition to the extracellular 
deposits of Aβ, almost all AD brains display deposits of fibrillar Aβ in the basement 
membranes of scattered microvessels, although the significance of these is not 
clear (Figure 1.2(C)). 
Unlike NFTs, the spatiotemporal progression of amyloid plaques does not correlate 
well with neuronal cell death or cognitive decline. There is also significant 
dissociation between the brain regions affected by NFTs and amyloid deposition. 
Although less predictable that NFT progression, staging of amyloid pathology into 
three stages has been possible. It begins in the isocortex, followed by deposition in 
isocortical association and limbic areas, and the final stage is characterised by 
amyloid deposits in primary isocortical areas and subcortical structures (Braak and 
Braak, 1991, Thal et al., 2002).  
Amyloid pathology is evident even at preclinical stages of AD, prior to any evidence 
of cognitive decline. The appearance of amyloid pathology early in disease 
progression and the lack of correlation with cognitive function have led to a 
growing consensus that Aβ is the driver of disease progression leading to increases 
in tau phosphorylation which initiates pathways involving loss of synaptic 
transmission that leads to neuronal cell death. 
1.3 Genetics of AD 
1.3.1 Familial AD 
 
Once APP had been identified as the precursor to Aβ, genetic studies were 
undertaken on brains of familial AD (FAD) patients to try and delineate the genetic 
causes of the disease. AD is generally considered a disease of the elderly, however 
like the first case described by Alois Alzheimer, a proportion of AD sufferers, 
currently estimated to be less that 1%, develop the disease before the age of 65. 
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This form of AD, called early onset AD (EOAD) or FAD, shows autosomal dominant 
inheritance. To date, more than 32 mutations in the APP gene linked with 
development of AD have been discovered (Cruts and Van Broeckhoven, 1998) 
http://www.molgen.ua.ac.be/ADmutations). Select mutations have been taken 
forward into transgenic rodent models of AD and have been shown to be sufficient 
to produce pathology associated with AD, including gross neuronal cell death, 
altered synaptic activity, plaque formation and intracellular tangles (Walsh et al., 
2002, Lesné et al., 2006, Meyer-Luehmann et al., 2008) (Table 1.1). Although APP 
mutations were identified first, the majority of mutations associated with FAD are 
found in the presenilin 1 gene on chromosome 14, where over 200 mutations have 
been reported (Larner, 2013). The presenilin 1 gene encodes for the catalytic 
domain of -secretase, the enzyme responsible for release of Aβ from the 
membrane (Kimberly et al., 2000). The remaining mutations identified are located 
on chromosome 1 in the homologous presenilin 2 gene. 
1.3.1.1 APP mutations 
  
In 1991, a point mutation was identified in a family from London on chromosome 
21 (V717I) that segregated with FAD patients (Goate et al., 1991). Following this 
initial identification, a wave of publications through the 1990’s and 2000’s reported 
further mutations (Table 1.1 and Figure 1.5(B)); all clustered around the cleavage 
sites of the A sequence in APP (Figure 1.5(B)). Like the initial mutant identified, 
most APP mutants were proximal to the C-terminus of A , these alter APP 
processing by increasing the proportion of longer, more aggregation prone, A 
peptides generated (Suzuki et al., 1994, Tamaoka et al., 1994, Eckman et al., 1997), 
affecting the A40:A42 ratio. 
 A further group of mutations cluster around the N-terminal of the Aβ sequence, 
causing increases in total A levels (Hendriks et al., 1992, Zhou et al., 2011). 
Cleavage at the N terminus of the A sequence can occur at two distinct sites called 








Effects on Aβ References 
K670N/M671L Swedish ↑ Aβ generation 
altered subcellular activity of BACE1 
(Citron et al., 1992, 
Mullan et al., 1992, Cai 
et al., 1993, Haass et al., 
1995b) 
A673T Iceland ↓ Aβ generation (Jonsson et al., 2012) 
E682K Leuven ↑ Aβ generation 
shift cleavage from β’ to β site. 
(Zhou et al., 2011) 
A692G Flemish Microvascular Aβ accumulation (Hendriks et al., 1992) 
E693G Arctic ↑ Aβ fibrillogenesis (Nilsberth et al., 2001) 
E693K Italian Microvascular Aβ accumulation (Bugiani et al., 2010) 
E693Q Dutch Microvascular Aβ accumulation (Van Broeckhoven et al., 
1990) 
D694N Iowa ↑ Aβ fibrillogenesis (Grabowski et al., 2001, 
Van Nostrand et al., 
2001) 
T714I Austrian ↑ Aβ42 production 
↓ Aβ40 production 
↑ Aβ42:40 
(De Jonghe et al., 1998, 
Kumar-Singh et al., 
2000) 
V715A German ↑ Aβ42:40 (Cruts et al., 2003) 
V715M French ↓Aβ production 
↑ Aβ42:40 
(Ancolio et al., 1999, 
Campion et al., 1999) 
I716V Florida ↑ Aβ42 production 
↑ Aβ42:40 
(Eckman et al., 1997) 
V717I London ↑ Aβ42 production 
↑ Aβ42:40 
(Goate et al., 1991, 
Naruse et al., 1991, 
Karlinsky et al., 1992, 
Tamaoka et al., 1994) 
V717P unknown ↑ Aβ42 production 
↑ Aβ42:40 
(Murrell et al., 1991) 
Table 1.1: APP mutations associated with FAD 
Amino acid substitutions of APP that lead to onset of familial AD and their 
effects on Aβ. A673T is the only mutation shown to be protective 
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 rather than ’ site, this leads to generation of more full length Asuch as in the 
case of the Flemish mutant E682K (Zhou et al., 2011). Perhaps the most well studied 
mutant of APP is the Swedish, double point mutation of K670N/M671L, located 
immediately adjacent to the -cleavage site. This causes 6-8 times more production 
of A than WT APP due to alterations in the subcellular compartment in which 
cleavage occurs, promoting A production (Citron et al., 1992, Cai et al., 1993, 
Citron et al., 1994, Haass et al., 1995b). In contrast to the Swedish and Flemish 
mutations, a further mutant in this region, the Icelandic A673T reduces 
amyloidogenic peptide formation by 40% in in vitro tests (Jonsson et al., 2012), the 
first mutant identified that confers Aβ lowering effects. 
 Another cluster of mutations are located within the A sequence, such as the Arctic 
(E693G), Iowa (D694N) and Dutch (E693Q) mutations. These are suggested to affect 
the aggregation properties or the degradation efficiency of the Apeptide (Van 
Broeckhoven et al., 1990, Nilsberth et al., 2001, Van Nostrand et al., 2001)(Table 
1.1).  
1.3.1.2 PSEN mutations 
 
PSEN1 mutants show dominant inheritance and are responsible for 70% of FAD 
cases (Sherrington et al., 1995, Larner, 2013). There are no nonsense mutations 
identified to date, suggesting the mutations in Presenilin 1 alter the function of -
secretase, rather than resulting in a loss of function (Clark et al., 1996). This is in 
contrast to the observation that Presenilin 1 mutations are distributed throughout 
the gene, with no obvious clustering (Figure 1.3). This paradox is hard to align, 
however it may relate to essential role for presenilins where complete loss of 
function would be lethal and therefore only mutations leading to partial loss can 
persist in the population, although further evidence is required to confirm this. 
 There is broader heterogeneity in phenotypes associated with PSEN1 mutations 
compared to APP mutations. Individuals with PSEN1 mutations often display 
behavioural and psychiatric symptoms not typically seen in individuals with APP 
mutations. These additional phenotypes have been well documented although the 
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mechanisms are not well understood. For example, the splice mutation E9 leading 
to frame skipping of exon 9 and an amino acid substitution introducing a cysteine 
has additional clinical features including spastic paraplegia (Cruts and Van 
Broeckhoven, 1998). Other mutations also present with additional features such as 
early language impairment (V272A), myoclonus (L226F) or seizures (H163R and 
L282R) (Larner, 2013).  
Unlike APP mutations, the age of onset varies depending on the specific PSEN 
mutant expressed, with a range from 30-60 years old. PSEN1 mutants reduce -
secretase activity, reducing the absolute levels of A but also alter the cleavage 
activity of the enzyme, favouring production of longer Aspecies, and increasing 
the A42:40 ratio (Bentahir et al., 2006, Bergmans and De Strooper, 2010, Quintero-
Monzon et al., 2011) therefore increasing the likelihood of A aggregation. 
PSEN2 mutations were originally identified through 7 families with FAD where 
linkage to chromosomes 14 and 21 had been excluded (Levy-Lahad et al., 1995a, 
Levy-Lahad et al., 1995b). PSEN2 mutations are much less prevalent than PSEN1 
mutations and cause a later age of onset (50-70 years) (Rogaev et al., 1995). 
Mutations in PSEN2 occur at amino acids conserved within the presenilin family, 
suggestive of similar mechanisms to PSEN1 mutations. This is supported by studies 
such as that looking at the N141I missense mutation of PSEN2, found in the Volga 
German kindred, which found increased A42 levels in a transgenic mouse from 2 
months of age (Levy-Lahad et al., 1995a, Oyama et al., 1998) 
1.3.2 Genes associated with LOAD 
 
Despite the large number of highly penetrant mutations identified that lead to FAD, 
these mutations are rare and the majority of AD cases show no clear genetic linkage 
and present in patients over 65 years old; these are termed ‘sporadic’ or late onset 
AD (LOAD). In these cases age is the biggest risk factor, however genetic studies 
have also identified high frequency but low penetrance genetic risk factors, 




Figure 1.3: Presenilin mutations 
Amino acid sequence of the 9 TM topology and mutations of PS1 including exon 
boundaries. FAD- linked mutations are indicated in red.  Residues involved in 
the interaction with amyloid precursor protein (APP), PEN-2, Nicastrin (NCT) 
and APH1 are indicated in blue. The point of endoproteolytic cleavage is 






The most well established genetic risk factor for LOAD, consistently identified in all 
genome wide association studies (GWAS), is the apolipoprotein E (ApoE) gene. 
ApoE, produced by astrocytes and neurons in the central nervous system (CNS), 
regulates lipid homeostasis through transport of cholesterol to neurons. ApoE has a 
3 allele haplotype: Apoɛ2, Apoɛ3 and Apoɛ4 differing in the amino acids at residues 
112 and 158, affecting the lipid carrying abilities of the protein in a dose dependent 
manner (Corder et al., 1993, Liu et al., 2013). The 4 (Arg112, Arg158) allele 
increases risk between 3.7 (single copy) and 10 fold (two copies) (Suh et al., 2013). 
Contrary to increased risk with 4, the 2 (Cys112, Cys158) allele has been shown to 
exert protective effects and is associated with healthier aging. The 3 (Cys112, 
Arg158) allele appears to be neutral in comparison (Bertram et al., 2010). The 
different binding properties of the ApoE isoforms to Aβ and tau have been 
suggested to form the bases of the individual phenotypes. The Apoɛ4 isoform has 
been shown to bind Aβ much more rapidly than the other isoforms, leading to 
increased fibrillisation (Strittmatter et al., 1993, Sanan et al., 1994) and exhibits 
impaired binding to tau in comparison to Apoɛ2 and Apoɛ3, suggesting that the 
ApoE/tau interaction is protective (Strittmatter et al., 1994). 
1.3.2.2 Other risk factor genes 
 
Early genomic studies consistently identified ApoE as the single significant genetic 
risk factor for AD. Subsequent larger studies have identified risk loci with smaller 
effect sizes leading to identification of clusterin, phosphatidylinositol binding 
clathrin assembly (PICALM), complement receptor 1 (CR1) and triggering receptor 
expressed on myeloid cells 2 (TREM2) genes as novel risk genes.  
The Clusterin gene encodes for the second major apolipoprotein in the brain after 
ApoE and was identified as a novel susceptibility locus in two independent GWAS 
studies (Harold et al., 2009, Lambert et al., 2009). Elevated Clusterin expression in 
the hippocampus and entorhinal cortex of AD brains and presence of Clusterin in 
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senile plaques provides functional evidence of clusterin involvement in AD 
pathogenesis (May et al., 1990, Oda et al., 1994). Variants of Clusterin appear to 
have a positive effect in AD, as it can modify clearance of Aβ at the blood brain 
barrier and together with Apoɛ4 suppress Aβ fibrillisation (DeMattos et al., 2004, 
Bell et al., 2007). Clusterin also plays a role in ameliorating Aβ-mediated activation 
of an immune response, possibly through masking fibrillar structures from the 
immune system (Nuutinen et al., 2009). 
PICALM encodes for the phosphatidylinositol-binding clathrin assembly protein. It 
was initially identified as a risk locus in one of the same GWAS studies as clusterin 
(Harold et al., 2009). PICALM is ubiquitously expressed with particularly high 
expression in neurons. It is involved in clathrin mediated endocytosis, a processing 
essential for correct lipid and protein trafficking (Kim and Kim, 2001). In neurons, 
PICALM is essential for Vesicle-associated membrane protein (VAMP2)-mediated 
neurotransmitter release at the pre-synaptic membrane (Harel et al., 2008). 
Variants of PICALM in AD have therefore been proposed to cause synaptic 
perturbations or alterations in APP processing through endocytic pathways. 
Depletion of PICALM in vitro and in vivo led to dendritic dystrophy and disrupted 
secretory transport, and caused selective alterations to Aβ42 production, reducing 
the Aβ42:40 ratio (Bushlin et al., 2008, Kanatsu et al., 2014). 
CR1 encodes a type 1 transmembrane glycoprotein. It is the main receptor for 
complement C3b protein that mediates binding of particles and immune complexes 
that have activated complement. Both the classical and alternative complement 
pathways are associated with AD. mRNA levels of components from each pathway 
are elevated in AD brains and the complement system is activated by both amyloid 
plaques and NFTs (McGeer et al., 1989, Strohmeyer et al., 2000, McGeer and 
McGeer, 2001). Chronic inflammation in AD is a consistent event, however whether 
it is beneficial or a mediator of neurodegeneration is as yet undecided. Therefore 
whether variants of CR1 are having a positive or detrimental impact remains 
unclear. 
The TREM2 (triggering receptor expression on myeloid cells 2) gene encodes 
another type 1 transmembrane protein that triggers activation of an immune 
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response. TREM2 is expressed on microglial cells throughout the CNS. It stimulates 
phagocytosis, enhancing cell debris clearance and also suppresses cytokine 
production and inflammation. Reduced activity of TREM2 variants is central to their 
pathogenic effects, potentially through reduced clearance of Aβ by phagocytosis or 
a relief of the block on inflammatory cascades (Frank et al., 2008, Guerreiro et al., 
2013). 
1.3.2.3 ADAM10 mutation 
 
 ADAM10 encodes for a type 1 transmembrane protein with zinc metalloprotease 
activity. ADAM10 acts as the major α-secretase activity in neurons that prevents 
production of Aβ from APP through cleavage within the Aβ sequence (Kuhn et al., 
2010). Missense mutations in the prodomain of the ADAM10 gene have been 
shown to cause LOAD. In contrast to other genes associated with LOAD, genetic 
association studies of SNPs in the ADAM10 gene led to identification of two 
mutations that showed high although incomplete penetrance (Kim et al., 2009). The 
two mutations, Q170H and R181G, located proximal to the prodomain cleavage 
site, were introduced separately into mice to generate 2 transgenic lines. Both 
showed reduced ectodomain shedding and attenuated ADAM10 activity and 
crossing with an APP mutant mouse (Tg2576) increased Aβ levels, plaque load and 
reactive gliosis.  The APP family are particularly vulnerable to changes in ADAM10 
activity, as N-cadherin and notch levels were unaffected by the mutations whilst 
APLP2 showed a similar sensitivity to APP. ADAM10 plays a critical role in 
neurogenesis through release of sAPPα, which was also severely impaired in the 
mutant mice (Suh et al., 2013). Studies of sAPPα levels in AD patients carrying these 
mutations have not been published, however there have been no previous reports 
of changes in sAPP levels in AD brain therefore the mechanism of these mutants 
remains unclear (Brinkmalm et al., 2013). 
It has been estimated that APP, PSEN1, PSEN2 and ApoE gene mutations account 
for less that 30% of the genetic variance in FAD and LOAD (Guerreiro et al., 2012). 
Clusterin, PICALM, CR2 and TREM2 are therefore likely to be just the tip of the 
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iceberg in further genetic risk factors. These examples give an indication of the 
complexity of AD, and give an indication of the range of cellular pathways involved 
in AD pathogenesis. 
1.4 Amyloid cascade hypothesis 
 
An early clue for the cause of AD pathology was the link between trisomy 21 
(Down’s syndrome) and AD: Down’s syndrome patients will invariably develop AD-
like symptoms in their fourth or fifth decade (Tanzi et al., 1988), linking 
chromosome 21 to Alzheimer’s-like symptoms. A second disease called cerebral 
haemorrhage with amyloidosis (Dutch type) was shown to result from a mutation in 
APP, located on chromosome 21,, suggesting that mutations in the APP protein can 
lead to formation of amyloid plaques (Van Broeckhoven et al., 1990). As discussed 
previously, histopathological analysis of post-mortem AD brains showed Aβ to be 
the main constituent of amyloid plaques and subsequent genetic analysis identified 
APP gene mutations that were sufficient to cause AD (Wang et al., 1984, Masters et 
al., 1985, Selkoe et al., 1986, Bertram et al., 2010). 
In the early 1990’s a number of people attempted to bring the symptomatic, 
biochemical and genetic observations together and build a model for  the sequence 
of events leading to the pathology of AD.  The hypothesis that Aβ deposition is an 
early and causative event in the disease progression is central to the amyloid 
cascade model (Figure 1.4). Specifically, it was proposed that mis-regulation of APP 
processing and increased deposition of Aβ was the causative agent in AD pathology. 
Subsequent increases in neuritic plaques then caused, through unknown 
mechanisms, neuronal damage, activation of microglia and astrocytes, depletion of 
neurotransmitters and formation of NFTs. These downstream effects led to the 
clinical symptoms of dementia and gross neuronal cell loss (Hardy and Allsop, 1991, 
Selkoe, 1991a, Hardy and Higgins, 1992) (Figure 1.4). Due to significant  sporadic AD 
cases, where no genetic linkage was apparent, it was  proposed that environmental 
factors could also initiate Aβ deposition such as head trauma, as there was evidence 




Figure 1.4: Amyloid cascade hypothesis 
A schematic demonstrating the amyloid cascade where misregulation of APP, through missense mutations in APP or PSEN1/2 in FAD 
or through gradual increases in Aβ production with age in LOAD, leads to increased Aβ monomers which polymerise and generate 
toxic oligomers. These oligomers can then aggregate to form amyloid plaques or exert deleterious effects on synapses, subsequent 
hyperphosphorylation of tau and activation of inflammatory cells. This causes progressive synaptic and neuritic injury and eventual 
neuronal cell death and brain atrophy presenting as AD.  
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Direct neurotoxicity of Aβ is a contentious issue which has yet to be resolved. Aβ 
has convincingly been shown to have subtle effects at synapses (Walsh et al., 2002, 
Minano-Molina et al., 2011); however this has not been shown to translate into the 
neuronal loss observed in AD. Identification of tau mutations and creation of human 
tau transgenic mice showed that they do not lead to AD but to frontotemporal 
dementia and Parkinsonism, showing no amyloid deposition (Spillantini et al., 
1998), suggesting mutations in tau are not the drivers of disease progression. A 
double tau (P301L)/APP (K670N/M671L) mutant however, increased the tangle 
pathology in the limbic system and olfactory cortex compared to the single tau 
transgenic, implying that APP can modulate tau pathology. (Lewis et al., 2001). 
Aβ-mediated promotion of tau pathology and the tight correlation of NFT 
progression with cognitive decline, suggests that Aβ acts as an upstream activator 
of tau hyperphosphorylation, which then mediates Aβ-induced neurotoxicity. This 
lends further support to the amyloid cascade hypothesis that Aβ is the driver of 
pathogenicity in AD (Lewis et al., 2001, Rapoport et al., 2002, Roberson et al., 2007). 
Identification of further mutations in APP and realisation that they were clustered 
around the Aβ cleavage sites, and identification of mutations in the presenilins, 
strengthened the hypothesis that misregulation of Aβ production was central to AD 
progression (Hardy and Selkoe, 2002). Since its conception, the amyloid cascade 
hypothesis has shaped the progress of Alzheimer’s research, and it remains the best 
model for the progression of AD. 
1.5 Amyloid Precursor protein 
 
APP is a highly conserved, type I transmembrane domain glycoprotein with 
orthologues identified from Caenorhabditis elegans, Drosophila melanogaster, 
Xenopus laevis, and Danio rerio (Zheng and Koo, 2011).  
In Mammalia, APP is part of a family containing three homologous proteins: APP, 
APP like protein 1 (APLP1) and APLP2. These proteins show high sequence identity, 
with a large N-terminal extracellular domain, a single trans-membrane domain and 
42 
 
short C-terminal domain, although it is only APP that contains the A sequence. APP 
and APLP2 undergo alternative splicing; in contrast only one isoform of APLP1 has 
been detected. All undergo complex glycosylation and processing to release soluble 
ectodomains (De Strooper and Annaert, 2000). APP, APLP1 and APLP2 are 
abundantly expressed in the brain, whilst APLP1 expression is entirely restricted to 
neurons, APP and APLP2 are also expressed in the periphery (Zheng and Koo, 2011), 
suggesting non-redundant roles for the family members.  
The human APP gene encodes a 19 exon, 770 amino acid polypeptide (Yoshikai et 
al., 1991), which can undergo alternative splicing of exons 7, 8 and 15, all resulting 
in structural changes to the N-terminal, extracellular domain (De Strooper and 
Annaert, 2000). These alternative splicing events give rise to three APP isoforms in 
humans of 770, 751 and 695 amino acids; termed APP770, APP751 and APP695 
respectively. APP695 is the primary source of APP in the brain, whilst its expression is 
barely detectable in other tissues (Tanaka et al., 1989). It is estimated that APP695 
mRNA accounts for 0.2% neuronal mRNA and shows little regional variability 
(Beyreuther et al., 1996), suggesting the physiological role of APP695 in the brain is 
not region-specific. APP770 and APP751 are expressed at much lower levels in the 
brain, with the ratio of APP770/APP751/APP695 estimated to be 1:10:20 (Tanaka et al., 
1989). 
1.5.1 APP structure 
 
APP is a multi-domain protein, broadly segregated into the N-terminal, the trans-
membrane and the C-terminal domains. Due to its large size and its properties as a 
transmembrane protein, the crystal structure of the holoprotein is yet to be solved. 
The N-terminal domain of APP contains a number of sub-domains: with the E1 and 
E2 domains showing high conservation across the APP family (Figure 1.5 (A)). The E1 
domain consists of a heparin binding/growth factor like domain (GFLD) containing 
disulphide bridges essential for neurite outgrowth and mitogen activated protein 






Figure 1.5: APP structure and FAD linked mutations 
(A) The positions of the signal peptide (SP), growth factor-like domain (GFLD), copper (II) and zinc (II) binding domain (CuBD), Kunitz-type 
protease inhibitor domain (KPI), sequence implicated in growth promotion (RERMS), amyloid β (Aβ) and protein interaction motif (YENTPY). 
Above indicates the locations of the highly conserved E1 and E2 domains and the chrondroitin sulphate glycosaminoglycan attachment site (CS-
GAG). Below indicates the locations of N- and O-glycosylation sites (C=O) and phosphorylation sites (yellow- ser/thr, blue- tyr). (B) Mutations in 
APP695 (letters in red) occur in the Aβ sequence (purple box) or near the secretase cleavage sites (black arrows) and alter APP metabolism to 
favour Aβ production or aggregation. A single protective mutation (A673T) has been identified that reduces risk of AD (green) close to the β 
secretase cleavage site 
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binding domain (CuBD) that is responsible for the redox sensitivity of APP (Casella 
and Gullotti, 1993). The E1 domain is followed by a Kunitz type serine protease 
inhibitor domain (KPI) that is subject to alternative splicing and absent from APP695 
(Kitaguchi et al., 1988, Ponte et al., 1988). The E2 domain contains a RERMS 
sequence implicated in growth promotion (Ninomiya et al., 1993) and putative 
interaction sites for binding partners including a second heparin binding domain 
and two N-glycosylation sites (Zheng and Koo, 2011). This is followed by a 
chondroitin sulphate glycosaminoglycan attachment site (Shioi et al., 1995) which, 
along with the KPI domain is subject to alternative splicing to generate the three 
isoforms of APP. The transmembrane domain (TMD) contains the Aβ sequence, the 
first 28 residues are located outside the membrane and the last 12-14 are part of 
the trans-membrane sequence itself. The TMD also contains two putative 
sumoylation sites immediately prior to the Aβ sequence (Lys 587 and Lys 595), 
which have been associated with negative regulation of Aβ production (Zhang and 
Sarge, 2008). The TMD contains all known amino acid substitutions associated with 
FAD (Figure 1.5(B)). The C-terminal, intracellular domain contains the protein 
interaction motif YENTPY which is conserved from C. elegans to humans (Reinhard 
et al., 2005). The C-terminal domain also contains phosphorylation sites, including 
Thr668 (APP695 numbering), the most well-characterised phosphorylation site, 
conserved in all homologs. Further sites include a second threonine site (Thr686) 
and two tyrosine phosphorylation sites (Tyr682 and Tyr687) (Jacobsen and Iverfeldt, 
2009).  
1.6 APP metabolism 
 
Metabolism of APP is central to its function evidenced by rescue of the APP 
knockout phenotype by introduction of the APP metabolite, sAPPα. APP was one of 
the first proteins to be identified that undergoes a specific type of metabolism 
termed regulated intramembrane proteolysis (RIP) (Brown et al., 2000).RIP is an 
evolutionarily conserved pathway which mediates efficient release of membrane 
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anchored, bioactive molecules by proteolytic cleavage at a site within the 
membrane (Brown et al., 2000). RIP has been found in all organisms studied to date, 
controlling communication between cells and the extracellular environment 
(Lichtenthaler et al., 2011). Three families of intramembrane cleavage proteases 
(iCliPs) have been described: GxGD type aspartyl proteases, S2P metalloproteases 
and rhomboid serine proteases, each evolutionarily and structurally distinct. 
RIP is tightly controlled, with deregulation associated with AD, Parkinson’s disease 
(PD), and type 2 diabetes (Lemberg, 2011). Substrate tailoring, an initial cleavage 
event by a sheddase must occur to generate a membrane stub that is then 
accessible to the iCliPs, regulating substrate availability (Lemberg and Martoglio, 
2002, Lichtenthaler et al., 2011). The initial shedding event of most RIP substrates is 
mediated by members of the ADAM family or aspartyl proteases BACE1 and BACE2 
(Lichtenthaler et al., 2011). There is also intricate subcellular compartmentalisation 
of substrates and proteases, keeping the substrate and protease separate; only 
through compartment targeting is the process activated (Lemberg, 2011). RIP is 
associated with a range of disparate cellular functions; it can lead to relocation of a 
substrate domain, activation of a dormant activity or initiation of membrane 
protein degradation. A variety of membrane proteins including cytokines, growth 
factors, cell adhesion proteins, viral proteins and signal peptides are cleaved by RIP. 
Through these, the process is essential for a multitude of essential cellular functions 
including embryonic development, normal immune system function and the 
nervous system (Lemberg, 2011, Lichtenthaler et al., 2011). 
In humans, APP is constitutively processed in all cell types by two RIP pathways, 
involving three proteases. The first pathway, termed the amyloidogenic pathway, 
gives rise to Aβ whilst the second pathway, termed the non-amyloidogenic pathway 
precludes Aβ formation. -secretase, the GxGD type aspartyl protease-containing 
complex responsible for the intramembrane proteolysis of APP, is common to both 
pathways. The pathways are differentiated by the sheddase enzymes responsible 
for the substrate tailoring of APP allowing the secondary cleavage to occur. This is 
the α-secretase activity for non-amyloidogenic and β-secretase activity for 







Figure 1.6: APP processing pathways 
Primary cleavage of APP is performed by either α or β secretase activities 
following by intra-membrane proteolysis by γ secretase. Non-amyloidogenic 
processing (left) is initiated by α-secretase (ADAM10/17). Cleavage occurs 
between residues 16 and 17 of the Aβ sequence, precluding its formation, 
allowing release of soluble ectodomain sAPPα and retaining C89 (αCTF) in the 
membrane. Amyloidogenic processing (right) is thought to be the dominant 
pathway in neurons and is initiated by β secretase (BACE1). Cleavage occurs 
at 2 sites, the major site at the N-terminal of the Aβ sequence, however a 
second cleavage site at +11 (β’) also exists, generating soluble ectodomain 
sAPPβ and retaining C99 (β’/β CTF) in the membrane. Following ectodomain 
shedding, the membrane tethered C89 and C99 undergo γ secretase 
cleavage, leading to release of P3 from C89 cleavage and Aβ release from C99 
cleavage. Due to heterogeneity in γ secretase cleavage sites different amino 
acid length Aβ species are produced, the major isoforms being 40 and 42 
amino acids in length (Aβ40 and Aβ42), N-terminally truncated Aβ species are 
generated by β’ secretase activity. γ secretase cleavage of both pathways also 




Non-amyloidogenic processing is initiated by cleavage of APP between residues 16 
and 17 of the A sequence by the  secretase, precluding formation of A and 
releasing the soluble ectodomain fragment, sAPP(Sisodia, 1992b) (Figure 1.6: 
green box). This is followed by -secretase cleavage releasing the P3 peptide and 
the APP intracellular domain (AICD). The truncated Aβ sequence of the released P3 
peptide does not appear to have toxic properties (Dulin et al., 2008). 
In contrast, amyloidogenic processing is initiated by β-secretase cleavage at the N-
terminal of the Aβ sequence, between Met670 and Asp671 (+1 site). This causes the 
release of a slightly shorter ectodomain fragment compared to α-secretase 
cleavage, termed sAPPβ (Figure 1.6: red box). This is followed by -secretase 
cleavage, releasing the AICD and due to its heterogeneous cleavage activity, a 
number of different length Aβ fragments. The major product is Aβ40 and the minor 
product is Aβ42 at an approximate ratio of 9:1 under physiological conditions 
(Lichtenthaler et al., 2011). Despite sequence specificity of the β-secretase enzyme, 
it can also cleave at a second site in Aβ termed the β’ site (+11 site), the regulation 
of this preference has been associated with AD (Sisodia and St George-Hyslop, 
2002).  
The amyloidogenic and non-amyloidogenic pathways have been suggested to exist 
in equilibrium; the non-amyloidogenic pathway is the predominant APP cleavage 
route in peripheral cells whilst the amyloidogenic pathway is predominant in 
neurons due to increased β-secretase expression in comparison to non-neuronal 
cells (Colombo et al., 2012). Studies using genetic and pharmacological methods to 
increase α-secretase activity have shown a concomitant decrease in Aβ production 
and β-secretase activity (Postina et al., 2004, Bandyopadhyay et al., 2007). 
Overexpression of β-secretase was also shown to reduce α-secretase activity in the 
inverse relationship (Vassar et al., 1999, Kuhn et al., 2010). Observations from the 
study of the Swedish APP mutation which caused more efficient cleavage of APP by 
the β-secretase,, pointed to cellular compartmentalisation changes as a mechanism 
for altering the equilibrium (Haass et al., 1995b). However, study of endogenous 
secretase activities suggested the relationship was not bidirectional. β-secretase 
inhibition could not impact on the α-secretase pathway, although α-secretase 
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inhibition could increase β-secretase activity. This calls into question the 
physiological relevance of earlier overexpression observations and suggests a more 
complex relationship (Colombo et al., 2012).  
1.7 Secretase enzymes 
 
α-, β- and -secretase activities that cleave APP were described many years prior to 
identification of the protease responsible. Within the last few years, elucidation of 
α-secretase enzyme activity has completed the puzzle of secretase identities. These 
proteases are necessary and sufficient for the generation of the full range of 
metabolic products generated from RIP of APP. 
1.7.1 Alpha secretase 
 
α-secretase activity on APP was first reported over 20 years ago and was shown to 
cleave within the Aβ sequence between Lys16 and Leu17, precluding formation of 
the neurotoxic species (Esch et al., 1990, McDermott and Gibson, 1991). Further 
work characterised the enzyme activity showing it to be an integral membrane 
metalloendopeptidase of 105-120 kDa in size (McDermott and Gibson, 1991, 
Roberts et al., 1994).  
1.7.1.1 Identity of α-secretase 
 
The A disintegrin and metalloprotease (ADAM) family of zinc metalloproteases were 
highly implicated as the protease responsible for α-secretase activity due to their 
identification as the sheddases of other RIP substrates such as notch and TNFα. Two 
ADAMs in particular, ADAM10 and ADAM17, were suggested as the most likely 
family members to cause cleavage of APP at the α- cleavage site (Black et al., 1997, 
Buxbaum et al., 1998, Artavanis-Tsakonas et al., 1999, Lammich et al., 1999, Slack et 
al., 2001). -secretase activity of APP occurs constitutively and can also be 
stimulated by a variety of molecules. This stimulated response is termed ‘regulated’ 
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α-secretase activity. Through two studies, one in primary neurons and the other 
using conditional ADAM10 knockout mice, ADAM10 was shown to be responsible 
for the constitutive α-secretase activity (Jorissen et al., 2010, Kuhn et al., 2010). 
These were supported by the observation of coordinated expression of ADAM10 
and APP in the brain, which was not seen with other implicated ADAMs (Karkkainen 
et al., 2000, Marcinkiewicz and Seidah, 2000). Furthermore transgenic studies 
showed ADAM10 overexpression in a mouse model of AD attenuated plaque 
pathology and enhanced sAPP production. Conversely a mouse model expressing 
a dominant-negative mutant of ADAM10 displayed reduced sAPP, increased 
amyloid plaques and showed learning deficiencies in the Morris water maze 
(MWM) (Postina et al., 2004, Schroeder et al., 2009). 
The identity of the enzyme(s) responsible for the regulated α-secretase activity has 
not fully been elucidated, however ADAM10 itself can be upregulated in response 
to the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) 
(Kojro et al., 2006). In addition, ADAM17 expression is upregulated following 
phorbol myristate ester (PMA) treatment concurrent with changes in α-secretase 
activity and Aβ production. This was not seen in ADAM17 knockout cells, whilst 
constitutive α-secretase activity was maintained (Buxbaum et al., 1998). ADAM17 
activity was also shown to be upregulated following treatment with M1 muscarinic 
agonists, this was in parallel with increases in sAPPα, which although not a direct 
link between ADAM17 and increased non-amyloidogenic processing, is indirect 
evidence for ADAM17 as the regulated α-secretase activity (Caccamo et al., 2009). 
Taken together these studies suggest a joint role for ADAM10 and ADAM17 as the 
regulated α-secretase activity. 
1.7.1.2 Structures of ADAM10/17 
 
ADAMs are a family of approximately 750 amino acid, type I transmembrane, zinc 
proteinases characterised by their structure. There are 24 known ADAM genes in 
humans, however only half of these are active proteases (van Goor et al., 2009). 
They are generated as a zymogen with a signal peptide and prodomain at the N-
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terminus. This is followed by a catalytic domain with a conserved zinc binding 
sequence (HEXGHXXGXXHD), a cysteine-rich disintegrin-like domain, a single 
transmembrane domain and a short cytoplasmic domain (Figure 1.7(A)). The 
prodomain holds the catalytic Zn2+ ion and protease domain in an inactive state and 
in the case of ADAM10 it appears the prodomain also acts as a chaperone molecule 
during maturation (Endres and Fahrenholz, 2010). Evidence from the solved crystal 
structure of the human ADAM17 catalytic domain shows a central five-stranded β-
sheet surrounded by five α-helices with a relatively flat active site (Maskos et al., 
1998). ADAM10 and ADAM17 show little sequence specificity, cleavage is instead 
dependent on the presence of an alpha-helical conformation, substrate association 
with a membrane and the distance of a hydrolysable bond from the membrane (12-
13 amino acids) (Sisodia, 1992a). 
1.7.1.3 Alternative functions of ADAM10/17 
 
ADAM10 is responsible for cleavage of over 40 membrane proteins, making it one 
of the major brain sheddases. ADAM10 cleavage occurs at the plasma membrane 
and can occur on the same cell surface but also in trans, on a neighbouring cell 
surface (Lichtenthaler, 2011). ADAM10 is responsible for ectodomain shedding of 
proteins involved in a number of pathways, including the well characterised notch 
signalling pathway (Tian et al., 2008, De Strooper et al., 2010), E- and N-cadherin 
cleavage, involved in cell migration (Maretzky et al., 2005, Reiss et al., 2005) and the 
cleavage of low affinity immunoglobulin E receptor in the immune system 
(Weskamp et al., 2006). The ADAM10 knockout mouse showed embryonic lethality 
at E9.5 displaying severe developmental defects in the CNS and heart; this 
phenotype closely resembles a loss of notch signalling phenotype, one of the major 
substrates of ADAM10 (Hartmann et al., 2002). In the CNS, the classic cadherins are 
involved in axon guidance and synaptogenesis during development, and synaptic 
plasticity in adults. Cleavage by ADAM10 leads to disassembly of adherens junctions 
at the synapse and modification of synaptic strength (Maretzky et al., 2005, 







Figure 1.7: Structure of secretase enzymes 
(A) α-secretase activity is mediated by two A disintegrin and metalloprotease 
(ADAM) family members, ADAM10 and ADAM17, which have very similar 
structures. The positions of the signal peptide (SP), prodomain, which keeps 
the enzyme in an inactive state, catalytic domain with conserved zinc binding 
sequence, a cysteine-rich disintegrin-like domain, a single transmembrane 
domain (TMD) and cytoplasmic domain are indicated. (B) The β-secretase 
enzyme, BACE1, is a single transmembrane aspartyl protease. The positions 
of the signal peptide (SP), prodomain which mediated correct folding of 
BACE1, catalytic domain which contains two conserved motifs, GTGS and 
DSGT containing the catalytic aspartates, the single transmembrane domain 
(TMD) and cytoplasmic domain which contains trafficking and recycling 
motifs. (C) γ secretase is composed of four essential proteins: presenilin (PS), 
nicastrin, anterior pharynx-defective 1 (APH1) and presenilin enhancer 2 
(PEN2) in a 1:1:1:1 ratio. Presenilin undergoes endoproteolytic cleavage 
between transmembrane domains (TMD) 6 and 7. The subunits form a 
barrel-like structure with a central hydrophilic chamber (blue arrow) where 
APP is cleaved by a di-aspartate active site (stars) (Image taken from (St 




Like ADAM10, ADAM17 has a broad range of substrates and cleavage occurs at the 
plasma membrane (Vingtdeux and Marambaud, 2012). It is critical for the activation 
of TNFα and endothelial growth factor (EGF) receptor ligands, regulators of 
inflammation and cell growth (Black et al., 1997, Sahin et al., 2004). ADAM17 gene 
depletion caused perinatal lethality displaying severe heart development defects 
whilst the knockout mouse phenotype closely resembles TNFα knockout mouse 
phenotype, showing embryonic lethality (Saftig and Reiss, 2011). 
1.7.1.4 Regulation of α-secretase activity 
 
α-secretase ectodomain shedding can be modulated at multiple levels including 
transcription, phosphorylation, protein maturation and trafficking. ADAMs are 
regulated by tissue inhibitors of metalloproteases (TIMPs); ADAM10 is inhibited by 
TIMP1 and TIMP3 whilst ADAM17 is inhibited by TIMP3 (Vingtdeux and 
Marambaud, 2012). Cholesterol has been implicated in regulation of these 
interactions through cholesterol mediated activation of liver X receptors. These 
down-regulate TIMP3 leading to increased ADAM10 and ADAM17 activity (Amour 
et al., 2000, Hoe et al., 2007). ADAM10 activity has also been shown to be 
negatively regulated by reversion-inducing cysteine-rich protein with Kazal motifs 
(RECK), which is crucial for appropriate ADAM10-mediated notch signalling during 
development (Muraguchi et al., 2007). Up-regulation of ADAM activity also occurs 
through direct activators of protein kinase C (PKC) which phosphorylate the ADAM 
protein and targets it to the plasma membrane. Insulin-like growth factor 1 (IGF1)-
mediated α-secretase activity stimulation through PI3-K- and cdk5-mediated 
signalling pathways has also been reported (Adlerz et al., 2007).  
Synaptic activity can further regulate α-secretase activity, through interaction of 
ADAM10 with synapse associated protein 97 (SAP97), calcium (Ca2+)-dependent 
NMDAR activation affects its distribution, targeting ADAM10 to the post-synaptic 
membrane, leading to increased α-secretase activity (Marcello et al., 2007). 
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1.7.2 Beta secretase 
1.7.2.1 Identity of β- secretase 
 
The protease responsible for the -secretase cleavage of APP was the first secretase 
to be identified. It was isolated and characterised by five separate groups in 1999. 
Together, these studies showed it to be a 501 amino acid, transmembrane aspartic 
protease that has been termed beta-site APP-cleaving enzyme 1 (BACE1) (Hussain 
et al., 1999, Sinha et al., 1999, Vassar et al., 1999, Yan et al., 1999, Lin et al., 2000). 
BACE1 has a low optimum pH and is predominantly localised to early endosomes 
and the TGN. Its highest tissue expression is in the pancreas and brain, more 
specifically neurons (Vassar et al., 2009). BACE1 is only found in vertebrates, with 
no homologs in C. elegans or Drosophila, suggesting a role in vertebrate specific 
systems such as the complex immune system and the brain. BACE1-/- mice are 
viable and fertile (Luo et al., 2001), however they present with a higher risk of 
premature mortality, impaired memory, reduced axonal myelination and altered 
synaptic plasticity. There is no cerebral Aβ produced indicating BACE1 is the major if 
not only -secretase in the brain (Vassar et al., 2009). When BACE1-/- mice are 
crossed with APP transgenic mice, Aβ generation, amyloid pathology and cognitive 
deficits are abrogated, further supporting BACE1 as the major β-secretase enzyme 
(Harrison et al., 2003, Ohno et al., 2004, Laird et al., 2005, Hu et al., 2010). 
1.7.2.2 Structure of BACE1 
 
 In humans, there are four different BACE1 isoforms due to alternative splicing of 
exons 3 and 4, of 501, 476, 457 and 432 amino acids in length. These show different 
β-secretase activities and are thought to be responsible for the different activities 
of BACE1 in the brain and pancreas (Mowrer and Wolfe, 2008). Soon after 
identification of BACE1, a second homologous protein termed BACE2 was 
discovered, this however has low neuronal expression and does not have the same 
cleavage activity on APP as that seen with the β-secretase. 
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BACE1 is synthesized in the endoplasmic reticulum (ER) as a zymogen with a signal 
peptide and short prodomain. The prodomain does not inhibit BACE1 activity, but 
mediates correct folding of BACE1 in the late Golgi network and then is removed by 
furin in the TGN (Bennett et al., 2000). C-terminal to the prodomain is the catalytic 
domain, containing two conserved motifs, DTGS and DSGT, with catalytic aspartate 
residues; mutation of either of these annihilates enzyme activity (Hussain et al., 
1999, Bennett et al., 2000, Hong et al., 2000). This is followed by the TMD and then 
the cytoplasmic domain, which contains motifs that dictate trafficking and recycling 
of BACE1 (Figure 1.7(B)). The crystal structure of the catalytic domain was solved in 
2000, revealing N and C-terminal lobes with the substrate binding and catalytic 
active sites in the cleft (Hong et al., 2000). Unlike the ADAMs, which show little 
sequence specificity, the active site of BACE1 accommodates 12 residues at 
positions P4’ to P8 with residue preferences at each site. P1 is  the most stringent, 
getting more relaxed towards the outer sites (Wang et al., 2013). 
1.7.2.3 Alternative functions of BACE1 
 
It was thought that the  secretases ADAM10 and ADAM17 were the major 
sheddases in the brain, whilst BACE1 was responsible for shedding of a small 
number of proteins. Those originally identified included APP, neuregulins and 2 
subunits of voltage gated sodium channels (Hu et al., 2006, Kim et al., 2007, Hu et 
al., 2008, Gersbacher et al., 2010). This was recently challenged following 
identification of 34 neuronal membrane proteins whose ectodomain shedding was 
affected by BACE1 inhibition (Kuhn et al., 2010). Of these several were almost 
exclusively BACE1 substrates such as seizure protein 6 like 1 (SEZ6L1) and the APP 
homolog APLP1, whilst others, such as APP, showed significant levels of BACE1 
dependence. These findings suggest BACE1 is also a major sheddase in the brain, 
responsible for cleavage in a wide range of developmental cellular pathways such as 





1.7.2.4 Regulation of BACE1 
 
BACE1 expression is upregulated in response to energy deprivation and elevated 
levels of stress-related transcription factors such as nuclear factor kappa-light-
chain-enhancers of activated B cells (NFκB) and hypoxia inducible factor 1 (HIF1) 
(Sambamurti et al., 2004, Velliquette et al., 2005, Zhang et al., 2007). Changes in the 
lipid environment also stimulate BACE1 activity in vitro (Kalvodova et al., 2005). 
BACE1 activity is further regulated by its subcellular localization through protein 
interactions predominantly via its cytoplasmic domain. Interaction with the myelin 
component reticulon retains BACE1 in the ER, spatially restricting its activity (He et 
al., 2007). Golgi-localised -ear-containing ARF-binding proteins (GGAs) bind to the 
cytoplasmic domain of BACE1 and regulate its trafficking from the late Golgi to 
endosomes. Decreased levels of these proteins lead to enhanced localization of 
BACE1 in its favoured endosomal compartment and also reduced trafficking to 
lysosomes where BACE1 is degraded, thus increasing BACE1 activity (He et al., 
2005). 
1.7.3 Gamma secretase 
 
In 1993, ‘-secretase’ was the name given to the unusual proteolytic activity that 
released Aβ within the TMD of APP. The same paper predicted that it would be the 
same protease responsible for the C-terminal cleavage of the non-amyloidogenic 
pathway (Haass and Selkoe, 1993). 
1.7.3.1 Identity of -secretase 
 
 Two genes were identified on chromosome 1 and chromosome 14 that segregated 
with identified cases of FAD. These genes were confirmed as coding for the catalytic 
activity of -secretase and were called presenilin 1 and presenilin 2. Through 
generation of presenilin knockout primary cultures, the presenilins were shown to 
be critical for A generation (De Strooper et al., 1998, Herreman et al., 1999), thus 
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identifying them as the catalytic components of -secretase. Presenilin 1 was shown 
to be responsible for the majority of -secretase activity. Following identification, 
biochemical characterisation of the presenilins highlighted they were not solely 
responsible for the -secretase activity through a number of observations: 
1. cellular presenilin levels were tightly controlled by the levels of another 
component (Thinakaran et al., 1997), 
2.  when presenilins were co-fractionated with the -secretase activity they 
were part of a very high molecular weight complex (Li et al., 2000),  
3. mutagenesis of the key catalytic aspartate residues not only ablated activity 
but also reduced the size of the large complex (Yu et al., 2000a). 
 
Through interactions studies and genetic screens nicastrin, anterior pharynx 
defective 1 (APH1) and presenilin enhancer 2 (PEN2) were identified as the other 
components of the complex and together the four proteins were shown to be 
necessary and sufficient for -secretase activity in a 1:1:1:1 stoichiometry (Yu et al., 
2000b, Francis et al., 2002, Takasugi et al., 2003) (Figure 1.7 (C)).  
1.7.3.2 Structure of -secretase 
 
All proteolytic enzymes require an activated water molecule to execute their 
catalysis. -secretase is one of a growing number of enzymes identified that is able 
to execute catalysis in the hydrophobic environment of the lipid bilayer of a 
membrane (Lichtenthaler et al., 2011). Due to this unusual capability, the structure 
of the -secretase is of significant interest. Difficulties due to its size and membrane 
association means the crystal structure of the -secretase complex has not been 
solved, however low resolution structural studies predict it to be a barrel-like 
structure with a central aqueous cavity (Lazarov et al., 2006, St George-Hyslop and 
Fraser, 2012).  
Presenilins have two catalytic aspartate residues in TMD 6 and 7, closely opposed to 
each other. Cysteine scanning mutagenesis of these two TMDs identified a number 
of residues that were water accessible including both catalytic aspartates, 
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biochemically supporting the presence of a hydrophilic channel in the membrane 
(Tolia et al., 2006). Due to the presence of this cylindrical interior chamber the 
proteolytic site is occluded from the hydrophobic environment, allowing access for 
crucial water molecules (De Strooper et al., 2012). 
The presenilins are synthesised in the ER as 50 kDa precursor proteins with 9 
transmembrane domains with a cytoplasmic N-terminal and luminal/extracellular C-
terminal. Cleavage between TMD 6 and 7 at the final stage of maturation produces 
an N-terminal 30 kDa and C-terminal 20 kDa fragments which remain stably 
associated (Thinakaran et al., 1996, Fukumori et al., 2010). 
Nicastrin is a type 1 transmembrane glycoprotein with a large extracellular domain 
which initially interacts with APH1 to create a scaffold in the ER for presenilin to 
associate with, it is also thought to be the ‘gate-keeper’, restricting substrate access 
to the active site in the mature complex (De Strooper et al., 2010, St George-Hyslop 
and Fraser, 2012).  
APH1 is an integral membrane protein that exists as two homologs in humans, 
APH1a and APH1b of which APH1a can also undergo alternative splicing (Gu et al., 
2003). It contains 7 TMDs and is the most stable part of the complex. Due to its 
different isoforms it may alter the catalytic activity of -secretase, some favouring 
formation of A.  
PEN2 contains two TMDs and is the final component to associate with the complex. 
This stabilises the complex via a conformational change, preventing its degradation 
by the proteasome and allowing endoproteolysis of presenilin, causing full 
activation of the complex (De Strooper et al., 2010). The full complex is a highly 
hydrophobic, 19 TMD protease localised to the plasma membrane and endosomes 
(Figure 1.7(C)). 
1.7.3.3 Alternative functions of -secretase 
 
-secretase cleaves type 1 transmembrane proteins with short ectodomains with 
little sequence specificity, although more than 50 residues N-terminal to the 
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membrane inhibits activity. Over 90 substrates of -secretase have been identified, 
implicating -secretase in regulation of critical signalling pathways in development, 
immune responses and cellular differentiation (Wakabayashi and De Strooper, 
2008, Jurisch-Yaksi et al., 2013). Single and double knockout PSEN mice die 
perinatally and during early embryonic development respectively (Shen et al., 1997, 
Donoviel et al., 1999, Herreman et al., 1999). They display disorders in neuronal 
migration, midline defects in the body wall, defective somatogenesis and show 
haemorrhages into the brain parenchyma (Shen et al., 1997, Wong et al., 1997, De 
Strooper et al., 1998, Hartmann et al., 1999). Mutations in PSEN are associated with 
five diseases: AD, fronto-temporal dementia, acne inversa, dilated cardiomyopathy 
and breast cancer, underlining the critical role of -secretase across a wide range of 
body systems including the heart, brain, vasculature and immune system (Li et al., 
2006, To et al., 2006, Wang et al., 2010, Cruts et al., 2012). 
Along with APP, notch is the most famous -secretase substrate and is thought to 
be responsible for the major phenotypes of PSEN knockout mice. During 
development, -secretase-mediated notch signalling regulates cell proliferation, 
survival, positioning and differentiation through a signalling mechanism involving 
ligand-dependent release of the notch intracellular domain (NICD). The NICD then 
translocates to the nucleus and modulates gene transcription (Kopan and Ilagan, 
2009). In adulthood, notch signalling still has critical functions including modulation 
of stem cell maintenance and cell fate decisions (Grabher et al., 2006, Lavado and 
Oliver, 2014).  
Many substrates of -secretase have brain-specific functions: for example, ephrin B 
and the ephrin B receptor and netrin and its receptor, deleted in colorectal cancer 
(DCC) which are involved in axonal guidance (Bai et al., 2011, Georgakopoulos et al., 
2011). -secretase plays an important role at the synapse in maintaining proper 
neuronal communication. The cell adhesion protein neuroligin, present at the post-
synaptic membrane, binds its pre-synaptic ligand neurexin and initiates -secretase 
dependent signalling across the synapse. Furthermore, -secretase-dependent 
ephrinA4 receptor activation regulates dendritic spine morphogenesis through 
activation of the Rac signalling pathway (Inoue et al., 2009, Suzuki et al., 2012). 
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Down-regulation of -secretase expression leads to an autoimmune phenotype, 
predominantly through a notch dependent impairment of T cell receptor signalling 
(Grabher et al., 2006). Other -secretase substrates are also associated with the 
immune system, although the functional relevance of their -secretase cleavage is 
not clear. These include CD46, lipoprotein receptor related protein 1 (LRP1) and a 
number of interleukin receptors (Jurisch-Yaksi et al., 2013). 
-secretase is also responsible for cleavage of growth factors including vascular 
endothelial growth factor (VEGF) and EGF through which -secretase plays a crucial 
role in angiogenesis and cellular migration and proliferation (Ni et al., 2001, Cai et 
al., 2006).  
1.7.3.4 Regulation of -secretase 
 
 Several different cleavage events are mediated by the -secretase complex (Figure 
1.6): the  cleavage generates soluble intracellular domain fragments such AICD 
(APP). The cleavage generates small, short lived fragments and the  cleavage 
between residues 38 and 43 gives rise to the neurotoxic amino terminal A 
fragments and P3 fragment from the non-amyloidogenic pathway (St George-
Hyslop and Schmitt-Ulms, 2010). It has suggested that these cleavages occur 
sequentially from  to  and that different PSEN and APH subunit combinations 
affect the preferred activity of the complex. PSEN2 containing -secretases are 
suggested to be less effective producers of Aβ and APH1b-containing -secretases 
favour production of longer Aβ peptides (Acx et al., 2013).  
Non-essential protein components affect -secretase activity on specific substrates. 
Down-regulation of transmembrane emp24 domain-containing protein 21 (TMP21), 
caused an increase in -secretase mediated A generation with no effect on the  
activity responsible for notch cleavage, and had no effect on AICD mediated 
transcriptional regulation of proteins such as neprilysin (Chen et al., 2006, Dolcini et 
al., 2008). More recently another protein, the gamma secretase activating protein 
(GSAP) was identified that via direct interaction with the APP, is able to selectively 
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affect the  cleavage activity whilst the  cleavage activity remains unaffected (He et 
al., 2010). These findings are finally starting to help elucidate how -secretase 
specificity is conferred, although there are still significant gaps in our 
understanding. 
1.8 Regulation of APP processing 
1.8.1 Spatial regulation 
 
As already discussed, APP undergoes a particular type of proteolytic cleavage 
termed RIP. The spatial and temporal localisation of the substrates and proteases 
play a critical role in the regulation of this type of processing.  
APP is synthesised and N-glycosylated in the ER. Whilst in this state it is not subject 
to cleavage by proteases. Following trafficking to the Golgi it is O-glycosylated, 
which allows release into the TGN and the late secretory pathway (Suzuki and 
Nakaya, 2008) (Figure 1.8(1)). Following delivery to the cell surface, APP co-localises 
with the non-amyloidogenic sheddases, the  secretase enzymes, ADAM10/17 
(Figure 1.8(2)). The localisation of α-secretase at the cell surface was deduced from 
endocytosis inhibition experiments. These showed increased cell surface APP 
concurrent with increased sAPPα and decreased Aβ (Koo and Squazzo, 1994). 
Further studies also showed ADAM10 and ADAM17 interact via an SH3 domain in 
their cytoplasmic tails with SAP97, ensuring localisation at the synaptic membrane 
(Peiretti et al., 2003, Marcello et al., 2007). 
At the cell surface, APP has a relatively rapid endocytosis rate, internalised via the 
clathrin-dependent pathway (Figure 1.8(3)). Internalisation into the endosomal-
lysosomal pathway presents APP to the  secretase (BACE1) activity, concentrated 
in these compartments (Small and Gandy, 2006) (Figure 1.8(4)). Evidence for β-
secretase localisation includes the presence of a sorting signal (DXXLL) in the 
cytoplasmic tail of BACE1, mediating trafficking between the TGN to endosomes (He 
et al., 2005) (Figure 1.8(5)) and FRET analysis of the BACE1: APP interaction that 
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Figure 1.8: Trafficking and proteolysis of APP 
APP (blue bars) matures through the constitutive secretory pathway (1). 
At the cell surface it is susceptible to α-secretase (green bars) and γ 
secretase (brown pentagons) activities. Once at the cell surface APP (2) 
is rapidly endocytosed and trafficked through the endocytic pathways 
(3) where it is susceptible to β secretase (4) (red bars) and γ secretase 
activities or recycled back to the plasma membrane. As well as in the 
endosomes, β secretase activity is also present in the trans-golgi 
network (TGN) and trafficking of APP regulates the availability of 
substrate for amyloidogenic processing in these compartments (5). A 




showed greatest efficiency in the endosome (Kinoshita et al., 2003). Furthermore, 
endocytosis blockade experiments reduced A production (Small and Gandy, 2006) 
and immunofluorescence studies showed BACE1 staining co-localised with the 
endosomal marker, transferrin receptor (Huse et al., 2000). BACE1 is also present 
on the cell surface, however due to spatial segregation, possibly due to membrane 
lipid content and the low optimal pH for BACE1 activity, this is not a major APP 
cleavage site (Marquer et al., 2011). 
The localisation of the -secretase cleavage event has been difficult to elucidate due 
to its commonality to both pathways and its subunit composition. Components of 
the -secretase have been identified in most cellular compartments including the 
cell surface, golgi and endosomes; however this does not necessarily reflect mature, 
active -secretase complexes. Indirect measures of the -secretase complex utilising 
fluorescent reporters or A production as surrogate markers of -secretase activity, 
have shown it to be focussed at the plasma membrane and in endosomes 
(Caporaso et al., 1994, Kaether et al., 2006). This corresponds with the localisation 
of α- and β-secretase activities and suggests -secretase is not the rate limiting 
enzyme in Aβ generation, but that it is presentation of APP to the endosomal BACE1 
sheddase. 
1.9 APP protein interactions 
 
Discrete subcellular localisations of secretase enzyme activities means the 
regulation of APP processing can be finely controlled by APP trafficking and 
competitive interactions with other proteins. Interactions with binding proteins at 
its cytoplasmic domain can alter the stability of APP at the cell surface and the 
likelihood of APP internalisation. LRP1 interacts with APP at the plasma membrane, 
increasing its rate of endocytosis (Marzolo and Bu, 2009). In contrast, 
apolipoprotein E receptor 2 (ApoER2), which is highly expressed in the brain, 
stabilises APP at the cell surface through interactions via f-spondin (N-terminal 
domain) and Fe65 (cytoplasmic domain). Due to its lower endocytosis efficiency, 
ApoER2 slows the APP endocytosis rate whilst bound (Willnow and Andersen, 
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2013). Through the study of genes down-regulated in sporadic AD, sorting-related 
receptor with A-type repeats (SORLA) was shown to regulate APP (Scherzer et al., 
2004). SORLA directly interacts with APP and stabilises the holoprotein, preventing 
both amyloidogenic and non-amyloidogenic processing pathways and also 
sequesters APP from the endosomes to the TGN through retromer transport, 
spatially preventing secretase cleavage (Willnow and Andersen, 2013). 
1.9.1 APP adaptor protein interactions 
 
APP protein interactions are often mediated by a group of cytoplasmic adaptor 
proteins, the most common being Mint/X11s, Fe65 and JIPs (Suzuki and Nakaya, 
2008).  
1.9.1.1 X11 family 
 
The X11 family of multi-domain adaptor proteins have an evolutionarily highly 
conserved interaction with APP. In humans, they are a three protein family: X11, 
X11 and X11. X11 and  are expressed primarily in neurons, predominantly in 
the TGN and at the plasma membrane. Binding of either X11 or X11 to APP 
stabilises the holoprotein and increases its half-life, reducing the levels of A 
production (Miller et al., 2006, Rogelj et al., 2006). The X11 family are also known as 
Munc interacting proteins (MINTs) due to their interaction with munc18, a synaptic 
vesicle docking protein. This interaction has been shown to synergistically enhance 
the stabilising effect of X11 on APP, further reducing A production (Ho et al., 
2002). X11s can also tether cargo to molecular motors. X11as part of a larger 
protein complex, binds the dendritic motor kinesin superfamily motor protein 17 
(KIF17) whilst an X11/alcadein complex was co-purified with the kinesin heavy 
chain (Setou et al., 2000, Araki et al., 2003) These interactions suggest the X11 
family play a role in axonal and dendritic transport, although direct evidence is 




1.9.1.2 Fe65 family 
 
In humans, Fe65, Fe65L1 and Fe65L2 are another three protein family of 
multidomain adaptor proteins, however only Fe65 is brain enriched. They all 
contain an N-terminal WW domain and 2 C-terminal phosphotyrosine binding (PTB) 
domains (McLoughlin and Miller, 2008). As well as mediating interactions such as 
that between LRP or ApoER2 and APP as described previously, Fe65 also stabilises 
the -secretase-mediated APP cleavage product AICD via its YENTPY motif (Fiore et 
al., 1995, McLoughlin and Miller, 1996). Phosphorylation at Thr668 of APP 
modulates this interaction, with phosphorylation causing a conformational change, 
which enables Fe65 binding (Chang et al., 2006). Binding of the AICD to Fe65 targets 
it to the nucleus where it has been reported that a further adaptor, the histone 
acetyltransferase Tat interacting protein 60 (Tip60), associates to form a 
transcriptionally active complex (Cao and Sudhof, 2001, Kimberly et al., 2001). It 
remains controversial whether it is AICD or Fe65 that is the dominant 
transcriptional activity (Perkinton et al., 2004, Yang, 2006), however studies have 
implicated the complex in the transcriptional regulation of GSK3β, BACE1, neprilysin 
and APP (Miller et al., 2006) suggestive of feedback loops in APP regulation. Due to 
competition for the same YENTPY motif on APP, X11 proteins inhibit Fe65 
interactions with APP, therefore indirectly inhibiting the transcriptional activity of 
APP (Rogelj et al., 2006). 
1.9.1.3 JIP 
 
The scaffold proteins, C-Jun N-terminal kinase (JNK) interacting proteins (JIPs), can 
also interact with the YENTPY motif of APP (King and Scott Turner, 2004). JIP1a and 
JIP2 bind weakly to APP and do not affect its processing. In contrast, JIP1b causes 
evolutionarily conserved enhancement of JNK mediated, neuron specific 
phosphorylation at the critical Thr668 residue, the major regulatory 
phosphorylation site of APP. JIP1b also interacts with kinesin light chain-1, 
67 
 
suggesting a similar trafficking role to the X11 family (Taru et al., 2002, Inomata et 
al., 2003).  
Although much is left to be elucidated about the regulation of APP and how its 
trafficking affects this, the picture is becoming clearer as to the complexity 
surrounding the pathway through which APP will be processed and the level to 
which it will be processed. The physiological spatial segregation of the secretase 
enzymes and tight control of trafficking of APP highlights the importance of 
studying modulators of APP processing in primary neurons, where all neuronal 
specific cellular compartments are present and functional. 
1.10 Degradation of APP fragments 
 
Full length APP695 has a half-life of 10 minutes at the plasma membrane where its 
physiological role is thought to take place and its half-life in the cell is approximately 
an hour (Gralle and Ferreira, 2007). Although proteolytic fragments of APP are 
known to have independent functions and to be more stable that the full length 
protein, little specific information is available about their degradation pathways. 
The exception to this is degradation and clearance of A. 
A production in the brain is much higher than in the periphery. Excess 
accumulation is prevented by drainage from the extracellular space into the muscle 
walls of arterioles (Weller et al., 2000, Bell et al., 2009). Specific enzymes have been 
identified that are involved in the degradation of Aincluding neprilysin, insulin 
degrading enzyme (IDE), endothelin converting enzymes 1 and 2 (ECE1 and ECE2), 
plasmin, matrix metalloproteinases (MMP2 and MMP9) and cathepsin B (De 
Strooper, 2010). These have distinct subcellular localisations, suggesting 
complimentary activities in ensuring efficient A degradation (Turner and 
Nalivaeva, 2006). Supporting this, genetic reduction in expression of neprilysin and 
ECE1 both lead to an increase in A accumulation and polymorphisms in ACE are 
associated with LOAD risk (Eckman et al., 2001, Hu et al., 2001, Iwata et al., 2001). 
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Also a double knock-out of neprilysin and ECE1 further enhanced A accumulation, 
suggesting the proteases are complimentary (De Strooper, 2010). 
1.11 Functions of APP 
 
Despite the intense research activity focussed on APP, its physiological function is 
yet to be fully elucidated, although its structure and processing give clues to 
potential roles in cell adhesion and cell signalling. APP is one of the most abundant 
proteins in the brain and therefore there was initial shock when APP knock-out mice 
showed little phenotype (Muller et al., 1994, Zheng et al., 1995). APP-/- mice are 
viable and fertile with a subtle phenotype. They show reduced locomotor activity, 
reduced body and brain weight, reactive gliosis, and hypersensitivity to kainate 
induced seizures (Zheng et al., 1995, Steinbach et al., 1998). However, when 
APP/Amyloid precursor-like protein 2 (APLP2), APLP1/APLP2 and APP/APLP1/APLP2 
combined knockouts were made, these resulted in early postnatal lethality. These 
knock-outs revealed the APP family play a role in development of the nervous 
system; specifically synapse structure and function, neuronal migration and 
adhesion (von Koch et al., 1997, Heber et al., 2000, Herms et al., 2004).  
1.11.1 Full length APP 
 
Due to its structural and processing similarities to receptor proteins such as notch, 
APP has been proposed to act as a cell surface receptor (Wolfe and Guenette, 2007, 
Muller and Zheng, 2012). The ability of the APP family to form both homo- and 
hetero-dimers intercellularly through their E1 domains, and their interactions with 
extracellular matrix proteins such as collagen and laminin (Kibbey et al., 1993, Beher 
et al., 1996, Caceres and Brandan, 1997), led to the proposal that they may play a 




1.11.2 Soluble ectodomains 
 
The initial secretase cleavage event causes release of soluble ectodomains of APP 
(sAPP), sAPPα is released via α-secretase-mediated APP cleavage whilst sAPPβ, 
which is slightly smaller, is released via β- secretase-mediated APP cleavage. Ring et 
al (2007) showed that all phenotypes of APP deficient mice could be rescued by 
sAPP knock-in, suggesting that this is the physiologically important component of 
APP. sAPPα has been shown to be required for LTP, a crucial mechanism in 
cognition and memory (Taylor et al., 2008), supported by findings that intracerebral 
sAPP injections enhance memory performance in adult rats (Gralle and Ferreira, 
2007). sAPP is also neurotrophic and neuroprotective under stressed conditions 
(Mattson et al., 1993, Gralle and Ferreira, 2007). Application of sAPPα to neural 
progenitor cells led to increased proliferation both in vitro and in vivo in the adult 
mouse CNS, suggesting a similar role to notch in adult stem cell regulation (Caille et 
al., 2004, Demars et al., 2011). 
In contrast, sAPP although highly stable and abundant, does not rescue APP 
knockout phenotype (Li et al., 2010), thus highlighting the importance of regulation 
of APP processing to maintain appropriate levels of these different functionalities. 
Furthermore, unlike sAPP, sAPP can be further processed by caspases and bind 
death receptor 6 (DR6), which is associated with axonal pruning and degeneration 
(Nikolaev et al., 2009). This suggests sAPP plays a physiological role in the selective 
neuronal loss required during development, but in adults could also be part of the 
pathological process of neuronal degeneration seen in AD.  
1.11.3 AICD 
 
The AICD is produced by ɛ cleavage of APP by -secretase. Through its binding 
partners the AICD has been implicated in a number of APP-dependent functions, 
including synaptic activity (King and Scott Turner, 2004, Ghosal and Pimplikar, 2011) 
and axonal guidance (Guenette et al., 2006). Due to the short half-life of AICD in the 
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cytoplasm it is difficult to study its biochemical features and physiological functions. 
The AICD contains three phosphorylation sites including the main regulatory site, 
Thr668. Phosphorylation at this site is neuron specific and therefore thought to be 
central to the physiological function of APP. It regulates interactions with binding 
partners such as Fe65 and may facilitate BACE1 processing and the subsequent -
secretase cleavage of the C99 stub (Lee et al., 2003, Chang et al., 2006, Mazzitelli et 
al., 2011). 
Alterations to cellular levels of AICD through -secretase inhibition or increased 
AICD degradation caused decreased Ca2+ stores in the ER, reduced ATP content and 
disrupted mitochondrial function. This suggests that AICD plays a role in calcium 
homeostasis of neurons, which is critical for neuronal activity (Hamid et al., 2007).  
The transcriptional activity of the AICD is still a hotly contested debate. Cao and 
Sudhof (2001) reported that AICD could form a transcriptionally active complex with 
Fe65 and Tip60, however it was later shown that Fe65 could induce transcription 
outside of an AICD complex, following AICD-dependent modification of its structure 
(Cao and Sudhof, 2004). Despite these uncertainties as to the dominant 
transcriptional molecule, the putative target genes suggest a role for AICD in 
regulation of APP processing, with an elaborate feedback loop involving APP itself 
and enzymes involved in its degradation (Beckett et al., 2011). 
AICD can be cleaved by caspases, which are traditionally associated with apoptotic 
cell death (Bertrand et al., 2001, Madeira et al., 2005). This may indicate the AICD 
plays a similar role to that suggested for sAPPβ during development in mediating 
selective neuronal loss. However, caspases have cellular roles other than mediation 
of apoptosis, although less well characterised. Caspase 3 activation has been shown 
to induce changes in growth cone direction, which could indicate a role in the 
axonal guidance function of APP or caspase 1 can affect synaptic plasticity 
(Campbell and Holt, 2003, Lu et al., 2006). As the identity of the caspase(s) 




1.11.4 Amyloid β 
 
Much of the work on A has focussed on its role as the aggregation prone, 
neurotoxic species that interferes with synaptic function in affected neurons (Walsh 
et al., 2002, Lesné et al., 2006, Li et al., 2009, Wu et al., 2010), however it has also 
been shown to have neurotrophic and signalling functions (Yankner et al., 1990, 
Kamenetz et al., 2003). Low picomolar concentrations of Aβ monomers and 
oligomers, including the more hydrophobic, aggregation prone Aβ42, cause an 
increase in LTP mediated by α7 nicotinic acetylcholine receptors, associated with 
improved cognition (Puzzo et al., 2008). Further to this, Aβ42 monomers are able to 
support survival of developing primary neurons in the absence of trophic factors. 
They also protect mature neurons against excitotoxic death through a mechanism 
involving phosphatidylinositol 3-kinase (PI3K) signalling and IGF1 receptors 
(Giuffrida et al., 2009). 
Misregulation and overproduction of Aβ have a toxic, gain of function phenotype at 
the neuronal synapse. A can form dimers, trimers and low n-number soluble 
oligomers. These can then go on to form insoluble protofibrils and eventually the 
fibrils seen in amyloid plaque pathology. Initial in vitro tests suggested that the 
insoluble fibrils were neurotoxic. This was not supported by parallel work in post-
mortem brains showing amyloid pathology had a weak correlation with the severity 
of dementia and that there was a better correlation with soluble forms of A. Small 
Aβ42 oligomers were able to kill mature neurons at nanomolar concentrations 
(Lambert et al., 1998), with initial Aβ mediated inhibition of synaptic LTP long 
before the cellular degeneration.  Although direct neurotoxicity of Aβ remains 
controversial, oligomers of Aβ secreted from primary neurons were shown to 
inhibit LTP in vivo in rats and this was abrogated by IDE breakdown or 
immunodepletion of Aβ from the medium, confirming Aβ-mediated synaptic 
dysfunction (Walsh et al., 2002).  
A number of studies have suggested that Aβ mediates its effect through disruption 
of trafficking of key receptor subunits. Low nanomolar Aβ increased trafficking of 
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NR2B subunits which led to down-regulation of extracellular signal-regulated kinase 
(ERK) and cAMP response element binding protein (CREB)-mediated pathways and 
disruption of LTP (Li et al., 2011). Another study showed Aβ oligomers reduced 
GluA1 phosphorylation, crucial for its transport, this reduction in phosphorylation 
was shown to be due to Aβ-mediated changes in Ca2+ influx (Minano-Molina et al., 
2011). 
As well as Aβ being able to modulate synaptic activity, synaptic activity is also able 
to regulate Aβ. Physiological changes in neuronal activity are sufficient to 
dynamically modulate ISF Aβ concentrations, which themselves are correlated with 
plaque growth in vivo (Bero et al., 2011). Neuronal activity also regulates the 
equilibrium between the amyloidogenic and the non-amyloidogenic pathway. 
Synaptic glutamate release causes a shift away from Aβ production. Conversely, 
extrasynaptic release and high levels of glutamate release increase Aβ levels (Hoey 
et al., 2009, Bordji et al., 2010, Verges et al., 2011). 
These conflicting functions of Aβ suggest it plays a physiological role in maintenance 
of synaptic activity, promoting LTP at low concentrations and inhibiting it at higher 
concentrations. 
1.12 Flavonoids and AD risk 
 
An increasing body of evidence suggests that a group of plant-derived compounds, 
the flavonoids, might be effective in preventing the onset and/or slowing 
progression of AD (Williams and Spencer, 2012). Due to the prolonged failure of 
conventional pharmaceutical drug development to bring AD modifying therapies to 
market, there is considerable interest in alternative strategies to reduce the burden 
of the disease. 
As secondary metabolites present in fruits and vegetables, flavonoids are present in 
human diets, with a mean daily intake of approximately 14 mg (Commenges et al., 
2000, Letenneur et al., 2007). There is great variability in flavonoid bioavailability; 
many are directly excreted but it has been shown that select flavonoids and their 
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metabolites are detectable in the bloodstream hours after ingestion (Ramassamy, 
2006). The extensive metabolism of flavonoids following absorption and the lack of 
bioavailability of many flavonoids has proved a significant hurdle in the study of 
their reported beneficial effects in AD. However a number of studies have now 
been conducted suggesting flavonoids hold promise in the prevention of AD. 
1.12.1 Flavonoid structures 
 
Flavonoids are the largest group of polyphenolic compounds and have several 
thousand known members (Ramassamy, 2006). They occur ubiquitously in plant-
derived foods with the major dietary sources being fruits, vegetables and beverages 
such as tea and red wine. In plants, they are synthesised from phenylalanine 
through either the phenylpropanoid or the acetate-malonate pathways in a series 
of diverse, plant specific reactions to generate molecules with the same central 
structure but many different substitutions (Weston and Mathesius, 2013).  
All flavonoids have the same basic structure of two aromatic rings (A and B) bound 
together by 3 carbons forming an oxygenated heterocycle (C) (Spencer, 2010) 
(Figure 1.9). Flavonoids can be divided into 6 subclasses dependent on the type of 
heterocycle present in the molecule, these are: flavonols, flavones, isoflavones, 
flavanones, anthocyanidins and flavanols (Manach, 2004) (Figure 1.9).  
The flavonols are the most abundant subclass of flavonoid, the most prevalent 
molecules being kaempferol and quercetin, and are rich in foods such as broccoli 
and curly kale. They are distinguished by the presence of a 3-hydroxy-pyran-4-one C 
ring (Figure 1.9). The flavones, such as apigenin and luteolin, are rich in celery and 
cereal grains. These lack the 3 hydroxyl substitution on the C ring (Figure 1.9). 
Isoflavones, such as genistein and daidzein, are rich in soy products. They have their 
B ring located at the 3 position on the C ring (Figure 1.9). Flavanones, such as 
naringenin and hesperetin, are rich in citrus fruits and are lacking the 2, 3 double 
bond and 3-hydroxyl on the C ring (Figure 1.9). Flavanols such as (-) epicatechin, are 
rich in chocolate and green tea and are lacking the 2, 3 double bond.
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Figure 1.9: Flavonoid structures and families 
All flavonoids have the same basic structure: 2 aromatic rings (A and B) and an oxygenated heterocycle (C). Flavonoids are 
categorised according to the type of heterocycle present into flavonols, flavones, isoflavones, flavanones, flavanols and 
anthocyanidins. Flavonoids from each group are prevalent in different foodstuffs. Flavonoids within a sub-family are 
categorised according to substitutions on the aromatic rings. 
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Anthocyanidins, such as cyanidin and pelargonidin, are rich in berries, and are 
lacking the 2, 3 double bond and the 4-one group (Rice-Evans et al., 1996, Manach, 
2004) (Figure 1.9). Flavanols can also exist as polymers, known as 
proanthocyanidins, which vary based on the constitutive monomers and linkages. 
1.12.2 Epidemiological evidence of efficacy 
 
Epidemiological evidence suggests that regular intake of flavonoid-rich foods, such 
as berries and green tea, may result in cognitive benefits (Kuriyama et al., 2006, 
Letenneur et al., 2007, Devore et al., 2012) (Table 1.2). The Personnes âgées quid 
(Paquid) and Nurses’ Health study, two independent population studies focussing 
on the health of ageing populations have shown that consumption of flavonoid-rich 
foods resulted in improved cognition in the elderly. The Paquid study carried out 
dietary assessments four times over a ten year period in people over sixty-five at 
base line concurrent with cognitive ability assessments. They showed a decreased  
rate of decline in MMSE score associated with increased flavonoid intake 
(Letenneur et al., 2007). The American Nurses’ Health study of retired nurses over 
seventy years old, carried out semi-quantitative dietary assessments and cognitive 
performance assessments over a four year period. Results showed that increased 
flavonoid intake, especially berries, resulted in a two and a half year mean 
difference in relative years of cognitive decline (Devore et al., 2012). The Tsurugaya 
Project cross-sectional study supported these prospective analyses: in Japanese 
subjects over seventy years old, increased flavonoid-rich green tea consumption 
had an inverse dose-response relationship with cognitive impairment, defined as an 
MMSE score less than twenty-six (Kuriyama et al., 2006).  
Studies more specifically focussed on dementia suggested that higher flavonoid 
intake was inversely related to risk (Commenges et al., 2000, Dai et al., 2006, 
Barberger-Gateau et al., 2007) (Table 1.2). As part of the Paquid population study, 
cognition in 1367 over sixty-five year olds was measured every two years from 
1991-96. Estimations of total flavonoid intake from wine, tea, fruits and vegetables 







Length of study 
(years) 
Methodology Outcomes Reference 
Paquid (French) Flavonoid intake 65+ 5 Questionnaires 
Intake of flavonoids inversely related to risk of 
dementia incidence 








24h dietary recall 
5 psychometric tests 
Midlife dietary intake of antioxidants doesn’t 
modify risk of late life dementia. 










every 2 years 
Consumption of juices associated with 
decreased risk of developing AD  
effects larger with ε4 allele 









1 psychometric test 
Cognitive impairment decreased with 
increasing tea consumption 






65+ 4 Questionnaire 
Daily fruit and veg consumption assoc. with 
decreased risk of dementia 
(Barberger-Gateau 
et al., 2007) 
 
Paquid (French) Flavonoid intake 65+ 10 
3 psychometric tests  
4 sets over 10 years 
 
Flavonoid intake associated with better 
cognitive performance at baseline & better 
evolution over time. 






65+ 5 4 psychometric tests 
Better adherence to Mediterranean diet 
associated with slower MMSE decline 







70+ 6 years 
Questionnaires 
6 psychometric tests 
Women with higher berry intake delayed 
cognitive aging 
(Devore et al., 
2012) 
Table 1.2: Epidemiological evidence of flavonoid efficacy 
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Adjusted relative risk of dementia in those with the highest intakes of flavonoids 
was significantly lower than those with the lowest intake of flavonoids (Commenges 
et al., 2000). Following these results, the same group looked in a different French 
population. The Three-City Cohort conducted in Bordeaux, Dijon and Montpellier 
measured the incidence of AD over four years and correlated this with daily intake 
of fruits and vegetables. Once again this concluded that there was a reduced risk of 
incident AD following regular intake of fruit and vegetables (Barberger-Gateau et 
al., 2007). In separate work, the Kame project, a study of aged (mean 71.8 years) 
Japanese-Americans living in Washington, USA, showed that consumption of three 
or more fruit or vegetable juices per week decreased the risk of developing AD 
compared to drinking less than one juice per week. This effect was enhanced in 
people carrying the Apoɛ4 allele and in those less physically active (Dai et al., 2006). 
These promising observations have led to significant interest in identifying the 
underlying mechanisms through which flavonoids exert their beneficial effects and 
which specific flavonoids are conveying the benefits. 
1.12.3 In vivo flavonoid studies 
 
Due to the promising data from epidemiological studies, many studies have 
investigated the impact of flavonoid treatment on transgenic models of AD in 
attempts to understand the mechanisms through which flavonoid-rich diets are 
reducing the risk of AD. These have suggested select flavonoids can have positive 
effects on a number of AD-related outcomes including amyloid pathology, toxic APP 
metabolite levels, and memory deficits (Williams and Spencer, 2012).  
According to the amyloid cascade hypothesis, APP metabolism and its misregulation 
are the most direct targets for flavonoids to impact on disease progression (Hardy 
and Higgins, 1992). Rodent models of AD, where pathological APP processing has 
been induced have been utilised to study the effect of flavonoid treatment on 
amyloid pathology. Flavanols have shown particular efficacy in reducing Aβ burden: 
three flavanols epigallocatechin gallate (EGCG), tannic acid and a grape seed 
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polyphenol extract reduced Aβ immunoreactive deposits and EGCG additionally 
reduced thioflavin S-positive Aβ deposits, indicating reduced Aβ plaques (Rezai-
Zadeh, 2005, Rezai-Zadeh et al., 2008, Wang et al., 2008, Mori et al., 2012). This 
activity is not unique to the flavanols however, curcumin via gavage and 
intraperitoneal (IP) injection reduced plaque burden in the hippocampus and 
cortical areas (Yang et al., 2005, Garcia-Alloza et al., 2007). 
APP metabolite levels following chronic flavonoid treatment show consistent 
changes using a range of individual flavonoids and different methodologies. 
Reductions in soluble A levels were evident following sixty-day and four-month IP 
injection with EGCG and nobiletin respectively, following ten months of curcumin 
and myricetin via gavage and following five months of monomeric catechins in 
drinking water (Rezai-Zadeh, 2005, Onozuka et al., 2008, Hamaguchi et al., 2009, 
Wang et al., 2012). Additionally, EGCG and a Cabernet Sauvignon extract increased 
sAPP levels following chronic IP injection and oral delivery in aged Tg2576 mice 
respectively (Rezai-Zadeh, 2005, Wang et al., 2006, Rezai-Zadeh et al., 2008). 
AD is characterised by the gradual deterioration of mental faculties. Most of the 
epidemiological evidence for flavonoid efficacy was based on cognitive test score 
comparisons. Therefore, several in vivo studies of flavonoids have focussed on their 
proposed ability to affect memory. In wild type (WT) mice, chronic (-) epicatechin 
treatment via gavage and in drinking water improved latency in the standard MWM 
test of spatial memory (van Praag et al., 2007). Further studies have been carried 
out on an AD background. Monomeric grapeseed polyphenols (main constituent (-) 
epicatechin), and a grape seed polyphenolic extract (GSPE) reduced latency in 
female Tg2576 mice in the MWM test (Wang et al., 2008, Wang et al., 2012). Green 
tea catechins reduced errors in the radial maze, a test of working and reference 
memory, following cerebral Aβ injections in Wistar rats (Haque et al., 2006, Haque 
et al., 2008). Cabernet Sauvignon treatment led to reduced latency of escape in 
Tg2576 mice following training in the Barnes’ maze, a test of spatial learning and 
memory (Wang et al., 2006). 
Taken together, these in vivo studies suggest flavonoids are able to impact on brain 
Aβ pathology in a variety of models and that flavonoid treatment can lead to 
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improvements in cognitive deficits associated with AD. Despite these positive 
results, these studies did not elucidate the cellular mechanism(s) through which 
flavonoids are able to exert these effects. 
1.12.4 Mechanism of action of flavonoids 
 
It has mainly been through in vitro studies that clues as to the underlying 
mechanism of action of flavonoids have been discovered. The findings of these 
segregate into several distinct biological processes: actions as antioxidant 
molecules, interactions with APP and its processing machinery and interactions with 
neural signalling pathways. The specific mechanisms through which flavonoids may 
affect risk, delay onset or slow progression of AD have been particularly intensively 
examined.  
1.12.4.1 Flavonoids as antioxidant molecules and AD risk 
 
Due to their chemical structure, initially flavonoids were predicted to act as 
antioxidants. Oxidative stress is defined as a disturbance between the pro-oxidant 
and antioxidant systems in favour of the former (Ben Mahdi et al., 2000). Pro-
oxidant systems, particularly ATP generation in the brain, give rise reactive oxygen 
species (ROS) including superoxide, hydroxyl radicals and hydrogen peroxide (H2O2). 
These are neutralised by antioxidant enzymes such as superoxide dismustase (SOD-
1), heme oxygenase-1 (HO-1), catalase and glutathione, maintaining the redox state 
of the cell (Petersen et al., 2007). 
The CNS is particularly vulnerable to oxidative stress due to its high oxygen 
consumption rate, high lipid content, and the relatively low levels of endogenous 
antioxidant enzymes compared to other tissues (Markesbery, 1997). AD brains 
exhibit evidence of increased oxidative stress including increased lipid peroxidation, 
increased protein and DNA oxidation, increased levels of advanced glycation end 
products (AGE) and increased iron levels (Smith et al., 2000, Wang et al., 2013). The 
pathology of AD is increasingly being associated with oxidative stress, such as the 
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presence of glycated proteins in amyloid plaques, and evidence suggesting A 
oligomers generate H2O2 and hydroxyl radicals (Kapogiannis and Mattson, 2011). 
These findings implicate the use of antioxidants as a potential treatment strategy. 
Flavonoids have been proposed to act as antioxidants through several mechanisms, 
as reducing agents, hydrogen donating antioxidants or as singlet oxygen quenchers 
(Rice-Evans et al., 1996) (Figure 1.10(A)). Studies measuring their antioxidant 
capacity have shown them to be more effective per mole than the traditional 
antioxidants such as ascorbate (Rice-Evans et al., 1996, Pietta, 2000). The rate of 
reaction of flavonoids with free radicals and the subsequent stability of the reduced 
free radical and flavonoid radical also provides a strong basis for them to act as 
antioxidants in vivo (Bors et al., 1990). The structural basis of the flavonoids’ 
antioxidant effects were dissected and highlighted the hydroxyl groups on the B 
ring as the most significant determinant of scavenging ability (Heim et al., 2002). 
These increase delocalisation of electrons in the phenol ring, allowing greater 
stability of the flavonoid radical and therefore greater hydrogen donating 
capabilities. The double bond at the 2, 3 position in concert with the 4-one 
functional group and the 3’ and 5 hydroxyl of the A and C rings are also required for 
maximal scavenging potential. The 2, 3 double bond is thought to be especially 
critical for the lipid peroxidation inhibition activities of flavonoids (Rice-Evans et al., 
1996).  
However, following ingestion flavonoids are heavily metabolised in the liver and 
small intestine, often methylated and glucuronidated. Additionally, glycosides are 
often the natural forms of flavonoids found in the human diet (RiceEvans and 
Miller, 1997). These additional groups create steric hindrance and alter the 
planarity of the molecule, reducing the antioxidant capacity significantly. Therefore, 
orally administered flavonoids probably only serve as antioxidants in the 
gastrointestinal tract (Jovanovic et al., 1998) Availability studies have also shown 
that levels of flavonoids entering the brain are in the nanomolar range(van Praag et 
al., 2007, Wang et al., 2012). The high concentrations required to have an additive 
effect over endogenous brain antioxidants, makes it is unlikely that this is their 
mechanism of action.  
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Figure 1.10: Potential mechanisms of flavonoid-mediated effects in AD 
(A) Flavonoids as antioxidants. Due to their structure, in vitro, flavonoids can act as hydrogen donators, singlet oxygen quenchers 
and as reducing agents. (B) Flavonoid modulation of Aβ pathology. They can increase α-secretase activity or inhibit β secretase 
activity. They can alter the aggregation of Aβ into less toxic structures or inhibit fibrillisation. They can enhance Aβ clearance 
through improved blood flow. (C) Flavonoid modulation of neuronal signalling pathways involved in cell survival and cognitive 
performance.  Flavonoids activate the ERK-CREB and PI3K-mTOR pathways leading to changes in LTP and cognitive performance. 




1.12.4.2 Flavonoids as APP metabolism modulators 
 
Another possible mechanism that has been investigated is through direct 
interaction of flavonoids with APP, its metabolites and proteolytic machinery. 
Flavonoids from across the families are effective at reducing A levels (Rezai-Zadeh, 
2005, Obregon et al., 2006, Wang et al., 2006, Lin et al., 2009, Ho et al., 2013). 
Flavonoids have been shown to achieve this through different mechanisms (Figure 
1.10(B)). EGCG was shown to increase sAPPα production (Giunta et al., 2010) 
through maturation of the  secretase enzyme ADAM10 via PKC phosphorylation 
(Levites et al., 2003, Obregon et al., 2006) possibly through estrogen receptor 
ER) activation (Fernandez et al., 2010). This favoured non-amyloidogenic 
processing and precluded formation of A Treatment of Tg2576 primary neurons 
with Cabernet Sauvignon, which has a high flavanol content and treatment with (-) 
epicatechin, showed reduced A production were also due to increased non-
amyloidogenic metabolite production (Rezai-Zadeh, 2005, Wang et al., 2006).  
The  secretase enzyme BACE1 has also been identified as a potential site of 
interaction, select flavones and flavonols are able to reduce BACE1 activity in 
primary neurons, and in silico docking studies predict catalytic domain binding sites 
(Shimmyo et al., 2008b). Furthermore, A-induced BACE1 up-regulation can be 
attenuated by EGCG and curcumin treatment (Shimmyo et al., 2008a).  
Although the production of A from APP is central to AD pathogenesis, it is the 
oligomerisation and fibrillogenesis of these peptides that is thought to confer the 
associated neurotoxic effect (Walsh and Selkoe, 2007). Studies show that flavonoids 
are capable of reducing production of high molecular weight A oligomers and 
fibrillogenesis (Ono et al., 2003, Ehrnhoefer et al., 2008, Wang et al., 2008, Ho et al., 
2013). However, all of these studies were conducted with synthetic A peptides 
mixed with micromolar concentrations of flavonoid, and so although promising 
observations, the biological relevance of these interactions remains to be explored. 
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1.12.4.3 Flavonoids as cell signalling modulators 
 
Away from direct effects on APP metabolism, flavonoids are also thought to be 
neuroprotective through activation of pro-survival pathways. Active MAPK 
pathways act as modulators for neuronal survival, regeneration and death. 
Activation of the ERK pathway has generally been associated with cell survival 
(Schroeter et al., 2002). Nanomolar concentrations of flavonoids, in particular 
flavanols, activate the ERK pathway through phosphorylation of ERK1/2 (Schroeter 
et al., 2001, Vauzour et al., 2007, Rainey-Smith et al., 2008) in a mitogen activated 
ERK kinase (MEK) dependent manner (Schroeter et al., 2007), possibly through 
activation of cell surface tyrosine receptors such as tropomyosin receptor kinase B 
(TrkB) (Jang et al., 2010). This results in downstream phosphorylation of CREB 
(Maher et al., 2006, Ho et al., 2013) which can then lead to up-regulation of 
signalling pathway genes such as those associated with increased basal synaptic 
transmission (Schroeter et al., 2007, Wang et al., 2012). This then leads to 
improvements in cognition such as the significant improvement in object 
recognition test seen with oral fisetin treatment in mouse (Maher et al., 2006) 
(Figure 1.10(C)).  
PI3K has been implicated in synaptic plasticity and as a mediator of the oxidative 
stress response (Schroeter et al., 2002), making it a central decision maker between 
neuronal survival and cell death (Figure 1.10(C)). Studies suggest these key 
decisions can be influenced by select flavonoids. Most compellingly, one of the 
most specific PI3K inhibitors, LY294002, is based on the chemical structure of the 
flavone quercetin, predicted to interact directly with the ATP binding domain of the 
kinase (Vlahos et al., 1994). Epicatechin-mediated up-regulation of glutathione has 
also been shown to be PI3K dependent (Bahia et al., 2008). Many of the flavonoid-
dependent effects mediated by ERK also have a PI3K/pAkt component. Hesperetin 
has been shown to have anti-apoptotic effects following H2O2 exposure, and this is 
mediated by phosphorylation of Akt and ERK leading to increased bcl-2-associated 
death promoter protein (BAD) phosphorylation (Vauzour et al., 2007).  
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Finally, the nuclear pool of mammalian abelson murine leukaemia viral oncogene 
homolog protein (c-Abl) has been implicated in neuronal cell death and is enhanced 
in Swedish mutant APP (APPswe) overexpressing cell lines. Nuclear levels of c-Abl 
were modulated by the flavanol EGCG, which attenuated increased APPswe 
expression and prevented binding of the normal APP nuclear trafficking partner, 
Fe65, thus enhancing neuronal survival (Lin et al., 2009). 
A wide range of mechanisms have been proposed for how flavonoids exert their 
beneficial effects and it may be that they are not mutually exclusive. Flavonoids 
may be able to mediate a number of different effects in a single cell. They may 
impact on general cell health through survival signalling pathways, and in parallel 




1.13 Hypothesis and Aims 
 
The hypothesis of this thesis was that flavonoids would inhibit amyloidogenic APP 
processing in primary cortical neurons. 
 
To investigate this hypothesis, a number of specific aims were defined: 
 
To characterise the APP-Gal4 assay as a measure of amyloidogenic APP processing 
in primary neurons. 
 
To screen a library of flavonoids for inhibitory actions on APP processing in primary 
neurons. 
 
To define the underlying cellular mechanisms through which effective flavonoids 














All bench chemicals were analytical grade, purchased from Sigma-Aldrich (Poole, 
UK), Fisher Scientific (Loughborough, UK) or VWR (Lutterworth, UK). Cell culture 
reagents were purchased from Invitrogen (Paisley, UK). Aβx-40 ELISA kits (Cat No. 
SIG-38954) were purchased from Covance (Princeton, USA). pFR-luciferase and TK-
Renilla plasmids used in luciferase assays were purchased from Promega 
(Southampton, UK).  
2.1.1. Compounds 
 
Flavonoids were purchased from Extrasynthese (Genay Cedex, France). N-[n-(3, 5-
difluorophenactetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester (DAPT), PD184352, 
UO126, NMDA and (s) - α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) were purchased from Tocris (Bristol, UK). TAPI-1 was purchased from Enzo 
Life Sciences (Exeter, UK). Amyloid Precursor Protein β-Secretase Inhibitor (BsI) and 
β-secretase Inhibitor IV (BiV) were purchased from Calbiochem (Merck Chemicals, 
Nottingham, UK). Complete Protease Inhibitor Cocktail tablets and PhosSTOP 
Phosphatase Inhibitor Cocktail tablets were purchased from Roche Applied Science 
(Burgess Hill, UK). Recombinant human BDNF was purchased from Peprotech 
(London, UK). 4', 6-diamidino-2-phenylindole (DAPI) was purchased from Invitrogen 
(Paisley, UK).TAPI, DAPT, BsI and BIV were made up as 1000x concentrated stocks in 
DMSO. Flavonoids were made up as 10 mM stocks in methanol. All other 
compounds were made up as 1000x concentrated stocks in ultrapure water. (See 
















Treatment Details Source Stock concentration Solvent Diluent Extra information 
NMDA Selective NMDA agonist Tocris 10 mM dH2O N/A Added directly to 
culture medium 
(s)-AMPA Selective AMPA agonist Tocris 10 mM dH2O N/A Added directly to 
culture medium 
UO126 Selective, non-
competitive inhibitor of 
MEK1/2 
Tocris 10 mM DMSO N/A Added directly to 
culture medium 
PD184352 Selective, non-
competitive inhibitor of 
MEK1/2 
Tocris 2 mM DMSO N/A Added directly to 
culture medium 
BDNF Recombinant human 
BDNF 
Peprotech 50 μg/mL dH2O dH2O Diluted to 100x 
required. 
Added directly to 
culture medium 
Flavonoids Analytical grade plant 
derived compounds (≥ 
99% purity) 













Table 2.2: Secretase enzyme modulators 
Treatment Details Source Stock concentration Solvent Diluent Extra information 
TAPI Metalloproteinase 
inhibitor 
Enzo life sciences 50 mM DMSO N/A Added directly to 
culture medium 
BsI BACE1 inhibitor Calbiochem 10 mM DMSO N/A Added directly to 
culture medium 
BiV BACE1 inhibitor Calbiochem 10 mM DMSO N/A Added directly to 
culture medium 






ERK1/ERK2 (p42/44, T202/Y204) rabbit polyclonal antibody was purchased from Cell 
Signalling Technology (Massachusetts, USA). ERK2 (C14) rabbit polyclonal antibody 
was purchased from Santa Cruz Biotechnology (California, USA).  MAP2 rabbit 
polyclonal antibody, ADAM10 (735-749) rabbit polyclonal and APP (22C11) mouse 
monoclonal antibody were purchased from Millipore Bioscience Research Reagents 
(California, USA). Tau mouse monoclonal antibody was purchased from Chemicon 
(Merck Millipore, California, USA). β-tubulin III mouse monoclonal antibody, β actin 
(AC-74) mouse monoclonal antibody and BACE1 (2C13) mouse monoclonal antibody 
were purchased from Sigma (Poole, UK). sAPPα (5G11) rat monoclonal antibody, 
specific for murine sAPPα in culture media, generated by immunisation against 
DAEFGHDSGFEVRHQKC-COOH peptide; sAPPα 14D6, specific for human sAPPα in 
culture media, generated by immunization against CYEVHHQ-COOH peptide; sAPPβ 
(192WT) rabbit polyclonal, specific for sAPPβ in culture media (all provided by S. 
Lichtenthaler).  
2.1.3. Plasmids and Viruses 
 
pRC-CMV-APP695-Gal4 and pRC-CMV-APP695-Gal4Δ were as described previously 
(Hoey et al., 2009). pRC-CMV vector containing a cDNA encoding for the Swedish 
familial mutation of human APP695 fused in-frame at its C-terminus to the Gal4 
yeast transcription factor was created using pRC-APP695-Gal4 plasmid (see Appendix 
1) and introduction of a double point mutation at positions K595N/M596L of APP695 
using the QuikChange XL Site-Directed Mutagenesis kit according to the 
manufacturer’s instructions (Stratagene). pFR-Luciferase reporter vector with Firefly 
(Photinus pyralis) luciferase gene under the control of a synthetic promoter 
containing 5 tandem repeats of the yeast Gal4 upstream activation sequence (UAS) 
upstream of a minimal TATA box and phRL thymidine kinase (TK) vector containing 
sea pansy (Renilla reniformis) luciferase gene under control of the herpes simplex 
virus (HSV)–TK promoter, from Promega. pC1-CMV vector containing cDNA 
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encoding human Fe65 has been described previously (Perkinton et al., 2004). 
pSecTag2 vector containing cDNA encoding for human notch3 fused in frame at its 
C terminus to the yeast transcription factor Gal4 was kindly provided by Dr Michael 
Perkinton (King’s College, London) (see Appendix 2). The adenovirus vector Ad5-
Egr1-Luciferase containing cDNA for luciferase under the control of the murine Egr1 
promoter was kindly provided by Dr C. Caunt. (Department of Biology and 
Biochemistry, University of Bath, Bath, UK). This was generated by subcloning an 
Egr-1 promoter Sal1 fragment into an Xho1 digest of pAd5-luciferase.  Viral 
generation from this shuttle vector has been previously described (Caunt et al., 
2008) (see Appendix 3). 
2.1.3.1. Large Scale Plasmid Purification 
 
QIAgen Hi Speed Maxi kits were used according to the manufacturer’s instructions. 
Bacterial glycerol stocks were cultured over day in 5 ml Luria-Bertani (LB) broth, 250 
μL were then transferred to 250 mL LB and cultured overnight. The culture was 
pelleted (6000x g for 15 minutes at 4oC) and completely resuspended by pipetting. 
Cells were then lysed and filtered using QIAfilter Maxi Cartridge. Cell supernatant 
was washed, eluted and precipitated in isopropanol (0.7 x volumes). The 
eluate/isopropanol mixture was passed through a QIAprecipitator, collecting the 
DNA. DNA was washed with 70% ethanol and eluted with UltraPure water 





2.2.1. Primary neuronal culture  
 
Nunc tissue culture plates of appropriate size for experimental design were coated 
overnight with 20 μg/mL poly-D-lysine (Sigma) dissolved in tissue culture standard 
water (Gibco, Invitrogen). Plates were then washed with 1/2 well volume tissue 
culture standard water, 1x PBS, then Neurobasal wash media (Phenol Red free 
Neurobasal, 60 μg/mL Penicillin, 100 μg/mL Streptomycin, 2 mM L-glutamine, 10% 
foetal calf serum (Invitrogen). 
CD1 or C57/BL6 pregnant mice were sacrificed by cervical dislocation at gestation 
day 15-16. Embryos were removed and placed in PBS (Ca2+ and Mg2+ free PBS, 
Invitrogen). Embryos were kept in PBS throughout the dissection. Embryonic 
cortices were dissected, striatal regions and meninges removed. 
Cortices were mechanically dissociated using a fire polished glass pipette pre-
coated with heat inactivated foetal calf serum. The homogeneous cell suspension 
was centrifuged at 500xg for 5 min at RT. The resultant pellet was resuspended in 
Neurobasal media (Phenol Red free Neurobasal, 60 μg/mL Penicillin, 100 μg/mL 
Streptomycin, 2 mM L-glutamine (Invitrogen)) and plated out at required densities 
for experimental design, stated in individual methodologies. Neurons were 
incubated at 37oC in a humidified atmosphere (95% air and 5% CO2), and were used 
between 5 and 10 days in vitro (DIV). 
2.2.2. Cell culture  
 
HEK293T cells were cultured in 10% FCS, 60 μg/mL penicillin, 100 μg/mL 
streptomycin supplemented Dulbecco’s modified Eagle’s medium (DMEM) 
Glutamax High glucose (Gibco). SH-SY5Y cells were cultured in 15% FCS, 60 μg/mL 
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penicillin, 100 μg/mL streptomycin and non-essential amino acids (NAA, Gibco) 
supplemented F12/DMEM (Gibco). Cells were incubated at 37oC in a humidified 
atmosphere (95% air and 5% CO2). 
2.2.3. Dual-Glo Luciferase reporter gene assay 
2.2.3.1. Plasmid transfection 
 
Details of all the plasmids can be found in Section 2.1.3 Plasmids and Viruses. 0.5 g 
each of pFR-luciferase and pRL-TKRenilla as well as pRC-APP-Gal4, pRC-APP-Gal4Δ 
or pRC-APPswe-Gal4 were transfected into primary cortical neurons at 5 DIV in 12 
well plates (3.3 x 105 cells per well) using 1 l/well Lipofectamine 2000 (Invitrogen). 
The DNA and Lipofectamine were first prepared separately in Opti MEM reduced 
serum media (75 μL per well) (Invitrogen). These were then combined in 1:1 ratio 
and incubated at RT for 25 min. 150 l per well of the DNA/Lipofectamine mix was 
added to 12 well plates; the neurons were then placed at 37oC to allow transfection 
to take place. 
2.2.3.2. Treatments and assay 
 
Treatments were carried out as detailed in Figure legends. 24 h after transfection 
(unless otherwise stated), the cells were lysed using 100 l 1x Glo lysis buffer and 
incubated at RT whilst rocking for 15 min. Firefly luciferase and Renilla luciferase 
expression was then quantified utilising the Promega Dual Glo luciferase assay kit 
according to the manufacturer’s instructions. Briefly, lysed cells were transferred to 
a 96 well microplate and 100 μL of 1x Dual Glo substrate was added, the plate was 
incubated in the dark for 10 min at RT followed by measurement of the first set of 
readings detected by a luminometer. The plate was then removed and 100 μL of the 
second Stop and Glo reagent, which quenches the first signal and activates the 
Renilla luciferase signal was added and incubated in the dark for 10 min at RT and 
detected by a luminometer. The luciferase signals were measured using a FluorBMG 
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microplate luminometer. The Firefly signals were normalised as a ratio of the 
Renilla constitutive readings. 
2.2.4. Site-directed mutagenesis of pRC-APP-Gal4 
plasmid 
2.2.4.1. Primer design 
 
Mutagenic oligonucleotide primers were designed according to the manufacturer’s 
guidelines. These guidelines included both forward and reverse primers annealing 
to the same sequence on opposite strands of the plasmid; primers of between 25 
and 45 base pairs in length, melting temperature (Tm) ≥78
oC; desired mutation(s) 
located in the centre of primer sequence with 10-15 bases of correct sequence each 
side; a minimum GC content of 40% and terminal C or G bases. Two complimentary 
oligonucleotides were synthesised containing the desired double point mutation, 
flanked by unmodified nucleotide sequence (see Table 2.3). 
2.2.4.2. Site direct mutagenesis 
 
Mutant strand synthesis control and sample reactions were prepared according to 
manufacturer’s instructions (QuikChange II XL site-directed mutagenesis kit, Agilent 
Technologies, La Jolla, USA) in thin-walled PCR tubes (SLS, Hessle, UK). Each reaction 
was then placed in the thermocycler and cycled according to the cycling parameters 
in Table 2.4. Following amplification, the amplification products were digested with 
1 μL/reaction Dpn1 restriction enzyme (10U/ μL) added directly to the amplication 
reaction. The mixture was then briefly centrifuged at maximum speed and 
immediately incubated at 37oC for at least 1h to digest the parental plasmid DNA. 




XL10-Gold Ultracompetent cells were gently thawed on ice and 45 μL aliquots 
transferred to pre-chilled 14 mL BD Falcon polypropylene round bottom tubes. 2 μL 
of β-mercaptoethanol mix was added to each tube and the contents swirled gently, 
then incubated on ice for 10 min, swirling every 2 min. TopTen Chemically 
competent cells were gently thawed on ice (Invitrogen, Paisley, UK). 2 μL of the Dpn 
1-treated control and sample reactions were transferred to separate aliquots of 
competent cells, gently mixed and incubated on ice for 30 min. Competent cell 
mixtures were then heat shocked for 45 seconds at 42oC and transferred back to ice 
for 2 min. 250 μL of SOC media was added to each transformation tube and 
incubated at 37oC for 1h. 200 μL transformation media was then plated onto LB 
agar + ampicillin (50 μg/mL) plates and plates were incubated at 37oC for more than 
16h. 
2.2.4.4. Plasmid DNA purification 
 
QIAprep spin miniprep kits were used according to manufacturer’s instructions. 
Single colonies were picked into 5 mL LB + ampicillin (50 μg/mL) and incubated at 
37oC on a shaker O/N. The culture was pelleted (6800x g for 3 min at RT) and 
completely resuspended by pipetting. Cells were lysed and filtered using a QIAprep 
spin column. Cell supernatant was washed and eluted in RNase free distilled water. 
DNA quantified by Nanodrop spectrophotometer. 
2.2.4.5. Agarose gel electrophoresis 
 
5x loading buffer was added to purified DNA preparations (final concentration 5% 
glycerol, 0.042% xylene cyanol, 0.042% bromophenol blue).  0.8 % agarose was 
heated in TBE buffer (90mM Tris Base pH 8, 90mM Boric acid, 2mM EDTA) and 
0.1µl/ml CYBRTM Safe, added before the gel was poured and set.  The gel was 
covered in TBE buffer and DNA preparations were electrophoresed: 20µl of sample 
was added to each well, and run at 90mV for 45 min. 1 kb DNA ladder, with a 
separation range of 500 – 10000 kbp (New England BIolabs, Ipswich, USA) was 
added to enable the calculation of fragment size.  Plasmid DNA was visualised by 
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staining under UV transillumination.  The size of the plasmid was determined from 
the known size of the ladder markers. 
2.2.4.6. Restriction enzyme digestion 
 
1 unit of Not1 (New England Biolabs) was incubated with plasmid DNA (1μg) and 1x 
NEB buffer 3.1 in a 50 μL reaction made up with endonuclease free water for 60 min 
at 37oC. 
2.2.4.7.  Plasmid sequencing 
Potential mutant DNA samples were sent for sequencing at Source Bioscience. 
Samples were provided as 100 ng/μL pure DNA preparations. Primers used to 
confirm mutagenesis of pRC-APP-Gal4 were: 5’-ACTTACCTCTCAAGTCGGACC-3’ 
(forward primer) and 5’-TCGTAGTGGTTCCACTACTGC-3’ (reverse primer). Freeware 
lalign was utilised to align sequence to template sequence of WT APP. 
2.2.5. Immunofluorescence  
2.2.5.1. Immunostaining 
 
Primary neurons at 5 DIV (plated at 3.3 x 105 cells per well), cultured on 13 mm 
glass coverslips (SLS, Hessle, UK) were washed 1x cold PBS and fixed at RT in PBS, pH 
7.4, containing 4% paraformaldehyde for 20 min. The cells were then washed with 
PBS and then incubated in blocking permeabilisation buffer (PBS, pH 7.4 containing 
5% skimmed milk powder, 0.1% triton X-100) for at least 15 min. Primary antibodies 
were applied in antibody buffer (PBS, pH 7.4, containing 1% skimmed milk powder, 
0.1% triton X-100) and incubated at RT O/N. The cells were washed 3 times for 5 
min in PBS followed by application of Alexa Fluor secondary antibodies in antibody 
buffer. DAPI was added at 600 nM in PBS (Sigma). Coverslips were mounted in 
Mowiol and allowed to set at RT O/N. (See Table 2.5 for details). 












Segment Cycles Temperature (oC) Time 
1 1 95 1 min 
2 18 95 50 sec 
60 50 sec 
68 1 min/kb plasmid* 
3 1 68 7 min 
* Control sample extension time was 5 min; reaction sample extension time was 12 
min. 
Table 2.4: PCR parameters  














APPsweFW 79.2 44 36 GAGATCTCTGAAGTGAATCTGGATGCAGAATTCCGA 
 




2.2.5.2. Image acquisition 
 
Stained cells were studied on a Zeiss LSM510 laser-scanning confocal microscope 
and images taken. LSM image examiner in ImageJ was used to analyse the images. 
2.2.6. Immunoblotting 
2.2.6.1. Sample preparation 
 
Primary cortical neurons cultured in 6 well plates (6.6 x 105 cells per well)  for 6-7 
DIV were treated, as detailed in figure legends, with treatments being added 
directly to the conditioned media. Following treatment, the media was aspirated 
and wells were washed once with cold PBS. 200 μL of 1x SDS-PAGE Laemmli sample 
buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol and 
0.0025% Bromophenol blue, 1x Complete protease inhibitor cocktail and 1x 
Complete phosphatase inhibitor cocktail) was added to each well. Wells were then 
scraped and cellular material transferred to fresh microcentrifuge tubes. These 
were then centrifuged (2000xg for 5 min) and the supernatant transferred to a new 
microcentrifuge tube, which was then boiled (100oC for 5 min), cooled and placed in 
-20oC freezer. 
For conditioned media samples, media was collected in separate microcentrifuge 
tubes, incubated on ice for 10 min, and centrifuged (13,000 rpm for 5 min). 120 μL 
media sample transferred to a new microcentrifuge tube and 40 μL 1x SDS-PAGE 










Table 2.5: Primary and secondary antibodies used for immunofluorescence 
Primary antibody Source Details Concentration Secondary 
antibody 
Concentration 
Tau Chemicon Axonal marker Mouse monoclonal 1:500 Goat anti- mouse 
Alexa Fluor 568 
1:1000 
MAP2 Millipore Dendritic marker Rabbit polyclonal 1:1000 Goat anti-rabbit 




2.2.6.2. Tris-Glycine SDSPAGE 
 
8% polyacrylamide Tris-Glycine resolving gels were prepared (0.375 M Tris-HCl, 
0.1% SDS, pH 8.8, 8% acrylamide, 0.5 mg/mL ammonium persulphate (APS), 0.06% 
TEMED). A clean interface was ensured by overlay of 100% isopropanol whilst the 
gel set. Resolving gel was overlaid with 4% stacking gel (0.125 M Tris-HCl, 0.1% SDS, 
pH 6.8, 4% acrylamide, 0.5 mg/mL APS, 0.06% TEMED). Tris-Glycine gels were run in 
1x Tris-Glycine SDS-PAGE running buffer (0.025M Tris, 0.192 M glycine, 0.1% SDS, 
pH 8.6, National Diagnostics). Prepared samples were loaded into the gel with a 
molecular weight marker (SeeBlue Plus marker, Invitrogen) adjacent and run at 90V 
until bands exit the stacking gel and then 120-130V for approximately 1h in a Bio-
Rad mini-PROTEAN Tetra cell. 
2.2.6.3. Western Blotting  
 
Filter papers were pre-soaked in blotting buffer (0.025M Tris, 0.192 M glycine, 0.1% 
SDS, pH 8.6, 20% methanol). Nitrocellulose membranes (0.45 μm, GE Healthcare) 
were pre-soaked in distilled water. Following completion of the electrophoresis, 
gels removed from cassette and stacking gel removed.  
Semidry transfer: Gels were stacked with 4 filter papers, nitrocellulose membrane, 
gel section and 4 filter papers onto the blotting surface. Proteins were transferred 
from the gel to the membrane using constant amperes (1.5 mA/cm2) for 1h.  
Wet transfer: Gel were equilibrated in blotting buffer then stacked into blotting 
cassette with sponge, 2 filters, gel, membrane, 2 filters, and sponge. The cassette 
was then placed in the blotting apparatus and filled with blotting buffer.  Proteins 
were transferred from the gel onto the membrane using constant amperes (0.4A for 
1h 05).  
Following completion of transfer, membranes were washed 1 x 5 min TBS-T (0.02 M 
Tris, pH 7.5, 0.1% Tween-20, 0.150 M NaCl). Membranes were then blocked in 5% 
milk blocking solution (5% milk powder in TBS-T) for 30 min after which membranes 
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were washed 1x 5 min TBS-T and incubated with primary antibody in antibody 
buffer (1% milk powder in TBS-T) O/N at 4oC on a rocker (See Table 2.6 for details). 
2.2.6.4. Protein detection 
 
Following appropriate primary antibody incubation, membranes were washed 2 x 5 
min in TBS-T. Complimentary secondary antibodies conjugated to horseradish 
peroxidase (HRP) were then applied in antibody buffer for 45 min at RT on a rocker. 
(See Table 2.6 for details). Membranes were then washed 2 x 5 min with TBS-T and 
1 x 5 min with TBS (0.02 M Tris, pH 7.5, 0.150 M NaCl). Following the final wash, 
excess fluid on the membrane was blotted away and the membrane placed flat on a 
clean surface. The required volume of ECL detection fluid was made up and applied 
to the membrane for 1 min. Excess fluid was once again blotted away and the 
membrane placed in a Fusion SL Chemiluminescence system to be visualised.  
Membranes from the wet method of western blotting were placed in an 
autoradiography film cassette and hyperfilm autoradiography films (GE Healthcare) 
were exposed to the membranes in the dark for varying lengths of time. They were 
then placed in a Fuji LAS 4000 X-ray processor to be developed.  
2.2.7. Mouse Aβ1-40 ELISA 
 
Colorimetric BetaMark x-40 Aβ ELISA was performed according to manufacturer’s 
instructions (Covance, Princeton, USA). Prepared standard samples (100 μL) were 
prepared and applied to the 96 well capture antibody coated plate in duplicate. 
Experimental samples diluted 1:2 with dilution buffer (100 μL) were applied in 
triplicate, covered and incubated O/N at 4oC. The next day, the plate was washed 
five times with wash buffer and then 200 μL/well substrate was applied and 





Table 2.6: Primary and secondary antibodies used for immunoblotting 
Primary 
antibody 
Source Details Concentration Secondary antibody Concentration 
p44/42 p-MAPK Cell signalling pThr202/p-Tyr204 (pERK) Rabbit polyclonal 1:2000 Goat-anti-rabbit 
HRP 
1:5000 
ERK2 Santa Cruz 
Biotechnology 
C-14 Rabbit polyclonal 1:5000 Goat-anti-rabbit 
HRP 
1:5000 
ADAM10 Millipore 735-749 Rabbit polyclonal 1:2000 Goat-anti-rabbit 
HRP 
1:5000 
BACE1 Sigma 2C13 Mouse monoclonal 1:2000 Goat-anti-mouse 
HRP 
1:5000 
APP Millipore 22C11 Rabbit polyclonal 1:5000 Goat-anti-rabbit 
HRP 
1:5000 
sAPPα Kind gift of SFL 5G11 
specific for murine sAPPα 
Rat monoclonal 
supernatant 
1:9 Goat-anti-rat HRP 1:5000 
sAPPα Kind gift of SFL 14D6 
specific for human sAPPα 
Rat monoclonal 
supernatant 
1:9 Goat-anti-rat HRP 1:5000 
sAPPβ Kind gift of SFL 192WT Rabbit polyclonal 1:100 Goat-anti-rabbit 
HRP 
1:5000 
β-tubulin Sigma Anti Tuj1 441-450 amino 
acids of β-III tubulin 
Mouse monoclonal 1:25,000 Goat-anti-mouse 
HRP 
1:5000 





2.2.8. BACE1 activity detection 
 
The cell free BACE1 activity assay is based on fluorescence resonance energy 
transfer (FRET) in which a fluorescent signal is observed following substrate 
cleavage by BACE1. The BACE1 activity detection assay was performed according to 
manufacturer’s instructions (Sigma, Missouri, USA). Assay components were mixed 
to a final volume of 100 µL in a black 96 well microplate. Test samples were 
incubated with inhibitors or flavonoid compounds as indicated in figure legends. 
Fluorescence readings (excitation 320 nm, emission 405 nm) were taken at time 
zero and then incubated at 37oC for 2h and the fluorescence levels measured again 
using a Molecular Devices VERSAmax microplate reader. Stop solution was then 
added to stabilise the signal for 24h.  
In order to measure endogenous BACE1 activity levels in primary cortical cultures in 
12 well plates 3.3 x 105 cells per well)  for 6 DIV were treated, as detailed in figure 
legends, with treatments being added directly to the conditioned media. Following 
treatment, the media was aspirated and wells were washed once with cold PBS. 
200 μL of CelLytic M (Sigma, Missouri, USA) was added to each well. Wells were 
then scraped and cellular material transferred to fresh microcentrifuge tubes. 
These were then centrifuged (2000xg for 5 min) and the supernatant transferred to 
a new microcentrifuge tube. 30 µL  cell lysates were then incubated with synthetic 
BACE1 substrate and fluorescent levels measured as per the cell free assay 
protocol. 
2.2.9. Phase contrast microscopy 
 
Morphological assessment of neuronal viability and phenotype was made by phase 
contrast microscopy. Images were captured with a Nikon E5000 digital camera 
using a NikonEclipse TS100 inverted microscope. 
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2.2.10. Viral transduction 
 
Details of pAd5-Egr1 can be found in Section 2.1.3: Plasmids and viruses and 
Appendix 3. 1x105 plaque forming units (pfu)/mL Ad5-Egr1-luciferase was 
transduced into primary cortical neurons at 6 DIV in 24 well plates (6.6x105 cells per 
well). Briefly, conditioned media was removed from the neurons and ½ volume 
fresh media containing viral dilution was added to the cells and incubated at 37oC 
for 4h. Media was then removed and 1x volume original conditioned media 
replaced onto the neurons. Neurons were then treated as detailed in figure 
legends. 24h post transduction, media was removed from the cells and 50 μL 1x Glo 
lysis buffer was added and incubated at RT whilst rocking for 15 min. Lysed cells 
were transferred to a white 96 well plate and 50 μL 1x Dual Glo substrate was 
added, the plate was incubated in the dark for 10 min at RT followed by 
measurement using a FluorBMG microplate luminometer. 
2.2.11.  Quantification and Statistics 
 
Immunoblot ECL bands captured using the Fusion SL Chemiluminescence system 
were quantified using FUSION-CAPT analysis software (Peqlab). Immunoblot 
Hyperfilm ECL bands were quantified by scanning into NIH Image J software at a 
resolution of 1200 dots per inch (dpi) using an Epson Perfection V700 Photo flatbed 
scanner, and the mean background corrected optical density (OD) of each band was 
interpolated from an OD calibration curve created using an OD step tablet. Mean 
data ± S.E.M. were graphed using Graph Pad Prism 6 software. APP-Gal4 luciferase 
assay, immunoblot, viral transduction and Aβ ELISA data were analysed by one-way 
ANOVA with Bonferroni post-test, two-way ANOVA with Bonferroni post-test or 
student’s t-test, using Graph Pad Instat software. For the APP-Gal4 luciferase assay 
the minimal experimental unit (n=1) was defined as a single independent 
transfection. Differences between treatments and conditions were considered to 





3. Characterisation and validation 






3.1.1 Use of primary cortical cultures to study APP 
processing 
 
Much of what we currently understand about APP and its metabolism has come 
from extensive characterisation studies in overexpressing cell lines. Whilst these 
studies have provided critical new insight into the underlying biochemistry of APP 
processing, they are much more limited for studying the physiology of APP and the 
modulation of APP proteolytic pathways. This is chiefly down to a lack of key 
phenotypic features of mature mammalian neuronal networks. This includes 
neuronal specific cellular architecture such as synapses, associated specialised 
protein expression such as at the post synaptic density (PSD) and spontaneous 
action potentials. Primary neurons have provided a crucial model in which detailed 
elucidation of APP processing regulation has been performed. Due to their faithful 
representation of neurons in situ, expressing the full complement of synaptic 
proteins and containing all neuronal specific cellular compartments, they are 
currently the best model for studying physiological regulation of APP processing.  
3.1.2 Methods for functional readout of APP processing 
in primary neurons 
 
In this chapter, the characterisation and development of a cell based reporter gene 
assay in primary cortical neurons has been described. Transfection of a plasmid 
expressing full length APP695 conjugated to the yeast transcriptional factor Gal4 into 
primary cortical neurons and subsequent measurement of Gal4-dependent 
luciferase reporter gene expression, allowed analysis of changes in -secretase 
mediated APP processing. APP-Gal4 assays have been used successfully in previous 
107 
 
studies to investigate APP processing-dependent activities. Two groups have 
described different utilities for an APP-Gal4 plasmid (Cao and Sudhof, 2001, Gianni 
et al., 2003). An APP-Gal4 construct was first used to investigate the ability of APP 
to activate gene expression. Full length APP695 was fused with Gal4 either at the 
cytoplasmic boundary of the TMD of APP or at the N terminus of the protein. It was 
through this study that the tripartite complex of APP, Fe65 and Tip60 was shown to 
be transcriptionally active (Cao and Sudhof, 2001). The second study utilised a 
different fusion protein consisting of human APP695 at the N terminus and the yeast 
transcription factor Gal4 joined by six glycine residues at the C terminus (APP-Gal4). 
This was used to identify extracellular signals that induced -secretase mediated 
processing. The APP-Gal4 plasmid was used in combination with a chloramphenicol 
acetyltransferase (CAT) reporter plasmid to visualise modulation of APP processing 
(Gianni et al., 2003) and identified PDGF as an activator of amyloidogenic 
processing, providing some of the earliest evidence for tyrosine kinase receptor 
regulation of APP processing.  
The reporter assay described in this thesis, which utilises the same APP-Gal4 fusion 
protein as Gianni et al (2003), provides a functional readout of APP processing. This 
is not possible through alternative methods of APP measurement such as 
biochemical analysis of APP carboxy-terminal fragments (CTFs) or sandwich ELISA 
assays of Aβ secretion. Analysis of APP CTFs (the membrane tethered products of α-
and β-secretase cleavage), by immunoblot is a powerful technique that allows 
detailed investigation of intracellular secretase mediated changes in APP 
processing. However, this technique is technically challenging and low throughput, 
therefore unsuitable for screening studies such as that proposed for this study. 
Measurement of pathway-specific, soluble APP ectodomain and Aβ secretion in 
primary neurons, although possible through much simpler methods than CTF 
analysis, such as specific ELISA assays or standard immunoblotting, present with 
different technical problems. Analysis of changes in these products is complex due 
to the significant levels of these stable products in the culture medium as a result of 
constitutive APP processing during neuronal culture maturation. Through simple 
manipulation of culture conditions or the APP-Gal4 gene construct, this system has 
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the potential to allow regulatory effects of APP mutations, post-translational APP 
modifications or general cell metabolism manipulations, on secretase-mediated 
APP processing to be analysed.  
In order to establish whether this assay could be utilised in primary neurons to 
identify novel modulators of APP processing, it was subject to validation and known 
environmental and genetic perturbations associated with AD. These challenges will 
determine whether the assay is sensitive to known modulators of APP processing 
and therefore whether it can be used to screen for novel flavonoid modulators of -






3.2.1 Characterisation of neuronal model systems 
 
This thesis of work has been carried out almost entirely using mouse embryonic 
cortical cultures. Neuronal cells are terminally differentiated, post mitotic cells that 
have exited the cell cycle. This property of neurons has made the development of 
high quality neuronal cell lines, which accurately recapitulate the physiology and 
cell biology of neurons extremely difficult and none exist that come close to 
modelling the complexity of a functional mammalian synapse. Therefore, the use of 
primary cell cultures, although more labour intensive and technically challenging to 
prepare and manipulate are a more faithful in vitro model for studying neuronal 
function in the mammalian brain. 
To confirm that the primary cultures prepared according to methods described in 
Section 2.2.1 had a predominantly neuronal phenotype, morphological analysis of 
neuronal maturation and cellular staining of neuronal-specific structures were 
performed. This process was necessary so that results extrapolated from these 
cultures could be attributed to neuronal responses rather than other neural cell 
types. 
Mouse embryonic primary cortical cultures were stained using anti-MAP2 and anti-
tau antibodies in order to identify axons (tau) and dendrites (MAP2). The cultures 
were also counter-stained with the nucleus marker DAPI. Cells showed extensive 
dendritic extensions and well-defined axons with numerous potential synaptic 
connections along the axonal projections, consistent with neuronal morphology 
(Figure 3.1). Staining for GFAP showed less than 2% GFAP positive cells in these 
cultures (data not shown). 
Phase contrast images taken of the neurons as they matured in culture initially 
showed highly polarised cells with large cell bodies (Figure 3.2(A)). As the neuronal 







Figure 3.1: Primary cultures express neuronal markers 
(A-C) Double immunofluorescence staining of primary cultured cortical neurons at 
5DIV. Neurons were fixed and double immunostained for MAP2 and tau. (C) Image 
overlay showing complex network of tau-positive axons and MAP2-positive 
dendrites. Tau was labelled with mouse monoclonal anti-tau (1:500) (Chemicon) 
and MAP2 was labelled with rabbit polyclonal anti-MAP2 (1:1000) (Millipore). 





Figure 3.2: Primary cortical cultures develop extensive network of connections 
by 5 DIV 
(A-D) Phase contrast images of primary cultured cortical neurons as they develop 
from 3 DIV-6 DIV. (A) At 3DIV, have polarised cells with large cell bodies (*), as 
maturation continues, the number of processes increase (B and C) until at 5 DIV 
there are large, tapering axons (white arrows) with extensive dendritic networks 
which are maintained at 6 DIV (D) 
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the maturation of the culture and formation of functional synapses. Supporting the 
immunocytochemistry results, by 5 DIV single, large, tapering axons extending from 
the cell bodies can be identified along with extensive, finer dendritic networks 
confirming these cultures have a neuronal phenotype (Figure 3.2C (white arrows)). 
3.2.2 An APP-Gal4 gene reporter assay in primary 
mouse embryonic cultures 
 
Despite the many advantages of primary neurons, the major disadvantage is the 
technical difficulty of genetic manipulation in these cultures. Despite this, an APP-
Gal4 gene reporter assay has previously been described in primary neurons, which 
allowed measurement of changes in APP processing in response to exogenous 
stimuli (Hoey et al., 2009). In order to utilise this approach for the identification of 
modulators of processing, the reporter first had to be thoroughly characterised and 
revalidated because the laboratory was now using a different mouse strain, CD1 as 
opposed to C57/BL6 and NIH Swiss White as previously reported.  
The APP-Gal4 assay utilises the well-known Gal4-UAS yeast system and takes 
advantage of the fact that APP is a type 1 transmembrane protein, meaning the 
holoprotein is retained at cell membranes. The assay measures levels of transfected 
human APP695 processing in primary neurons by coupling this processing, via the 
Gal4-UAS system, to transcription of a luciferase gene. To enable this to occur, a 
number of plasmids must be chemically transfected into the primary neurons. The 
plasmid pRC-APP-Gal4, encodes full length, human APP695 with the yeast 
transcription factor Gal4 inserted in frame at its C terminus via a glycine linker, 
allowing expression of the fusion protein APP-Gal4 (Perkinton et al., 2004). 
Following -secretase mediated APP cleavage, an AICD-Gal4 fragment is released, 
which, unlike the full length protein, is free to translocate and bind to the synthetic, 
Gal4 specific, UAS promoter of a second plasmid pFR-luciferase, which encodes the 
Firefly luciferase gene. Firefly luciferase expression can then be quantified utilising a 
standard luminescence assay as described in Section 2.2.3. A third plasmid, pRL-
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TKRenilla is also transfected, which constitutively expresses the Renilla luciferase 
gene, acting as an internal control to which the Firefly luminescence values can be 
standardised (Figure 3.3). 
3.2.3 APP-Gal4 gene reporter assay signal is dependent 
on Gal4-UAS coupling 
 
Initial work investigated the dependence of the reporter assay luminescent signal 
on the coupling of the Gal4 yeast transcription factor to the UAS-containing, 
synthetic promoter of the Firefly luciferase plasmid. It was important to determine 
that the signal detected was as a result of coupling of the APP-Gal4 cleavage 
product, AICD-Gal4, to the synthetic promoter of pFR-luciferase and consequent 
Firefly luciferase expression.  
To confirm this, a mutated version of the pRC-APP-Gal4 plasmid and combinations 
of the required plasmids were transfected and assayed for resultant luciferase 
expression. The mutated version of APP-Gal4 (pRC-APP-Gal4) contained a single 
base substitution, introducing a stop codon within the yeast Gal4 gene. This 
truncated the protein within its DNA binding domain so that it could not activate 
Firefly luciferase transcription (Hoey et al., 2009).  
Transfection of primary neurons with pRC-APP-Gal4 in combination with the pFR-
luciferase and pRL-TKRenilla plasmids showed a significant decrease (42%) in 
luciferase expression compared to transfection with pRC-APP-Gal4 (Figure 3.4). Co-
transfection of the neurons with pRC-APP-Gal4 and the control plasmid pRL-
TKRenilla showed a 66% decrease in expression compared to pRC-APP-Gal4 with 
pFR-luciferase and pRL-TKRenilla (Figure 3.4). Transfection carried out with pFR-
luciferase and pRL-TKRenilla in combination and pRL-TKRenilla on its own showed 
minimal luciferase expression, more than 10 times lower than transfection with 
pRC-APP-Gal4, pFR-luciferase and pRL-TKRenilla (Figure 3.4). This confirmed that 
the majority of luciferase expression was dependent on coupling of the APP-Gal4 to 




Figure 3.3: Schematic representation of APP-Gal4 gene reporter assay for 
measurement of γ-secretase mediated APP processing 
Cleavage by -secretase of human APP695 fused to the yeast transcription factor 
Gal4 (APP-Gal4) allows release of AICD-Gal4. Free AICD-Gal4 then binds to the 
synthetic promoter of Firefly luciferase plasmid consisting of 5 UAS repeats and a 
TATA box, driving expression of reporter gene Firefly luciferase. Resultant Firefly 






Figure 3.4: Luciferase expression is dependent on transfection of functional 
APP-Gal4 
5DIV primary cultured cortical neurons were transfected with pFR-luciferase 
Firefly luciferase reporter gene plasmid alone and in combination with pRC-APP-
Gal4 or pRC-APP-Gal4Δ plasmids encoding for APP695-Gal4 and APP695Gal4 with a 
non-functional DNA binding domain. All cells were co-transfected with pRL-
TKRenilla that constitutively expresses Renilla luciferase. Dual-Glo luciferase 
activity assays were performed 24h post transfection for quantification of firefly 
and Renilla luciferase expression. Firefly luciferase reporter expression was 
normalised using the Renilla luciferase expression. Each column is the mean ± 
S.E.M. of 6 separate transfections (n=6; * p<0.05, ****p<0.0001, one way 




3.2.4 APP-Gal4 gene reporter assay preferentially 
reporters β-mediated APP processing 
 
Following confirmation of Gal4-UAS dependence of the assay, the next step was to 
investigate the dependence of the reporter assay on secretase-mediated APP 
cleavage. This was achieved using commercial inhibitors of the secretase enzymes 
responsible for APP cleavage.  
Primary neurons were treated with the γ secretase inhibitor DAPT, transfected 30 
min later and luciferase expression measured 24h post-transfection. DAPT 
treatment reduced mean luciferase expression by 74% (Figure 3.5) indicating the 
majority of luciferase expression is driven by -secretase-mediated APP cleavage. 
APP undergoes RIP, therefore initial cleavage by α- or β-secretase activities must 
occur prior to -secretase cleavage (Lichtenthaler et al., 2011). As it has been 
proposed that the amyloidogenic and non-amyloidogenic pathways exist in 
equilibrium (Colombo et al., 2012, Suh et al., 2013) and primary rodent neurons 
appear to favour a BACE1 processing route (Colombo et al., 2012, Hoey et al., 
2013), it was necessary to determine the relative contributions of the α- and β-
secretase enzyme activities to the luciferase signal. Treatment of transfected 
neurons with two structurally distinct BACE1 inhibitors, BsI (peptide inhibitor) and 
BiV (cell-permeable catalytic BACE1 inhibitor), for 24h caused 50% and 38% 
reductions in luciferase expression respectively (Figure 3.5). Conversely, treatment 
of neurons for 24h with TAPI, a broad-spectrum metalloprotease inhibitor that 
reduces α-secretase activity caused a modest 10% increase in luciferase expression 
(Figure 3.5), suggesting the assay predominantly measured BACE1-mediated, 




Figure 3.5: APP-Gal4 reporter gene assay preferentially reports βγ-secretase 
mediated APP processing in primary cortical neurons 
5DIV primary cultured cortical neurons were treated with vehicle (Control), 50 μM 
TAPI, 10 μM BsI, 10 μM BiV, or 10 μM DAPT for 30 minutes prior to co-transfection 
with pRC-APP-Gal4, pFR-luciferase and pRL-TKRenilla plasmids. Inhibitors were 
present for throughout the experiment. Dual-Glo luciferase activity assays were 
performed 24h post transfection for quantification of firefly and Renilla luciferase 
expression. Firefly luciferase reporter expression was normalised using the Renilla 
luciferase expression. Each column is the mean ± S.E.M. of 12-18 separate 
transfections (n=12-18; ** p<0.01, *** p<0.001 ****p<0.0001, one way ANOVA 




3.2.5 Fe65 enhances reporter-dependent luciferase 
expression in mouse primary cultured neurons 
 
The APP-Gal4 gene reporter assay has been confirmed as dependent upon the AICD 
conjugated to the Gal4 transcription factor binding to the synthetic promoter of the 
pFR-luciferase plasmid. Due to the poor transfection efficiency of primary neurons, 
the low level of luciferase expression made changes between basal and modulated 
conditions difficult to detect. In order to increase the luciferase signal, allowing 
greater disparity between basal and APP processing-dependent luminescence, a 
physiological stabiliser of AICD, the adaptor protein Fe65 was employed. Via its 
YENTPY motif in the PTB2 domain, Fe65 binds directly to the AICD (Fiore et al., 
1995), stabilising AICD in the cytoplasm prior to nuclear translocation (Kimberly et 
al., 2001). Transfection with Fe65 was thought to be an effective way to increase 
the luciferase signal through stabilization of the AICD-Gal4 product.  
To determine the influence of Fe65 on luciferase expression, pC1-CMV-Fe65 was 
co-transfected with the required assay plasmids and luciferase expression was 
measured 24h later. This enhanced luciferase expression ~10 fold (Figure 3.6), 
confirming that the assay was sensitive to physiological stabilisers of the AICD and 
allowing greater disparity between basal and induced luciferase expression. 
3.2.6 APP-Gal4 reporter gene assay is sensitive to 
pathological challenges 
 
To further the potential utility of the assay, its sensitivity to known pathological 
cellular challenges associated with AD was investigated. To probe the sensitivity of 
the assay to AD-relevant cellular insults, differing paradigms were developed. The 
assay was carried out following neuronal maturation in antioxidant-free conditions 
and following transfection of a mutated version of the pRC-APP-Gal4 to introduce a 




Figure 3.6: Fe65 significantly enhances APP-Gal4 reporter gene expression 
5DIV primary cultured cortical neurons were co-transfected with pRC-APP-Gal4, pFR-
luciferase and pRL-TKRenilla plasmids alone and also with the addition of pC1-
CMVFe65 plasmid. Dual-Glo luciferase activity assays were performed 24h post 
transfection for quantification of firefly and Renilla luciferase expression. Firefly 
luciferase reporter expression was normalised using the Renilla luciferase expression. 
Each column is the mean ± S.E.M. of 18 independent transfections across 3 biological 
replicates (n=3; ****p<0.0001, Student’s t-test). 
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3.2.6.1 Neuronal maturation in antioxidant free media enhances 
reporter dependent luciferase expression 
 
In the AD brain, the cellular environment changes and cells are subjected to greater 
levels of oxidative stress, lower glucose levels and higher concentrations of protein 
aggregates (Markesbery, 1997). These conditions are thought to be some of the 
main environmental factors that contribute to enhanced pro-amyloidogenic APP 
processing, as oxidative stress is seen prior to increases in Aβ concentration (Smith 
et al., 2000).  
To test the sensitivity of the reporter assay to a pro-oxidant environment, a stress 
model had to be established in primary neurons. Antioxidants are essential for 
neuronal survival in vitro, however the window of necessity is within the first 24h 
post explantation only, after which antioxidants can be removed with little 
resultant cell death (Perry et al., 2004). This allowed a model of oxidative stress to 
be tested where the oxidative stress is generated by chronic removal of 
endogenous antioxidants rather than addition of exogenous oxidants.  
In primary cell culture, the major source of antioxidants is the B27 media 
supplement. This supplement contains reduced glutathione, tocopherol (vitamin E), 
catalase and SOD (Perry et al., 2004). To determine the effect of antioxidant 
withdrawal on APP cleavage-dependent luciferase expression, culture media was 
changed on 1 DIV to Neurobasal lacking antioxidants (B27 AO-free) or Neurobasal 
containing antioxidants (B27 AO+) and cells were maintained under physiological 
conditions.  
Phase contrast images were taken on 3 and 5 DIV to assess morphological changes 
occurring in B27 AO-free cultures compared to B27 AO+ cultures. These showed 
that the antioxidant free cultures had a slightly higher incidence of apoptotic cells, 
appearing as small, compact floating cells, however there was no widespread death 
(Figure 3.7(Aiii and iv)). Cell bodies appeared to be unaffected; however the 
dendritic networks developed in the antioxidant free media were much less 
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extensive compared to those that developed in the presence of antioxidants (Figure 
3.7(A)). The microscopic analysis therefore suggests that any changes seen in the 
APP-Gal4 gene reporter assay were not due to gross morphological changes or 
widespread cell death. Neurons that had matured in both the presence and 
absence of antioxidants were transfected and levels of luciferase expression 
measured 24h later. APP cleavage dependent luciferase expression more than 
doubled when compared to neurons cultured in the presence of antioxidants 
(Figure 3.7(B)). This lends support to the hypotheses that oxidative conditions drive 
amyloidogenic APP processing or increase APP expression. 
3.2.6.2 Introduction of the Swedish mutation in APP enhances reporter-
dependent luciferase expression. 
 
BACE1 sensitivity of the assay predicted that familial AD mutations known to 
enhance Aβ production, such as the Swedish mutation of APP (K670N/M671L) 
(Citron et al., 1992), would increase luciferase expression. To investigate the 
sensitivity of the APP-Gal4 reporter to known disease-causing mutations in APP and 
to generate a cellular model of pathogenic APP processing, site-directed 
mutagenesis of pRC-APP-Gal4 was undertaken. A double point mutation causing 
two amino acid substitutions, lysine to arginine and methionine to leucine 
(K670N/M671L), was introduced.  
Initially, PCR amplification using mismatched primers that introduced the double 
point mutation was carried out (Figure 3.8(A)) (see Section 2.2.4). Transformed 
clones were identified by DNA electrophoresis (Figure 3.8(B)). To ensure no gross 
DNA changes had occurred during the mutagenesis, a unique restriction site (Not1) 
digest was performed to linearise the plasmid DNA and assess total plasmid size of 
all mutants. Undigested pRC-APP-Gal4, digested pRC-APP-Gal4 and digestions of 
the 3 putative pRC-APPswe-Gal4 mutants were compared. These showed there 
were no gross changes in size in the putative mutant plasmids (Figure 3.8(c)). The 3 





Figure 3.7: Antioxidant withdrawal enhances βγ-mediated APP processing in 
primary neurons in the absence of gross neuronal cell loss 
(A) Phase contrast images of neuronal cell development at 3 DIV and 5 DIV in (i 
and ii) the presence of antioxidants and (iii and iv) in the absence of antioxidants. 
Primary cultured neurons were prepared and plated out in Neurobasal +B27 
media. At 1 DIV, media was removed and replace with Neurobasal +B27 (+AO) or 
Neurobasal +B27 minus antioxidants (-AO). Cultures were then allowed to mature 
to 5DIV. Phase contrast images were taken with 400x magnification. (B) 5DIV 
primary cultured cortical neurons matured in the presence (Control) or absence 
(AO free) of antioxidants were co-transfected with pRC-APP-Gal4, pFR-luciferase 
and pRL-TKRenilla plasmids. Dual-Glo luciferase activity assays were performed 
24h post transfection for quantification of firefly and Renilla luciferase 
expression. Firefly luciferase reporter expression was normalised using the Renilla 
luciferase expression. Each column is the mean ± S.E.M. of 18 independent 
transfections across 3 biological replicates (n=3; ***p<0.001, Student’s t-test). 
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sequence confirmed that pRC-APPswe-Gal4 #3 contained the double point 
mutation leading to K595N/M596L amino acid substitutions (Figure 3.8(D)).  
Following successful identification of the mutant, the level of luciferase expression 
resulting from pRC-APPswe-Gal4 compared to pRC-APP-Gal4 was investigated. 
Primary neurons were transfected with either pRC-APP-Gal4 or pRC-APPswe-Gal4 in 
the presence and absence of the -secretase inhibitor DAPT. Luciferase expression 
was measured 24h later.  Transfection with pRC-APPswe-Gal4 resulted in a 2-fold 
increase in luciferase expression compared to non-mutated APP, whilst remaining 
sensitive to DAPT (Figure 3.9). 
Collectively this chapter characterised the assay as being dependent on Gal4-UAS 
coupling and -secretase mediated APP cleavage. Taken together, the Fe65, 
antioxidant withdrawal and Swedish mutation results confirmed the assay 
tractability and the resultant activity shifts were consistent with the assay being 




Figure 3.8: Design and production of APPswe-Gal4 plasmid 
(A) Mutagenesis primers designed to introduce double point mutation into APP 
sequence of pRC-APP-Gal4. (B) Identification of plasmid DNA-containing miniprep 
samples. 0.8% agarose gel was run for 30 min of 11 samples loaded with 6x DNA 
loading buffer: 1-8 – samples transformed using XL Gold competent cells, single 
ampicillin resistant colonies were picked into 5mL LB broth and cultured O/N 
followed by standard DNA extraction and purification; 9-11 – samples transformed 
using TopTen chemically competent cells, single ampicillin resistant colonies were 
picked into LB broth and cultured O/N followed by standard DNA extraction and 
purification. (C) Three TopTen putative APPswe-Gal4 (c-e) and original APP-Gal4 (b) 
plasmid DNA preparations were digested with Not1 for 4h at 37oC to linearise DNA. 
Samples were run on 0.8% agarose gel alongside undigested control plasmid (a) for 
30 min. (D) Sequence alignment of clone #3 APPswe-Gal4 sequence with APP695 





Figure 3.9: Swedish APP mutation enhances βγ-mediated APP processing in 
primary neurons in a DAPT dependent manner 
5 DIV primary cultured cortical neurons were co-transfected with APP-Gal4 
plasmid point mutated at ‘Swedish’ site (K670N/M671L; APPswe) or WT APP-Gal4 
(Control), with pFR-luciferase and pRL-TKRenilla. Dual-Glo luciferase activity 
assays were performed 24h post transfection for quantification of firefly and 
Renilla luciferase expression. Firefly luciferase reporter expression was 
normalised using the Renilla luciferase expression. Co-transfection with APPswe-
Gal4 caused increase in luciferase expression compared to WT that was blocked 
by DAPT treatment (10 μM for 24h) Each column is the mean ± S.E.M. of 24 
independent transfections across 4 biological replicates (n=24 ****p<0.0001, 




3.3 Discussion  
 
In this chapter the APP-Gal4 gene reporter assay is confirmed as a sensitive method 
for assessment of APP processing modulation in primary neurons. Utilising 
commercial inhibitors of α- , β- and γ-secretase, it has been shown that the assay is 
strongly dependent on -secretase processing and preferentially reports βγ-
secretase-mediated processing. This is in agreement with previous reports utilising 
this assay in primary neurons (Hoey et al., 2009). The assay was stimulated by co-
expression of Fe65, introduction of APP mutations known to favour Aβ formation 
and following antioxidant withdrawal from the media.   
3.3.1 The APP-Gal4 reporter assay preferentially 
measures changes in amyloidogenic APP 
processing 
 
The APP-Gal4 reporter assay was sensitive to two, structurally unrelated, 
commercial β-secretase inhibitors (BsI and BiV) and a commonly used γ secretase 
inhibitor (DAPT). In contrast, the assay was not inhibited by a broad spectrum 
metalloprotease inhibitor (TAPI), known to inhibit α-secretase activity. Due to the 
complexity of APP processing regulation in primary neurons, there are a number of 
possibilities to explain why the assay preferentially reported βγ-mediated APP 
processing. The most basic explanation is that primary neurons do not undergo 
processing via the non-amyloidogenic pathway. However, despite neurons being 
unusual in exhibiting a higher proportion of amyloidogenic compared to non-
amyloidogenic processing, proteolytic fragments of the non-amyloidogenic 
pathway are easily detectable by western analysis and endogenous APP shows 
sensitivity to TAPI in primary neurons (Hoey et al., 2009, Colombo et al., 2012).  
Physiological control of APP processing is heavily reliant on spatial segregation of 
APP and secretase enzymes and therefore an alternative explanation is the 
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accumulation of APP-Gal4 in cellular locations associated with high BACE1 activity 
such as endosomes. Due to the low transfection efficiencies of the neurons, it was 
not possible to investigate this possibility further, however as spatial segregation 
plays a crucial role in APP processing regulation this is an attractive hypothesis 
(Haass et al., 2012).  
Alternatively, apparent preference for β mediated processing could be due to 
different activities of the AICD-Gal4 processing product from the amyloidogenic and 
non-amyloidogenic pathways. It may be that only the AICD-Gal4 fragments released 
from βγ-mediated processing have the ability to transactivate gene expression of 
the target reporter plasmid. The AICD has been shown to transactivate gene 
expression via formation of a complex involving adaptor protein Fe65 and histone 
acetyltransferase Tip60 (Cao and Sudhof, 2001). It has been suggested that only 
AICD produced via amyloidogenic processing is transcriptionally active and 
therefore responsible for nuclear signaling (Goodger et al., 2009, Belyaev et al., 
2010). This assay is a measure of secretase mediated processing, not a measure of 
the transcriptional activation activity of AICD, as it is the Gal4-UAS coupling that 
leads to activation of the luciferase gene, however evidence suggesting only AICD 
from the amyloidogenic pathway is able to form functional units with adaptor 
proteins provides a rationale to explain the βγ-mediated preference of the APP-
Gal4 assay. Studies of AICD transcriptional activity in primary neurons however, 
have not established a difference in functionality of AICD generated from the 
amyloidogenic or non-amyloidogenic pathways and so this hypothesis remains 
unproven.  
Differences in results from studies in cell lines and primary cells, especially in the 
CNS, are leading to many groups identifying candidate mechanisms and targets in 
the highly malleable system of cell lines, and then following these with studies in 
primary neurons. These follow up studies identify the fine mechanistic details in 
these highly specialized cell types. For example, cell lines overexpressing APP were 
used to demonstrate the inverse coupling of amyloidogenic and non-amyloidogenic 
processing. This simplistic model has recently been challenged as inhibition of 
endogenous BACE1 in primary neurons did not lead to increases in α-secretase 
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activity although inhibition of ADAM10 did lead to increased Aβ levels (Kuhn et al., 
2010, Colombo et al., 2012). Furthermore, spatial regulation of APP processing was 
initially demonstrated in non-polarised Madin-Darby canine kidney (MDCK) cells 
where differential sorting of full length APP and its proteolytic products to the 
apical and basolateral membranes were observed (Haass et al., 1995a). This gave 
the first indication of two separate pathways of APP processing, a discovery crucial 
to AD research, however when studies were conducted in primary neurons, critical 
differences in signal peptide requirements for APP delivery to neuronal specific 
compartments were described (Back et al., 2007). These studies highlight the 
relative strengths of primary neurons in accurate replication of the fine modulation 
of processing that is not possible in cell lines. Such mechanisms of regulation have 
been vitally important discoveries in investigation of the physiological role of APP to 
better understand the pathophysiological effects its misregulation causes. 
BACE1 inhibition using commercial inhibitors caused a maximal 50% reduction in 
luciferase expression, whilst DAPT caused a 75% reduction in luciferase expression. 
As the assay was insensitive to α-secretase inhibition, and even showed a small 
potentiation, it is worth considering the discrepancy between the DAPT and BACE1 
inhibition levels. Although it is well accepted that BACE1 is the major, physiological 
β-secretase enzyme, cathepsin B, an endosomal/lysosomal cysteine protease has 
been proposed as an alternative minor β-secretase enzyme (Hook et al., 2005). 
Inhibition and genetic deficiency of cathepsin B have been shown to reduce Aβ 
levels in transgenic mice overexpressing WT APP (Hook et al., 2008, Hook et al., 
2009), suggesting it plays a role in Aβ generation. Cleavage of APP by caspases has 
also been suggested to contribute to AD pathology. Specifically, caspase 3 was 
suggested to directly cleave APP following apoptotic stimuli contributing to 
increased Aβ secretion (Gervais et al., 1998). The discrepancy between BACE-
sensitive and DAPT-sensitive APP processing events could therefore be due to non-
secretase pathways of APP proteolysis such as the cathepsin B-mediated or 
caspase-3 dependent cleavage. Caspase activity is unlikely to be responsible as 
previous reports have shown the APP-Gal4 assay to be insensitive to caspase 
inhibition (Hoey et al., 2009) suggesting cathepsin is the more probable candidate. 
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3.3.2 Fe65 enhances the dynamic range of the APP-
Gal4 luciferase assay in primary neurons  
 
Due to the poor transfection efficiency of primary neurons, the level of luciferase 
expression was initially very low, making the differential between basal and 
stimulated conditions small. Co-expression of Fe65 enhanced luciferase expression, 
increasing the dynamic range of the assay. The role of Fe65 in modulation of APP 
processing is multifactorial and still not fully understood, however one of the first 
roles identified was as a stabiliser of the AICD. In the absence of Fe65 binding, the 
AICD is rapidly degraded (Kimberly et al., 2001, McLoughlin and Miller, 2008). 
Stabilising the AICD-Gal4 through co-expression of Fe65 and reducing the 
degradation rate of AICD, increases the number of APP processing events that lead 
to transactivation of the Firefly luciferase gene.  
3.3.3 The APP-Gal4 assay is sensitive to pro-oxidant 
conditions in primary neurons 
 
Following successful validation and characterisation of the APP-Gal4 assay, it was 
also shown to be sensitive to pathological changes associated with AD. Oxidative 
stress is intimately linked to AD, and is increased significantly earlier than Aβ 
burden in Down’s syndrome patients (Nunomura et al., 2000), suggesting it to be 
one of the earliest events of the disease process, preceding the biochemical 
changes. AD brains exhibit multiple pathologies indicating increased oxidative stress 
including increased lipid peroxidation and increased AGEs (Wang et al., 2013). 
These changes were parallel to increased BACE1 expression and activity levels in 
vulnerable regions of post-mortem AD brain (Fukumoto et al., 2002, Yang et al., 
2003).  
In primary culture, media supplements are the major source of antioxidants. 
Chronic removal of antioxidants from the media at 1 DIV led to significant 
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enhancement of luciferase expression, suggestive of increased amyloidogenic 
processing or increased APP expression. This is consistent with findings showing 
oxidative agents and oxidative products such as H2O2 and 4-hydroxynonenal (HNE) 
causing increased BACE1 expression and activity in a concentration-dependent 
manner, consequently increasing amyloidogenic processing and Aβ production 
(Tamagno et al., 2002, Tamagno et al., 2008, Chami and Checler, 2012, Tan et al., 
2013). Further to this, in vivo studies in mice have shown cortical levels of Aβ 
increase by 55% in animals fed a pro-oxidant diet compared with control, 
independent of changes in BACE1 expression implying redox sensitive changes in 
processing (Choudhry et al., 2012). This suggests that increased luciferase 
expression observed is more likely to be as a consequence of increased 
amyloidogenic processing rather than increased APP expression.  
Much of the evidence for up-regulation of the amyloidogenic pathway in response 
to oxidative stress has come from studies involving high concentrations of H2O2, 
when apoptosis and cell death were also occurring. However, the oxidative stress 
model presented here showed no signs of apoptosis through morphological 
examination and there was no gross cell death, although loss of dendritic 
extensions was observed. A recent study showed that mild oxidative stress, induced 
by low concentrations of H2O2, caused increased amyloidogenic processing through 
relocalisation of BACE1 to the TGN and early endosomes. This increased the ratio of 
BACE1 in the acidic environment optimal for its activity and increased co-
localisation of BACE1 with APP (Tan et al., 2013). It is therefore possible that 
chronic antioxidant withdrawal led to increased amyloidogenic processing through 
redistribution of BACE1 to cellular compartments favouring amyloidogenic 
processing although this is not something that has been explored. It cannot be 
discounted however, that apparent increases in amyloidogenic processing were due 
to increases in APP expression, thus increasing availability of the substrate causing a 
general increase in total APP processing. 
 Although no gross neuronal loss was observed following antioxidant withdrawal, a 
reduction in the dendritic network was noted. Activity-dependent APP processing is 
associated with potentiation of the non-amyloidogenic pathway (Hoey et al., 2009, 
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Verges et al., 2011); therefore a loss of dendritic connections and thus connectivity 
within the culture may reduce the activity input to oppose amyloidogenic APP 
processing, leading to increased levels of this pathway. 
These alternative hypotheses are not mutually exclusive and could cumulatively 
lead to the increased luciferase expression seen in the assay. As levels of APP, 
BACE1, measurements of BACE1 activity and synaptic transmission were not 
conducted, it is not possible to confirm a particular mechanism in this system. Up-
regulation of APP-Gal4 mediated luciferase expression showed the assay was 
sensitive to this known pathological insult that is strongly implicated in the 
development of AD. This lends additional indirect support to the conclusion that 
the assay is a measure of βγ-mediated APP processing. 
3.3.4 The APP-Gal4 assay is sensitive to FAD-causing 
APP mutations 
 
Development of an APP-Gal4 plasmid expressing the double point mutation 
(K670N/M671L) encoding the Swedish mutant of APP allowed a second model of 
pathological sensitivity to be assessed. The Swedish mutation of APP is a double 
substitution mutation immediately prior to the BACE1 cleavage site. It was 
identified in a Swedish familial AD (FAD) family and has been shown to produce 6-8 
fold more Aβ than cells expressing normal APP (Citron et al., 1992). It is thought this 
increase may be due to changes in the cellular location of β-secretase cleavage, 
with APPswe BACE1 cleavage occurring within secretory vesicles, the same site as 
α-secretase activity, rather than later in the endosomal pathway as has been shown 
for normal BACE1 processing (Haass et al., 1995b). Therefore rather than α-
secretase cleavage precluding BACE1 cleavage, there is direct competition between 
the two activities. This leads to increased levels of β-mediated APP processing 
products compared to WT. The higher levels of luciferase expression observed 
following transfection of neurons with APPswe-Gal4 compared with WT APP further 
supported the assay as a preferential readout of βγ-secretase-mediated APP 
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processing. Although transfection efficiencies were controlled for using an internal 
control plasmid, changes in APP expression levels between WT and mutant APP 
cannot be discounted as the cause of increased luciferase expression. As expression 
levels of both APP-Gal4 and APPswe-Gal4 proteins were too low for biochemical 
detection this concern could not be addressed. 
3.3.5 Summary 
 
This reporter assay is a sensitive and powerful approach for screening compounds 
with potential bioactivity at different points within the pathways regulating APP 
processing and is not simply a tool for identifying direct catalytic inhibitors of β and 
-secretase. Adopting the assay in a primary neuronal model represents a 
significant advantage over cell lines which lack the underlying neurophysiological 







4. In vitro screen identifies 
flavonoids as potent inhibitors of 







Epidemiological evidence collated over more than a decade, strongly suggests that 
there is a link between increased dietary flavonoid intake and reduced risk of 
developing AD. Foodstuffs including green tea, strawberries, blueberries, and fruit 
juices as well as adherence to a lifestyle such as the Mediterranean diet have been 
implicated in reducing risk of AD (Dai et al., 2006, Kuriyama et al., 2006, Feart et al., 
2009, Devore et al., 2012). Transgenic mouse models of AD have been used to 
demonstrate that select flavonoids have beneficial effects on different aspects of 
AD pathology: Tg2576 mice orally administered EGCG, showed reduced amyloid 
pathology and improved cognitive function in a radial arm water maze test of 
working memory (Rezai-Zadeh et al., 2008). A flavonoid-rich GSPE orally delivered 
for 5 months also showed reduced incidence of high molecular weight A oligomers 
and reduced amyloid plaque burden in adult Tg2576 mice (Wang et al., 2008). The 
flavonol myricetin, fed to Tg2576 mice for 10 months led to increased Aβ 
monomers, and concurrent decreased Aβ oligomers, suggesting a similarity to the 
GSPE-mediated oligomerisation reduction (Hamaguchi et al., 2009). IP injection of 
the flavone nobiletin for 4 months rescued memory impairment and reduced Aβ 
deposition in the hippocampus (Onozuka et al., 2008). Another flavone, diosmin, 
delivered by gavage for 6 months, reduced soluble Aβ, Aβ deposition and plaque 
burden (Rezai-Zadeh et al., 2009). The epidemiological evidence and in vivo studies 
suggest that flavonoids from across the families possess bioactivity at reducing 
amyloid beta pathology. However, the studies described thus far have been carried 
out on a chosen compound or small subset of compounds, investigating their 
effects in isolation, not in comparison. The flavonoid field has been held back by 
inconsistencies in findings and lack of a coherent, systematic approach across the 
families. 
For this reason, this chapter describes the utilisation of the previously characterised 
and validated APP-Gal4 luciferase reporter assay in primary neurons to screen 
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flavonoids from across the families for modulatory activity on βγ-secretase 
mediated luciferase expression.  
The flavonoids entered into the screen were selected based on a number of criteria:  
1. previously published activity at APP such as the flavanol EGCG (Rezai-Zadeh, 
2005);  
2. high content in implicated foodstuffs such as cyanidin and pelargonidin which are 
major flavonoid constituents of berries (Devore et al., 2012);  
3. activity at other relevant cellular targets such as fisetin, shown to activate ERK at 
1 μM (Maher et al., 2006).  
Further efforts were made to ensure the screen included a range of different 
flavonoid structures to enable basic structure activity relationships to be evaluated. 
Following initial identification of active compounds, more detailed concentration 
and kinetic analyses were carried out. Further analysis of efficacy was undertaken 
using the pathogenic APPswe-Gal4 system. In order to establish if flavonoid-
mediated inhibition of β processing resulted in reductions in Aβ production an Aβ 






4.2.1. Flavonoid screen identified potent inhibitors of 
β-mediated APP processing 
 
Previous reports have suggested that flavonoids may be able to confer a positive 
effect on synaptic health and cognitive function by reducing A levels through 
modulation of secretase-mediated APP processing (Obregon et al., 2006, Rezai-
Zadeh et al., 2009, Wang et al., 2012). To date, however, no comparative study of 
flavonoid bioactivity on APP processing at a physiologically relevant concentration 
has been conducted. To address this, a library of flavonoids were selected and 
screened for modulatory effects on the APP-Gal4 gene reporter assay, described 
and characterised as a measure of βγ-secretase mediated APP processing in 
Chapter 3. The flavonoids were chosen from across the subfamilies with 
representative molecules from the flavones, flavonols, flavanones, flavanols and 
anthocyanins. Two concentrations of flavonoids were tested: 100 nM as a 
physiologically relevant concentration that has been measured in rodent brain 
following oral flavonoid delivery (van Praag et al., 2007, Wang et al., 2012), and at 
10 M, in line with previous reports of bioactivity of flavonoids in other studies 
(Rezai-Zadeh, 2005, Ehrnhoefer et al., 2008).  
To assess flavonoid bioactivity on the APP-Gal4 reporter gene assay, primary 
neuronal cultures were transfected and 1h post transfection were treated with 
either 100nM or 10 μM flavonoid; levels of luciferase expression were measured 
24h post flavonoid application. Relatively young cultures were used to maximize 
the transfection efficiency but were sufficiently mature to have formed synaptic 
connections in the cultures.  
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Four flavonoids inhibited APP-Gal4 dependent luciferase expression at 100 nM 
(Table 4.1): the flavanol epigallocatechin (57%), the flavonol fisetin (67%), the 
anthocyanin pelargonidin chloride (61%) and the flavone sinensetin (51%). Of these, 
epigallocatechin, fisetin and pelargonidin chloride inhibited at 100 nM but not at 10 
M. Epigallocatechin and fisetin (149% and 188% respectively) promoted luciferase 
expression at 10 M. Sinensetin was inhibitory at both concentrations (51% and 
57%). The structural variety in the identified molecules and the different patterns of 
inhibition at the two concentrations tested was suggestive of a number of different 
inhibitory mechanisms. It was interesting to note that no flavonoid was inhibitory at 
10 μM but not at 100 nM. Only sinensetin, which was inhibitory at 100 nM also 
showed inhibitory action at 10 μM, suggesting flavonoids generally exert their 
beneficial effects on APP processing at low concentrations. 
The catechins have been some of the most intensely researched flavonoids. This 
has been due to discovery that they can cross the blood brain barrier and that they 
show no toxicity to humans (Abd El Mohsen et al., 2002, Schroeter et al., 2010). 
Two structurally similar catechins to epigallocatechin that was identified in the 
original screen, (-) epicatechin and EGCG have previously been proposed to have 
activity against APP processing. It was therefore decided to focus on the catechin 
family to conduct a detailed concentration and kinetic analysis of their activity. 
4.2.2. Epigallocatechin inhibits β-secretase dependent- 
luciferase expression  
 
The flavanol epigallocatechin was identified in the original screen as an inhibitor of 
APP-Gal4 dependent luciferase expression at 100 nM but potentiated APP-Gal4 
dependent luciferase expression at 10 μM. This suggested that inhibition of APP 
processing by the catechin family was strongly dependent on the concentration at 
which they were tested. To further investigate this, transfected primary cortical 
cultures were treated with epicatechin, epicatechin gallate, epigallocatechin or 





  % Activity Compared to 
Control 
Flavonoid group Compound name 100 nM 10 µM 
Flavonol Fisetin1 67.7±11.7 188±15.8 
Kaempferol 103±54.1 123±56.7 
Kaempferol 3O Rutinoside 83.0±44.7 85.8±19.7 
Quercetin 98.6±18.1 174±20.3 
Flavone Apigenin 90.9±27.9 154±17.0 
Apigenin 7O Glucoside 102±13.6 216±8.07 
Coumarin 137±15.1 139±27.4 
Diosmetin 90.4±14.3 322±14.1 
Hyperoside 94.1±14.3 108±17.9 
Sinensetin2’ 51.1±26.1 57.6±18.2 
Flavanone Hesperetin 134±14.5 1378±52.2 
Narirutin 126±20.7 145±26.4 
Anthocyanin Cyanidin Chloride 111±39.8 95.5±30.5 
Delphinidin Chloride 114±32.9 200±5.92 
Pelargonidin Chloride3 61.4±6.23 98.9±16.4 
Flavanol (+) Catechin 97.6±14.7 105±10.4 
(-) Epicatechin 107±35.1 87.5±34.2 
Epicatechin Gallate 115±28.1 114±20.4 
Epigallocatechin4’ 57.2±23.3 149±46.5 





Table 4.1: APP-Gal4 dependent-luciferase expression is modulated by select 
flavonoids in primary cortical neurons. 5 DIV primary cortical neurons were co-
transfected with 0.5 μg pRC-APP-Gal4, pFR-luciferase, pRL-TK-Renilla, after 0.5h, 
cells were treated with either 100 nM or 10 μM flavonoid compound for 24h. Cells 
were lysed and levels of luminescence quantified utilising the Dual-Glo luciferase kit 
according to manufacturer’s instructions. 1-4 Flavonoids showing largest inhibition of 
luciferase expression. 2 and 4 caused significant reduction in luciferase expression at 
100 nM (‘ p<0.05., One way ANOVA with Bonferroni post-test). Values expressed as 






The control level of luciferase expression achieved following transfection was very 
low. Co-transfection with the adaptor protein Fe65 increased luciferase expression 
levels significantly (Chapter 3). For this reason, parallel investigations of catechin 
efficacy were carried out following co-transfection with Fe65. This allowed 
assessment of the biological impact of Fe65 co-transfection on flavonoid 
modulation of APP-Gal4 dependent luciferase expression as it had been previously 
suggested that Fe65 decreased assay sensitivity (Hoey et al., 2009). 
Firstly, comparison of the modulatory effects of the catechin family on APP-Gal4 
dependent luciferase expression in either the presence or absence of Fe65 showed 
that Fe65 did not reduce assay sensitivity. 24h exposure to (-) epicatechin, 
epicatechin gallate or EGCG had no significant effect on luciferase expression at any 
concentration tested, either in the presence or absence of Fe65 (Figure 4.1(A, B and 
D)).  
Epigallocatechin, in accordance with the initial screening data, showed bioactivity in 
the assay, with significant inhibition of luciferase expression at 100 nM (Figure 
4.1(C)). Also consistent with the original screen was the lack of inhibition by 
epigallocatechin at higher concentrations. Following maximal inhibition at 100 nM, 
epigallocatechin showed no significant inhibition at higher concentrations and in 
the presence of Fe65 showed significant promotion of luciferase expression at 10 
μM. This was consistent with the original screen. In contrast, in the absence of 
Fe65, no significant promotion of luciferase expression was observed (Figure 
4.1(C)). 
4.2.3. (-) Epicatechin inhibits reporter-dependent 
luciferase expression following 6h treatment  
 
Flavonoids are quickly metabolised, with flavanol levels almost back to basal 8h 
following ingestion (Rein et al., 2000, Renouf et al., 2013). To investigate the time-
dependence of catechin bioactivity on APP processing, a second, more acute 




Figure 4.1: Concentration analysis at 24h identified epigallocatechin as 
biphasic inhibitor of APP processing.  
5 DIV primary cortical neurons were co-transfected with 0.5 μg pRC-APP-Gal4, 
pFR-luciferase, pRL-TK-Renilla, after 0.5h, cells were treated with  (A) EC - (-) 
epicatechin, (B) ECG - epicatechin gallate, (C) EGC - epigallocatechin and (D) 
EGCG -epigallocatechin gallate (0.01-10 μM) for 24h. In parallel, the same 
treatments were conducted following co-transfection with 0.5 μg pC1-Fe65, 
pRC-APP-Gal4, pFR-luciferase, pRL-TK-Renilla. Dual-Glo luciferase activity assays 
were performed 24h post transfection for quantification of firefly and Renilla 
luciferase expression. Firefly luciferase reporter expression was normalised 
using the Renilla luciferase expression and expressed as % control relative 
luminescence.  Each point is the mean ± S.E.M of 17 independent transfections 
across 3 biological replicates (n=17; * without Fe65, # with Fe65, p<0.05, two 




Figure 4.2: Concentration analysis at 6h identified (-) epicatechin as 
inhibitor of APP processing.   
5 DIV primary cortical neurons were co-transfected with 0.5 μg pRC-APP-
Gal4, pFR-luciferase and pRL-TKRenilla in the presence and absence of 0.5 
μg pC1-Fe65. After 18h, transfected cells were treated with (A) EC - (-) 
epicatechin, (B) ECG - epicatechin gallate, (C) EGC - epigallocatechin and (D) 
EGCG -epigallocatechin gallate (0.01-10 μM) for 6h. Dual-Glo luciferase 
activity assays were performed 24h post transfection for quantification of 
firefly and Renilla luciferase expression. Firefly luciferase reporter 
expression was normalised using the Renilla luciferase expression and 
expressed as % control relative luminescence. Each point is the mean ± 
S.E.M. of 15 independent transfections across 3 biological replicates (n=15; 
* without Fe65, # with Fe65 p<0.05, two way ANOVA with Bonferroni post-
test). )  
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vivo kinetics following flavonoid exposure. Cultures were treated with (-) 
epicatechin, epicatechin gallate, epigallocatechin or EGCG (10 nM-10 M), either in 
the presence or absence of Fe65. Luciferase expression levels were measured 6h 
post catechin application. 
Following 6h treatment, epicatechin gallate and EGCG had no significant effect on 
luciferase expression in either the presence or absence of Fe65, consistent with 24h 
treatment (Figure 4.2 (B and D)). In contrast, (-) epicatechin treatment, which was 
not inhibitory at 24h (Figure 4.1(A)), caused significant inhibition of luciferase 
expression at 6h (Figure 4.2 (A)). In addition, epigallocatechin, which was inhibitory 
after 24h treatment (Figure 4.1(C)), showed no significant inhibition of luciferase 
expression at 6h (Figure 4.2 (C)). These results indicated that the bioactivity of 
effective flavanols was time-dependent, suggesting potential differences in cell 
permeability or metabolism. 
4.2.4. Transfection of Fe65 does not alter the biological 
efficacy of the catechins 
 
Transfection of Fe65 has previously been suggested to alter the sensitivity of 
primary neurons to signalling pathways associated with APP processing (Hoey et al., 
2009). Due to low levels of transfection it was preferable for Fe65 to be utilised in 
the kinetic analyses of the catechins as Fe65 enhanced luciferase expression levels 
(Figure 3.6). To establish whether Fe65 had an impact on the efficacy or potency of 
the catechins, all experiments were performed in parallel either in the presence or 
absence of Fe65. In cultures transfected with Fe65, the pC1-Fe65 plasmid was 
added to the DNA transfection mix (see section 2.1.3.) and co-transfected with the 
required assay plasmids. 
Epigallocatechin and (-) epicatechin were identified as inhibitors of APP-Gal4 
dependent luciferase expression at 24h and 6h respectively both in the presence 
and absence of Fe65 (Figure 4.1 (A and C) and 4.2 (A and C)), supporting the 
conclusion that Fe65 does not alter the basic modulatory sensitivity of the assay. 
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Fe65 did however  alter the concentrations at which inhibiton by the catechins 
reached statistical significance. (-) Epicatechin (6h) inhibition of luciferase 
expression was significant at both 100 nM and 1 μM in the absence of Fe65 but only 
at 1 μM in the presence of Fe65 (Figure 4.2(A)). Epigallocatechin (24h) treatment 
however was unaffected by Fe65, with significant inhibition of luciferase expression 
at 100 nM in both conditions. The biphasic effect of epigallocatechin, with 
promotion of luciferase expression at the highest concentration (10 M) was less 
pronounced in the absence of Fe65, with a significant difference between the 
luciferase expression levels in the two conditions (Figure 4.1(C)). This is suggestive 
of a transcription-dependent mechanism for the epigallocatechin-mediated 
increase in APP processing.  
4.2.5. (-) Epicatechin and epigallocatechin identified as 
potent inhibitors of APP processing. 
 
Through the kinetic and concentration-dependent analyses, two effective flavanols 
were identified: (-) epicatechin and epigallocatechin. In order to make a direct 
comparison between them, their maximal concentration-responses were plotted 
against each other. Epigallocatechin was a more effective inhibitor, reducing 
luciferase expression to a maximum of 45% of control whilst (-) epicatechin showed 
a maximal inhibition of 70% of control. (Figure 4.3(B)). Despite the differences in 
the efficacy and kinetic of the responses, (-) epicatechin and epigallocatechin had 
similar potencies at their most effective time-point. (-) Epicatechin potently 
reduced luciferase expression (EC50 of 22.1 nM) at 6h (Figure 4.3(C)), whilst 
epigallocatechin potently reduced luciferase expression (EC50 of 14.3 nM) at 24h 
(Figure 4.3(C)). Epigallocatechin promoted amyloidogenic APP processing at 10 µM, 
therefore to calculate an accurate EC50 value for its inhibitory action, this point was 
excluded from the curve fit. (-) Epicatechin showed no concentration-dependent 
effect at 24h (Figure 4.1(A)) whilst epigallocatechin showed no concentration-




Figure 4.3: (-) Epicatechin and epigallocatechin are potent inhibitors of APP 
processing.  
(A) (i) (-) Epicatechin is a 3 ringed polyphenol with hydroxyl substitutions at 
position 7 of the A, ring 3 of C ring and 4’, 5’ of the B ring. (ii) Epigallocatechin 
has same core structure as (-) epicatechin with additional hydroxyl substitution 
at position 3’ of the B ring. (B) Direct comparison of effective concentration 
responses (0.01-10 μM) of (-) epicatechin (6h) and epigallocatechin (24h) 
expressed as % control relative luminescence. EC- (-) epicatechin, EGC- 
epigallocatechin. (C) (-) epicatechin (6h) treatment potently inhibited βγ-
secretase-dependent APP processing with an EC50 of 20.5nM. Epigallocatechin 
treatment (24h) potently inhibited βγ-secretase-dependent APP processing 
with EC50 of 18.6nM. Each point is the mean ± S.E.M. of 15-17 independent 
transfections across 3 biological replicates (n=15-17; * EGC p<0.05, # EC p<0.05, 
two way ANOVA with Bonferroni post-test).  
146 
 
4.2.1. (-) Epicatechin and epigallocatechin 
treatments show a trend towards inhibition of 
APPswe-Gal4 dependent luciferase expression 
 
The APP-Gal4 screen identified two potent inhibitors of non-stimulated -
mediated APP processing. In order to test the efficacy of (-) epicatechin and 
epigallocatechin against a more pathological insult, primary cortical cultures 
transfected with the APP Swedish mutant APPswe-Gal4 (see Section 2.2.4) were 
treated with either (-) epicatechin for 6h or epigallocatechin for 24h (10 nM-10 
M). As a positive control, the -secretase inhibitor DAPT (10 M for 24h) was 
included.  
Consistent with results in Figure 3.9, transfection with APPswe-Gal4 increased 
luciferase expression compared to APP-Gal4 (control) levels and this expression was 
sensitive to DAPT inhibition (Figure 4.4 and 4.5).(-) Epicatechin and epigallocatechin 
treatments both showed trends towards reduced luciferase expression . The 
inhibitory trend was more apparent following epigallocatechin treatment however 
there was higher variability.. 
4.2.2. (-) Epicatechin treatment of primary cortical 
neurons suggests flavanol-mediated reduction in 
secretion of Ax-40  
 
Consistent inhibitory trends by (-) epicatechin and epigallocatechin of both the WT 
and Swedish APP-Gal4 dependent luciferase expression supported their bioactivity 
at reducing amyloidogenic APP processing. To further validate these findings and to 
establish if the reduced levels of processing observed in (-) epicatechin treated 
neurons resulted in lower levels of Aβ production an Aβ ELISA was used to directly 
measure levels of Aβ secreted into the media.  
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Primary cultured cortical neurons were treated with DAPT (10 M) or vehicle for 
24h to confirm that any Aβ measured in the media resulted from APP processing 
rather than unregulated protein secretion or cell death. (-) Epicatechin was applied 
to vehicle pre-treated neurons for the final 6h of incubation at two concentrations: 
100 nM and 300 nM as a physiologically relevant concentration range that was 
effective in the APP-Gal4 luciferase assay. Following incubation, the media was 
removed and Aβ levels quantified from a standard curve. (-) Epicatechin treatment 
showed a concentration-dependent trend towards reduced Aβ levels; 300 nM (-) 
epicatechin treatment reduced mean Aβ levels to 43% of control (Figure 4.6(B)). 
Due to high variability of control levels of Aβ, this inhibition did not reach 
significance. Levels of Aβ following treatment with DAPT were negligible and 
therefore could not be extrapolated from the standard curve (Figure 4.6(A)), but 





Figure 4.4: (-) Epicatechin treatment causes a trend towards reduced 
pathogenic ‘Swedish’ mutant APP processing. 
5 DIV primary cortical neurons were transfected with either 0.5 μg pRC-APP-
Gal4 or pRC-APPswe-Gal4; all wells were co-transfected with 0.5 μg each of pFR-
luciferase, pRL-TK-Renilla and pC1-Fe65. 0.5h later pRC-APPswe-Gal4 
transfected neurons were treated with DAPT (10 μM). 18h post-transfection 
pRC-APPswe-Gal4 transfected neurons were treated with (-) epicatechin (0.01-
10 μM) for 6h. Co-transfection of pRC-APPswe-Gal4 significantly increased 
relative luciferase expression compared to pRC-APP-Gal4. Treatment with DAPT 
significantly inhibited APPswe-Gal4 dependent luciferase expression. (-) 
Epicatechin potently inhibited βγ-secretase dependent APP processing with an 
EC50 of 51 nM. Dual-Glo luciferase activity assays were performed 24h post 
transfection for quantification of firefly and Renilla luciferase expression. Firefly 
luciferase reporter expression was normalised using the Renilla luciferase 
expression and expressed as % APPswe-Gal4 control relative luminescence. 
Each column or point is mean ± S.E.M. of 24 independent transfections across 4 
separate cultures (n=24 **** compared to C (APP-Gal4 control) p<0.0001 # 
compared to S (APPswe-Gal4 control) p<0.0001 One way ANOVA with 





Figure 4.5: Epigallocatechin treatment shows an inhibitory trend on 
pathogenic ‘Swedish’ mutant APP processing 
5 DIV primary cortical neurons were transfected with either 0.5 μg pRC-APP-
Gal4 or pRC-APPswe-Gal4; all wells were co-transfected with 0.5 μg each of 
pFR-luciferase, pRL-TK-Renilla and pC1-Fe65. 0.5h later pRC-APPswe-Gal4 
transfected neurons were treated with DAPT (10 μM) or epigallocatechin 
(0.01-10 μM) for 24h. Treatment with DAPT significantly inhibited APPswe-
Gal4 dependent luciferase expression. Epigallocatechin potently inhibited βγ-
secretase dependent APP processing with an EC50 of 34 nM. Dual-Glo 
luciferase activity assays were performed 24h post transfection for 
quantification of firefly and Renilla luciferase expression. Firefly luciferase 
reporter expression was normalised using the Renilla luciferase expression 
and expressed as % APPswe-Gal4 control relative luminescence. Each column 
or point is mean ± S.E.M. of 25 independent transfections across 5 separate 
cultures (n=25, # compared to S (APPswe-Gal4 control) p<0.0001 One way 




Figure 4.6: Trend towards concentration dependent (-) epicatechin inhibition 
of Aβx-40 release into media in primary cortical neurons. 
 (A) Standard curve was generated through serial dilution of Aβ1-40 standard 
(n=3). (B) 5DIV primary cortical neurons were treated with vehicle (24h), 100 
nM (-) epicatechin, 300 nM (-) epicatechin (6h) or 10 μM DAPT (24h). Aβ 
levels were assessed by ELISA using Colorimetric BetaMark x-40 ELISA 
(Covance). DAPT levels were negligible and therefore could not be estimated 







The APP-Gal4 gene reporter assay was used to screen flavonoids leading to 
identification of four effective molecules that reduced levels of β-secretase 
dependent APP processing: epigallocatechin, fisetin, pelargonidin chloride and 
sinensetin. Further concentration and kinetic analyses of the catechin family of 
flavanols, chosen due to their favourable bioavailability and blood brain barrier 
permeability, identified (-) epicatechin, as well as confirming epigallocatechin, to be 
potent inhibitors of APP-Gal4 dependent luciferase expression. When challenged 
with more pathological levels of amyloidogenic processing, both (-) epicatechin and 
epigallocatechin remained potent inhibitors, although levels of inhibition were 
lower compared to the inhibition observed with WT APP. Finally, to validate the 
findings of the APP-Gal4 gene reporter assay, Aβ levels from the media of (-) 
epicatechin treated cultures were measured and showed reduction in Aβ levels. 
4.3.1. APP-Gal4 gene reporter assay identified 
inhibitors of βγ-secretase mediated APP processing 
 
The APP-Gal4 gene reporter assay identified four flavonoids with inhibitory actions 
at 100 nM. Only the flavone sinensetin was inhibitory at 10 μM, whilst a number of 
flavonoids promoted β-secretase processing at 10 μM. Epigallocatechin and fisetin 
showed bi-phasic effects inhibiting APP processing at 100 nM and stimulating APP 
processing at 10 μM. This biphasic profile has been reported previously for 
flavonoid modulation of ERK and Akt signalling pathways in neurons (Schroeter et 
al., 2007, Vauzour et al., 2007) and suggests that concentration is a critical 
determinant of flavonoid selectivity.  
The four flavonoids identified from the screen each originate from a different 
flavonoid subfamily. As flavonoids are segregated into families dependent on their 
structure, this suggests there is not a simple structural link between flavonoids and 
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predicted bioactivity at APP. Traditionally, flavonoids were suggested to exert their 
beneficial effects through their activities as antioxidants, however antioxidant 
capacity of flavonoids is heavily dependent on their structure, therefore it is 
unlikely that this property of flavonoids was the mechanism responsible in reducing 
amyloidogenic processing. The concentrations at which the flavonoids exerted their 
effects also supports this conclusion, as it would be highly unlikely that nanomolar 
concentrations of flavonoids would exert a strong enough antioxidant effect to be 
beneficial over endogenous and media supplemented antioxidants such as vitamin 
E and ascorbate.  
The identification of fisetin as an inhibitor of β-secretase mediated APP processing 
was consistent with previous work showing fisetin to be effective at reducing 
aspects of Aβ pathology. Fisetin has been shown to inhibit Aβ1-42 fibrillogenesis in 
vitro and long term oral administration of fisetin to APP/PS1 transgenic mice 
improved spatial memory and reduced soluble Aβ. This is suggestive of an ability to 
affect APP processing (Kim et al., 2005a, Currais et al., 2013) and provides strong 
support for the APP-Gal4 screen as an approach for identifying bioactive molecules. 
Fisetin has also been shown to activate signalling pathways associated with long-
term memory. Fisetin activated CREB in an ERK dependent manner, leading to 
increased LTP, the cellular mechanism highly implicated as crucial for memory 
formation. Similar to the fisetin-mediated inhibition of APP processing, LTP 
potentiation by fisetin was also a biphasic effect, maximal at 1 μM and lost at 10 
μM (Maher et al., 2006). Although not directly comparable, the concentration 
dependence of fisetin-mediated inhibition in this study and correlation with 
previous studies is suggestive of it acting through cell signalling pathways. 
Pelargonidin as a major flavonoid constituent of blueberries and strawberries has 
been implicated in reversing age-related cognitive decline (Joseph et al., 1999). 
Despite these promising results from epidemiological studies, no study has been 
published showing pelargonidin to be effective at reducing APP pathology. Thus, 
this is the first report of pelargonidin activity at APP. Although there was no 
previous evidence of pelargonidin being effective in AD, pelargonidin pre-treatment 
has been shown to be neuroprotective against neuronal injury induced by injection 
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of 6-hydroxydopamine and endogenous neurotoxins associated with PD (Vauzour 
et al., 2008, Roghani et al., 2010) providing additional evidence of activity in 
neuronal cell types. For flavonoids to be able to exert a positive effect on APP 
processing in vivo, the major hurdles of bioavailability and blood brain barrier 
permeability must be considered and overcome. Anthocyanidins are water soluble 
molecules and the pelargonidin aglycone reaches detectable levels in the brain 
following oral gavage, although it was shown to undergo rapid metabolism (El 
Mohsen et al., 2006). Pelargonidin may therefore be a structure of interest for drug 
development of APP processing modulation, despite the lack of mechanistic and 
efficacy data. 
Sinensetin was the only flavonoid that inhibited APP-Gal4 mediated luciferase 
expression at both concentrations tested. Like fisetin, sinensetin has been shown to 
promote LTP-associated signalling pathways, however unlike fisetin which only 
potentiated at concentrations up to 1 μM, sinensetin has been shown to activate 
CRE-mediated transcription in rat hippocampal neurons, at 100 μM(Kawahata et al., 
2013). It would therefore have been interesting to investigate the concentration-
dependence of the sinensetin-mediated inhibition of APP-Gal4 mediated luciferase 
expression as this apparent lack of concentration-dependence is currently 
suggestive of an independent mechanism of APP-Gal4 dependent luciferase 
expression for sinensetin compared to the other flavonoids.  
Epigallocatechin was perhaps the most significant positive hit from the assay, as it is 
a member of an intensively studied family of flavanol molecules called the 
catechins. The catechins have known bioavailability in a variety of mammalian 
models (van Praag et al., 2007, Ho et al., 2013) and have been previously postulated 
to have therapeutic potential (Williams and Spencer, 2012). For these reasons, 
further investigation of the catechin family was undertaken. Due to poor 
bioavailability (fisetin and sinensetin) and paucity of previous studies (pelargonidin 
and sinensetin) further investigation into these molecules was not carried out. 
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4.3.2. Flavanol inhibition of βγ-secretase-mediated APP 
processing is concentration and time-dependent 
 
Through the initial screen, flavonoid concentration was shown to be critical to 
bioactivity of the flavonoids. It is also documented that flavonoids are quickly 
metabolised, potentially altering their structure into inactive forms. For these 
reasons, the catechin family were screened further over a wider range of 
concentrations and at two time points – 6h and 24h. Further concentration and 
kinetic analysis of the catechin family revealed that (-) epicatechin, in addition to 
epigallocatechin, possessed potent inhibitory actions but only when applied for 
shorter time periods.  
Both (-) epicatechin and epigallocatechin showed maximal inhibition in the high 
nanomolar to low micromolar concentration range with neither causing inhibition 
at 10 µM. Epigallocatechin promoted amyloidogenic processing at the highest 
concentration tested, 10 µM and therefore this data point had to be excluded to 
enable accurate calculation of the EC50 value of its inhibitory action. Calculation of 
EC50 values for the activation of amyloidogenic processing by epigallocatechin was 
not possible due to a lack of data points at higher concentrations. The reason for 
this concentration dependent effect was not fully elucidated however may be 
linked to flavonoid activity at additional cellular targets at higher concentrations. 
Activation of PKC-dependent signalling pathways has been well characterised as a 
cellular mechanism for promotion of non-amyloidogenic processing (Mills and 
Reiner, 1999), causing a shift away from amyloidogenic APP processing (Hung et al., 
1993). A concentration dependent inhibition of PKC by micromolar concentrations 
of flavonoids has previously been reported (Ferriola et al., 1989). Although the 
study did not specifically identify epigallocatechin or (-) epicatechin, inhibition of 
PKC-dependent-α-secretase activity and resultant increases in the level of 
amyloidogenic processing could counteract the inhibitory activities of (-) 
epicatechin and epigallocatechin at lower concentrations. This would lead to the 
apparent loss of inhibitory activity at 10 µM. Activity at PKC could also be 
155 
 
responsible for the promotion of amyloidogenic APP processing seen with 
epigallocatechin at 10 µM and would suggest that epigallocatechin was a more 
effective inhibitor of PKC-dependent signalling than (-) epicatechin.  
The different kinetics of the catechins is difficult to address as previous studies have 
not investigated time-dependence of flavonoid activities. Epigallocatechin showed 
effective, potent inhibition of β-dependent APP processing at 24h but showed no 
activity at 6h. As cells were transfected for the same length of time for both the 6h 
and 24h treatments, it is unlikely to be due to insufficient luciferase expression 
levels in the 6h treatment.  The gallate group of epigallocatechin not only increases 
its size but also increases its polarity, two factors that will reduce its cell 
permeability and increase the time taken for epigallocatechin to reach its cellular 
target, which could be a simple explanation for the time-dependence of the 
epigallocatechin effect. A second explanation could point to a transcriptional 
mechanism of action, whereby a 6h treatment does not provide enough time for 
epigallocatechin to exert its beneficial effect. Thirdly, flavonoids are known to be 
heavily metabolised, as no measurements of catechin metabolites in treated 
cultures have been made, it may be that epigallocatechin is not the bioactive form 
and cellular metabolism must first occur to generate the active molecule which can 
then exert its beneficial effect, once again, delaying the time at which the 
epigallocatechin treatment exerts its effect. 
(-) Epicatechin exhibited the inverse time-dependence of epigallocatechin, showing 
inhibitory activity at 6h, but no activity at 24h. In vivo studies in rats and humans, 
measuring catechin absorption levels consistently identify the (-) epicatechin 
aglycone as a major constituent of the total catechin absorbed. This suggests that it 
is highly cell penetrant and therefore can reach intracellular targets rapidly to exert 
its effect (Rein et al., 2000, Spencer et al., 2001, Schroeter et al., 2006). Further 
bioavailability studies  of (-) epicatechin show it reaches maximal concentrations 2h 
post ingestion and levels are reduced back to basal by 6-8h, suggesting it is rapidly 
broken down (Rein et al., 2000). The acute effect seen with (-) epicatechin is 
therefore likely due to breakdown of the active compound. The acute nature of the 
(-) epicatechin effect is also suggestive of a post-translational mechanism of action 
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that is not maintained once (-) epicatechin is degraded. It would have been of 
interest to study the effect of 24h (-) epicatechin treatment with repeated doses to 
investigate whether the lack of 24h activity of (-) epicatechin was due to active 
compound degradation. 
Although (-) epicatechin and epigallocatechin showed similar potencies, (-) 
epicatechin was less effective than epigallocatechin. To ensure sufficient luciferase 
expression, cultures for the 6h catechin treatments were transfected 24h prior to 
luminescence detection. Therefore APP-Gal4 cleavage had been taking place for 
19h prior to treatment with the specific catechin molecule. The measurement of 
luciferase expression therefore contained a proportion of expression that was not 
modulated by (-) epicatechin which would lead to an underestimate of the efficacy 
of (-) epicatechin inhibition. 
4.3.3. Fe65 does not alter APP-Gal4 gene reporter assay 
sensitivity to modulators of APP processing 
 
One of the major limitations of the APP-Gal4 gene reporter assay in primary 
neurons was the transfection efficiency and the related low level of luciferase 
expression. In order to extend the dynamic range of the assay, the adaptor protein 
Fe65 was co-transfected and led to significant induction of luciferase expression, 
most likely due to stabilisation of the γ-secretase cleavage product AICD-Gal4. 
However, it had been suggested that introduction of Fe65 would alter the biological 
effect of novel modulators in the screen and therefore all concentration and kinetic 
analyses of the catechin family were carried out in parallel in the presence and 
absence of Fe65 (Hoey et al., 2009). 
In both the presence and absence of Fe65, epigallocatechin (24h) and (-) 
epicatechin (6h) were identified as potent inhibitors of APP-Gal4 dependent 
luciferase expression, supportive of Fe65 having no biological effect on modulation 
of APP by the catechin family. 
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4.3.4. (-) Epicatechin and epigallocatechin show 
inhibitory trends on pathogenic βγ-secretase-
mediated APP processing 
 
Previous studies have shown that certain flavanols reduce Aβ pathology in 
transgenic models of AD (Rezai-Zadeh, 2005, Wang et al., 2012). To determine 
whether (-) epicatechin and epigallocatechin were effective against higher, more 
pathological levels of β-mediated APP processing, primary neurons transfected 
with APPswe-Gal4 were treated with (-) epicatechin (6h) and epigallocatechin (24h). 
In agreement with the in vivo studies, (-) epicatechin and epigallocatechin showed 
inhibitory trends on APPswe-Gal4 luciferase expression. 
 The Swedish mutation of APP causes increased amyloidogenic processing through a 
relocalisation of amyloidogenic APP processing activity from the TGN and 
endosomes to secretory vesicles, the same compartment as the non-amyloidogenic 
APP processing. This increases competition at this site and increases the proportion 
of amyloidogenic APP processing (Haass et al., 1995b). The reduced efficacy of the 
catechins in the Swedish mutant assay may suggest that cellular localisation of APP 
is an important factor in catechin-mediated inhibition of β-mediated processing, 
however further investigation would be required to provide conclusive evidence for 
this. Analysis of catechin inhibition of other APP mutants associated with AD would 
further aid elucidation of the mechanism of action due to the range of mechanisms 
through which they increase Aβ pathology. This would allow assessment of flavanol 
efficacy at mutants reported to increase fibrillogenesis of Aβ, and mutants that 




4.3.5. (-) Epicatechin treatment shows inhibitory trend 
in production of Aβx-40 
 
Due to the limitations of the luciferase assay, it was important to validate its 
findings using a different technique. Therefore the effect of (-) epicatechin (6h) 
treatment on Aβ production by ELISA was performed. As the concentration of Aβ42 
released from primary neuronal cultures is below the sensitivity level of current 
commercial ELISA kits, an Aβ ELISA measuring concentrations of released Aβx-40 was 
used.  
(-) Epicatechin caused a maximal reduction of Aβx-40 of 43% of control, supporting 
the results from the APP-Gal4 luciferase gene reporter assay. This was also in 
agreement with an independent study that showed monomeric catechins, of which 
(-) epicatechin is a significant component, reduced Aβ1-40 levels by approximately 
50%, following chronic oral administration to transgenic Tg2576 mice (Wang et al., 
2012). In collaborative work, we also showed that (-) epicatechin reduced Aβ levels 
in primary TASTPM cortical cultures by 30% and reduced Aβ plaque load by 




This screen has identified potent inhibitors of amyloidogenic APP processing in 
primary neurons. Consideration of bioavailability and proven drug-like properties 
focussed study on the catechin family. (-) Epicatechin and epigallocatechin were 
potent inhibitors of amyloidogenic processing under physiological and 
pathophysiological conditions. Previous reports and collaborative data showed (-) 
epicatechin to be effective at reducing Aβ levels in vitro and in vivo in rodent 
models of AD, therefore the next chapter shall focus on (-) epicatechin to 






5. Mechanistic investigation of (-) 
epicatechin-mediated inhibition 






 The APP-Gal4 reporter assay and further kinetic analyses identified epicatechin as a 
potent inhibitor of βγ-secretase mediated APP processing (Chapter 4). (-) 
Epicatechin reduced luciferase expression in the APP-Gal4 and APPswe-Gal4 
reporter assays and also showed a trend toward reduced Aβ levels.  
The processing of APP can follow the amyloidogenic or the non-amyloidogenic 
pathway. Differentiating these pathways is the initial shedding step, mediated by β-
secretase in the amyloidogenic pathway and by α-secretase in the non-
amyloidogenic pathway. Cleavage of APP by β-secretase releases the sAPPβ 
ectodomain and leaves the C-terminal stub, a 99 amino acid peptide (C99) retained 
in the membrane (Haass and Selkoe, 1993, Vassar et al., 1999). Cleavage of APP by 
α-secretase mediates release of sAPPα and retention of an 83 amino acid (C83) C-
terminal stub in the membrane (Sisodia, 1992a, Lammich et al., 1999). The second 
cleavage step is common to both pathways, and is mediated by the γ-secretase, 
which releases the 49 amino acid AICD. This cleavage occurs in different cellular 
compartments depending on the processing pathway: at the plasma membrane for 
non-amyloidogenic and predominantly in endosomes for the amyloidogenic 
pathway (St George-Hyslop and Schmitt-Ulms, 2010). Due to the different N-termini 
of the C-terminal stubs, γ secretase mediates release of Aβ in the amyloidogenic 
pathway, and the 16 amino acid shorter P3 peptide in the non-amyloidogenic 
pathway (Lichtenthaler et al., 2011). Due to the differences in size and amino acid 
sequence at the C- and N-termini of the APP metabolites, they can be differentiated 
from each other using specific antibodies or size separation. This allows changes in 
APP processing to be deduced through measurement of specific APP metabolite 
levels. 
Despite intense research into the potential cellular mechanisms through which 
flavonoids mediate risk reduction of AD and modulation of APP pathology, there is 
still great uncertainty as to how they are exerting their effects. The best-
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characterised mode of action has been for the flavanol EGCG. Evidence from cell 
lines as well as primary transgenic neurons suggested that EGCG at micromolar 
concentrations enhanced maturation of ADAM10, leading to increased sAPPα and 
αCTF production and decreased Aβ levels (Rezai-Zadeh, 2005, Obregon et al., 2006). 
Although not supporting the ADAM10 involvement, independent studies have 
supported EGCG mediated increases in sAPPα in both cell lines (Levites et al., 2003) 
and primary neurons (Wang et al., 2006). Despite this well characterised 
mechanism for EGCG, it is still not clear-cut and other modes of action have been 
proposed. EGCG has also been shown to suppress Aβ-induced BACE1 up-regulation 
(Shimmyo et al., 2008a), to stabilise oligomers so that they do not stimulate 
fibrillogenesis (Ehrnhoefer et al., 2008) and to inhibit APP interactions with adaptor 
proteins (Lin et al., 2009). 
Although not as well defined, an alternative mechanism for flavonoid modulation of 
APP processing is as direct catalytic inhibitors of BACE1 (Shimmyo et al., 2008b). 
Two flavones, quercetin and myricetin (20 μM), decreased BACE1 activity and 
decreased Aβ1-40, and Aβ1-42 levels in primary neurons. Inhibition of BACE1 provides 
the most direct mechanism for flavonoid-mediated inhibition of amyloidogenic 
processing; however the concentrations at which these flavonoids showed activity 
are not achievable in the brain, suggesting this activity may not be physiologically 
relevant. In silico docking studies suggest that flavonoids can directly interact with 
the active site of BACE1 through hydrogen bonds (Shimmyo et al., 2008b). In silico 
work allows analysis of potential interactions between proteins and thus can give 
useful mechanistic information once direct interaction has been experimentally 
established, however as this has not been conclusively proven, this catalytic 
inhibition mechanism remains speculative. 
Flavonoid-mediated γ secretase modulation has also been proposed: another 
flavone, luteolin (20-40 μM), was shown to promote presenilin phosphorylation by 
GSK3α. This decreased γ secretase activity on APP through disruption of APP-PS1 
association, thus decreasing Aβ production (Rezai-Zadeh et al., 2009). 
Pharmaceutical attempts to target γ secretase through traditional drug design have 
failed due to off-target actions at other γ secretase substrates notably notch. 
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Further considerations include potential toxicity due to accumulation of β-CTFs; 
however in vitro evidence suggests the build-up of β-CTFs is much lower following 
luteolin treatment than following inhibition by a direct γ secretase inhibitor. 
Indirect γ secretase inhibition may therefore be a less toxic, more regulative mode 
of inhibition (Rezai-Zadeh et al., 2009). 
The complexity of APP processing regulation and the variety of flavonoids reported 
to have activity has made elucidation of a common mechanistic pathway extremely 
difficult. It was therefore important to try and elucidate the mechanism through 
which (-) epicatechin was exerting its effect in our system. 
In order to determine the mechanism underlying the (-) epicatechin-mediated 
changes, biochemical analysis of APP metabolites in primary cortical neurons and 
cell lines were measured with particular focus on sAPPα modulation. Further to 
this, a recombinant BACE1 activity assay and a gene reporter notch assay were 






5.2.1. Notch activity is unaffected by epicatechin 
treatment 
 
To investigate whether (-) epicatechin was acting through γ-secretase a notch-Gal4 
luciferase reporter assay was used. Transfected primary cortical neurons were 
treated with epicatechin (0.1-10 µM) or DAPT (10 µM) for 6h and luciferase 
expression measured. DAPT caused a substantial reduction in luciferase expression 
demonstrating that the assay was sensitive to -secretase cleavage of notch as 
expected. (-) Epicatechin did not affect luciferase expression at either concentration 
(Figure 5.1); strongly suggesting its bioactivity was not at the level of γ-secretase.  
5.2.2. (-) Epicatechin does not affect APP695 levels  
 
Chapter 4 identified (-) epicatechin and epigallocatechin as potent inhibitors of APP 
processing. Although these results were consistent with inhibition of β-secretase 
mediated APP processing there were a number of potential mechanisms through 
which this might be occurring. Changes in levels of APP695 could lead to altered APP 
processing. If levels were reduced, less APP would be available for processing which 
would lead to apparent inhibition of APP processing in the APP-Gal4 assay. This 
would however be due to lack of substrate rather than modulation of processing 
itself. To investigate whether the inhibitory actions of (-) epicatechin were the 
result of changes in APP expression, primary neurons were treated with 100 nM (-) 
epicatechin over 24h and APP695 levels were measured by western blot analysis. No 
significant change was observed (Fig 5.2(A and E)), indicating (-) epicatechin was 
not acting to down-regulate APP levels in primary neurons either through inhibition 




Figure 5.1: (-) Epicatechin does not affect γ-secretase activity 
 5 DIV primary cortical neurons were co-transfected with 0.5μg each Notch-Gal4, 
pFR-luciferase and pRL-TK-Renilla, after 0.5h and 18h, cells were treated with DAPT 
or (-) epicatechin (0.1 and 10 μM) respectively. Dual-Glo luciferase activity assays 
were performed 24h post transfection for quantification of firefly and Renilla 
luciferase expression. Firefly luciferase reporter expression was normalised using the 
Renilla luciferase expression and transformed to % control relative luminescence. 
Each column is the mean ± S.E.M. of 18 independent transfections from 3 separate 




Figure 5.2: (-) Epicatechin effects are independent of APP695 expression levels and 
ectodomain shedding in primary cortical neurons 
(A) 6 DIV primary C57/BL6 cortical neurons were treated with vehicle (C) or 100 nM (-) 
epicatechin (EC) for 30 min, 1h, 3h, 6h or 24h followed by immunoblotting with 22C11 
(APP and sAPPt), 5G11 (sAPPα), 192WT (sAPPβ) or β tubulin. sAPPα, sAPPβ and sAPPt 
levels were measured from conditioned media removed from the neurons. APP695 and β 
tubulin levels were measured from whole cell lysate. Levels of (B) sAPPα, (C) sAPPβ, (D) 
sAPPt and (E) tAPP relative to β tubulin were analysed by ECL protein band 
densitometry using calibrated Image J software. Each point represents the mean ± 
S.E.M. Representative blots from four independent experiments (n=4).  
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5.2.3. (-) Epicatechin does not affect sAPP levels in 
primary neurons 
 
Previous studies investigating the effects of flavanols on APP processing have 
suggested up-regulation of the constitutive α-secretase enzymatic activity, 
ADAM10, as the likely mechanism of action (Obregon et al., 2006, Fernandez et al., 
2010). Increased ADAM10 activity leads to increased levels of the neuroprotective, 
sAPPα. Furthermore, up-regulation of ADAM10-mediated APP processing has been 
shown to down-regulate production of amyloidogenic proteolytic products (Rezai-
Zadeh, 2005, Colombo et al., 2012). In order to investigate this possibility, sAPPα 
levels in the culture medium following 100 nM (-) epicatechin treatments over 24h 
were measured using a sAPPα specific antibody by western blot analysis. (-) 
Epicatechin showed no time-dependent changes in the levels of sAPPα (Figure 5.2(A 
and B)) suggesting that α-secretase was not the primary target. This was supported 
by measurement of total secreted APP levels, using an APP N-terminal antibody, 
which also showed no change (Figure 5.2(A and D)). 
Despite the literature favouring modulation of α-secretase as the mechanism of 
action of flavanols, the most direct mechanism through which (-) epicatechin exerts 
its inhibitory effects would be inhibition of BACE1-mediated APP processing. To 
investigate this, parallel measurements of sAPPβ expression levels following (-) 
epicatechin treatment were measured. (-) Epicatechin treatment caused no time-
dependent changes in the levels of sAPPβ (Figure 5.2(A and C)) suggesting that 
BACE1 cleavage of APP was also unaffected. 
5.2.4. (-) Epicatechin does not significantly affect APP or 
sAPPα production in SH-SY5Y or HEK293T cells 
 
Unlike most cell types and immortalised cell lines, which display non-amyloidogenic 
processing as their dominant APP processing pathway, primary neurons exhibit a 
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dominant amyloidogenic pathway, accounting for over 50% of the APP processed in 
the cell (Colombo et al., 2012). To investigate whether cell type specificity would 
affect the ability of (-) epicatechin to modulate sAPPα levels, two cell lines, 
HEK293T and SH-SY5Y cells were treated with (-) epicatechin (0.1-10 μM) for 3h and 
6h. sAPPα and APP695 levels were then measured by western blot analysis (Figure 
5.3 and 5.4). Both HEK293T and SHSY5Y showed a slight trend towards a time-
dependent increase in sAPPα levels following (-) epicatechin treatment, however 
this did not reach significance (Figure 5.3(A-B) and 5.4(A-B)). APP695 levels showed 
no significant change in either cell type (Figure 5.3(A and C) and 5.4(A and C)).  
5.2.5. Sheddase enzyme expression is unaltered 
following (-) epicatechin treatment 
 
APP metabolites provide an indication as to the levels and relative contributions of 
the two APP processing pathways. An alternative to measurement of the APP 
proteolytic products is to study expression levels of the secretase enzymes. 
Although this does not give a direct indication of the activity level of these enzymes, 
which is tightly controlled post-translationally, it allows (-) epicatechin mediated 
expression changes to be evaluated. 
Measurements of ADAM10 and BACE1 expression levels following (-) epicatechin 
treatment were conducted. Primary neurons were treated with 100 nM (-) 
epicatechin for 0.5h and 6h and levels of ADAM10 and BACE1 in cell lysate 
measured by western blot analysis. Neither ADAM10 nor BACE1 expression levels 
were altered at either time point (Figure 5.5). As ADAM10 and BACE1 are the 
secretase enzymes primarily responsible for APP ectodomain shedding this result 







Figure 5.3: (-) Epicatechin treatment does not affect released sAPPα levels in SH-
SY5Y cells 
(A) SHSY5Y cells were treated with vehicle (C) or (-) epicatechin (100 nM and 10 
μM) for 3h and 6h followed by immunoblotting for sAPPα (5G11), APP (22C11) or 
β actin. sAPPα levels were measured from conditioned media. APP695 and β actin 
levels were measured from whole cell lysate. Levels of (B) sAPPα and (C) tAPP 
relative to β actin were analysed by ECL protein band densitometry using 
calibrated Image J software. Each point represents the mean ± S.E.M. 




Figure 5.4: (-) Epicatechin does not affect released sAPPα levels in HEK293T cells 
(A) HEK293T cells were treated with vehicle (C) or (-) epicatechin (100 nM and 10 
μM) for 3h and 6h followed by immunoblotting for sAPPα (5G11), APP (22C11) or 
β actin. sAPPα levels were measured from conditioned media. APP695 and β actin 
levels were measured from whole cell lysate. Levels of (B) sAPPα and (C) tAPP 
relative to β actin were analysed by ECL protein band densitometry using 
calibrated Image J software. Each point represents the mean ± S.E.M. 




Figure 5.5: (-) Epicatechin treatment does not affect α- or β-secretase levels in 
primary cortical neurons 
(A) 6 DIV primary C57/BL6 cortical neurons were treated with vehicle (C) or (-) 
epicatechin (100 nM) for 30 min or 6h followed by immunoblotting for ADAM10 
(735-749), BACE1 (2C13) or β tubulin. Levels of (B) ADAM10 and (C) BACE1 relative 
to β tubulin were analysed by ECL protein band densitometry using calibrated 
Image J software. Each column is the mean ± S.E.M. of 4 independent treatments 
from 2 separate cultures. 
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5.2.1. (-) Epicatechin indirectly inhibits BACE1 
activity 
 
As it appeared that levels of BACE1 were not altered, the possibility that (-) 
epicatechin was acting at the level of BACE1 activity was investigated. To do this, a 
cell free, recombinant BACE1 assay was employed. Initial characterisation of the 
assay showed a direct, linear relationship between standard substrate 
concentration and fluorescence intensity (Figure 5.6(A)). To test the sensitivity of 
the assay, a concentration response utilising the β-secretase inhibitor BsI was 
performed. BsI (0.1-10 μM) was incubated with BACE1 for 6h and showed an IC50 of 
117 nM and maximal inhibition of 96.1% compared to control (Figure 5.6(B)). In 
order to validate the assay as a specific measure of BACE1 activity, two commercial 
β-secretase inhibitors, BsI and BiV, were incubated with BACE1 and showed 93% 
and 95% inhibition respectively compared to control. Incubation with the γ 
secretase inhibitor DAPT did not cause significant inhibition compared to control, 
supporting the specificity of the assay towards β-secretase modulators (Figure 
5.6(C)). To investigate the effect of (-) epicatechin on BACE1 activity, (-) epicatechin 
(100 nM) was incubated with BACE1 for 6h and showed no effect. This suggested it 
was not acting as a direct catalytic inhibitor (Figure 5.6(C)).  Alternatively, non-
catalytic actions might be responsible for the inhibitory effects of epicatechin. 
Primary neurons were therefore treated with (-) epicatechin or epigallocatechin 
(0.01-10 μM) for 6h, lysates prepared and incubated with synthetic BACE1 
substrate to measure endogenous BACE1 activity. (-) Epicatechin (100 nM) reduced 
BACE1 activity by 72% compared to BsI (Figure 5.6(D)). In comparison 
epigallocatechin caused maximum inhibition (86%) at 1µM. At higher 
concentrations of (-) epicatechin and epigallocatechin there was no inhibition of 







Figure 5.6: (-) Epicatechin indirectly modulates BACE1 activity  
(A) Standard curve was calculated by serial dilution of 100 μM stock assay 
standard solution with fluorescent assay buffer. Levels of fluorescence at 405 nm 
were measured after 2h incubation. Curve was generated by subtraction of assay 
blank from all signal readings at 2h. All points are the mean ± S.E.M. of 4 
independent experiments. (B) Assay components were incubated with vehicle or 
BsI (10 nM-10 μM) for 2h followed by measurement of fluorescence levels at 405 
nm. Results expressed as % BACE1 activity compared to vehicle (control). (C) Assay 
components were incubated with vehicle (C), BsI (10 μM), BiV (10 μM), DAPT (10 
μM) or EC (100 nM) for 2h followed by fluorescence measurement at 405 nm. 
Levels of fluorescence are expressed as % control levels. Each column is the mean 
± S.E.M. of 3 independent experiments (n=3; ****p<0.0001 One way ANOVA with 
Bonferroni post-test). (D) Reduction of BACE1 activity in primary cell lysates 
treated with (-) epicatechin and epigallocatechin. Primary neuronal cultures were 
treated with 10 μM BsI (24h), (-) epicatechin (6h) or epigallocatechin (24h), the 
cells were then lysed and levels of BACE1 activity were measured following 2h 
incubation with synthetic peptide substrate. Data is represented as % inhibition 






This chapter aimed to address whether (-) epicatechin, was exerting its inhibitory 
effects on βγ-mediated APP processing and released Aβ through direct modulation 
of the proteolytic machinery responsible for APP metabolism. Biochemical analysis 
of primary neurons showed (-) epicatechin treatment did not alter APP695 levels. 
Analysis of APP metabolites in primary neurons suggested that (-) epicatechin did 
not exert its effect through modulation of the non-amyloidogenic pathway, a 
finding supported by a lack of an (-) epicatechin mediated effect on ADAM10 
expression. Investigation into the effects of (-) epicatechin on the amyloidogenic 
pathway suggested (-) epicatechin acts through indirect inhibition of BACE1 
enzymatic activity.  
5.3.1. (-) Epicatechin does not interfere with γ-
secretase mediated notch cleavage 
 
With respect to the development of (-) epicatechin for use in humans, an important 
consideration is the potential for inhibitory actions at γ-secretase. There have been 
a number of recent clinical trial failures for AD drugs due to off target effects at 
notch, leading to gastrointestinal and immune cell toxicity (Imbimbo et al., 2011, 
Doody et al., 2013). Assessment of (-) epicatechin effects on γ secretase is 
technically more challenging that the other secretase enzymes as it is a complex of 
proteins, therefore biochemical measurement of component protein levels does 
not necessarily reflect active complex. Furthermore, proteolytic products of γ 
secretase are either dependent on sheddase activity in the cases of Aβ and P3 or 
extremely technically challenging to detect in the case of free AICD. For these 
reasons, an assay measuring γ secretase activity at an alternative substrate, notch, 
was utilised which also allowed determination of off-target effects of (-) 
epicatechin. (-) Epicatechin did not inhibit notch cleavage at any concentration 
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tested suggesting that this is unlikely to be a significant hurdle to the development 
of (-) epicatechin as a potential treatment or prophylactic for AD. Lack of inhibition 
at notch also suggested that (-) epicatechin was not acting at the level of γ-
secretase mediated cleavage of APP; however activity at the site of γ-secretase 
cleavage on APP could not be excluded.  
5.3.2.  APP695 protein levels unaffected by (-) 
epicatechin treatment 
 
APP695 expression levels in primary neurons following (-) epicatechin treatment 
were not significantly changed. This suggests that the reduction in amyloidogenic 
processing seen following (-) epicatechin treatment is not due to lack of APP 
substrate but due to modulation of the proteolytic process. Previous studies 
investigating structurally related flavanol-mediated effects on APP processing have 
been shown to be independent of APP695 levels, supporting an APP695 holoprotein 
independent mechanism (Rezai-Zadeh, 2005, Wang et al., 2006).  
5.3.3. (-) Epicatechin mediated effect on amyloidogenic 
APP processing is independent of up-regulation of 
sAPPα production. 
 
Previous studies of a structurally similar catechin, EGCG, showed that it mediated 
up-regulation of sAPPα via enhanced ADAM10 maturation and mitigated Aβ levels 
in Swedish mutant APP overexpression cell lines, primary neurons and transgenic 
mice (Rezai-Zadeh, 2005, Obregon et al., 2006, Fernandez et al., 2010). EGCG 
formed part of the original screen and did not show any bioactivity, however lower 
concentrations of EGCG were tested in this study than that at which EGCG was 
shown to have potentiating effect on sAPPα. Therefore it was considered logical 
that (-) epicatechin could be a more potent molecule which acts through the same 
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mechanism as EGCG, but at lower concentrations. For this reason, levels of secreted 
sAPPα relative to β- tubulin were measured in primary neurons following (-) 
epicatechin treatment to investigate whether the same mechanism of action was 
responsible; however no changes in sAPPα levels were detected at any time point. 
A kinetic analysis was performed as although (-) epicatechin mediated effects in the 
APP-Gal4 reporter assay showed inhibitory activity at 6h, the dependence on 
expression of the gene reporter luciferase protein made extrapolation of this time-
course difficult for measurement of endogenous APP modulations. 
Firstly it is important to stress that the fact increased sAPPα levels were not found 
does not directly contradict the mechanistic results from the studies that 
investigated EGCG-mediated effects on APP. At the chemical level, structural 
differences between (-) epicatechin and EGCG, with (-) epicatechin lacking the 
gallate moiety on its B ring could explain the differences in bioactivity. There were 
also a number of experimental and biological differences between the studies. The 
main aim of this work was to identify mechanisms through which (-) epicatechin 
might exert its effects at physiological concentrations shown to be achievable in the 
mammalian brain following oral delivery. Studies showing EGCG as effective at 
increasing sAPPα levels utilised micromolar concentrations of EGCG, with maximal 
potentiation of sAPPα production at 20 μM, however concentrations of flavanols in 
the mammalian brain peak at 200-400 nM (van Praag et al., 2007, Wang et al., 
2012). Therefore this mechanism of flavanol activation may be possible, however 
only at higher concentrations of flavanol. Although EGCG treatment in an in vivo 
mouse model of AD caused increased sAPPα levels and a concomitant increase in α-
secretase activity, this was following IP injection, bypassing the need for intestinal 
absorption and allowing higher in vivo concentrations to be achieved (Rezai-Zadeh, 
2005).  
Further to this, work investigating potential cellular mechanisms of action for (-) 
epicatechin in this thesis has been carried out in WT primary neurons, whilst EGCG 
mediated mechanistic studies were predominantly carried out in the Swedish 
mutant APP-overexpressing neuron-like cell line N2A or primary neurons derived 
from Swedish mutant APP overexpressing transgenic mice (Tg2576). Therefore to 
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assess the cell type specificity of sAPPα production, 2 cell lines were employed. The 
SH-SY5Y cell line was chosen as a well-characterised in vitro model of neuronal 
function that constitutively expresses APP and releases considerable amounts of 
sAPPα (Levites et al., 2003), and HEK293T cells as a commonly used transformed 
cell line with high levels of non-amyloidogenic APP processing (Colombo et al., 
2012). Both these cell lines when treated with (-) epicatechin showed no significant 
increases in sAPPα suggesting cell type or APP expression level does not impact on 
the underlying mechanism. It would still be of interest to investigate (-) epicatechin-
mediated effects on sAPPα in transgenic primary cultures to fully assess this 
conclusion.  
5.3.4. (-) Epicatechin acts as an indirect inhibitor of 
BACE1 activity independent of BACE1 expression 
 
As the mechanism of action by which (-) epicatechin was acting in WT primary 
cortical neurons did not appear to be through up-regulation of the non-
amyloidogenic pathway, the simplest potential mechanism for the observed (-) 
epicatechin effect was inhibition of BACE1.  
Following (-) epicatechin treatment of primary neurons, sAPPβ levels did not 
change. This was in conflict with other results showing (-) epicatechin mediated Aβ 
reductions and inhibition of the APP-Gal4 assay (Chapter 4). Furthermore, although 
shown not to be direct catalytic inhibitors of BACE1, lysates from (-) epicatechin 
(6h) and epigallocatechin (24h) treated cells exhibited reduced endogenous BACE1 
activity. This suggests an indirect inhibitory mechanism of action at BACE1 that is 
common to both catechin family members, although (-) epicatechin was a more 
potent inhibitor of endogenous BACE1 activity. To address the cause of reduced 
BACE1 activity, measurements of BACE1 expression levels were made. However, no 
changes in BACE1 protein expression were detected following (-) epicatechin 
treatment. It was therefore more likely that post-translational mechanisms were 
responsible. The precise mechanism is unclear but could involve actions at an 
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allosteric site, post-translational modification, or modulation of BACE1 localisation 
as recently reported for stigmasterol, a plant-derived phytosterol, which also 
reported no significant changes in BACE1 expression (Burg et al., 2013).  
The lack of effect on sAPPβ levels following (-) epicatechin treatment whilst Aβ and 
amyloidogenic processing were reduced could be due to different sensitivities of 
the techniques used to measure the various APP metabolites. As a product of the 
dominant APP processing pathway in neurons, secreted sAPPβ levels are substantial 
in primary cultures, and due to its high stability, it accumulates as the neurons 
mature (Morales-Corraliza et al., 2009). The sensitivity of immunoblotting therefore 
may not be sufficient to identify small modulations by (-) epicatechin that were 
evident in measurements of Aβ and AICD-dependent signals. 
Elucidation of an indirect mechanism of action for (-) epicatechin at the level of 
BACE1 means that the primary cellular target of (-) epicatechin is still to be 
identified. Several factors are known to affect BACE1 activity, including membrane 
cholesterol content, neuronal activity and the oxidative status of the cell.  
Mild oxidative stress alters BACE1 subcellular compartmentalisation, increasing its 
co-localisation with APP and subsequently increasing BACE1 activity in neurons (Tan 
et al., 2013). Although the growing consensus is that flavonoids do not act as 
antioxidants in the brain, they have been shown to up-regulate antioxidant 
enzymes such as endothelial nitric oxide synthase (Mann et al., 2007). Therefore (-) 
epicatechin may reduce BACE1 activity through indirectly reducing the oxidative 
stress levels of the neuronal culture. BACE1 C-terminal domain phosphorylation has 
been heavily implicated in BACE1 cellular distribution and in particular C-Jun N-
terminal kinase (JNK) activation has been shown to mediate oxidative stress-
induced modulation of BACE1 (Tamagno et al., 2009). Interestingly, (-) epicatechin 
protects primary neurons from pro-oxidant insults through inhibition of JNK 
activation (Schroeter et al., 2001) suggesting (-) epicatechin could modulate BACE1 
localisation through inhibition of this signalling pathway.  
Alternatively, (-) epicatechin may be able to modulate BACE1 activity through 
signalling pathways associated with neuronal activity. Neuronal activity modulates 
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production and secretion of Aβ by modulating APP processing upstream of γ 
secretase cleavage (Kamenetz et al., 2003). Recent evidence suggests that neuronal 
activity stimulated by glycine or picrotoxin regulates co-localisation of APP and 
BACE1. Following activity induction, APP is directed to BACE1 containing endosomal 
compartments, leading to increased amyloidogenic processing. This co-localisation 
was shown to be clathrin-mediated endocytosis dependent (Das et al., 2013). In 
contrast, independent studies report that NMDAR- and AMPAR-dependent 
neuronal activity reduce Aβ production through a MAPK-dependent up-regulation 
of sAPPα production and concurrent suppression of amyloidogenic APP processing 
(Hoey et al., 2009, Verges et al., 2011, Hoey et al., 2013). These reports appear 
contradictory, however regulation of APP at the synapse has been shown to be 
dependent on the level of activity. In particular, NMDA-mediated stimulation of 
neurons is pro-amyloidogenic at low concentrations but anti-amyloidogenic at high 
concentrations (Verges et al., 2011). Both mechanisms are thought to be active 
simultaneously and it is the balance between them that determines the relative Aβ 
production level.  
Stimulation of ERK activation and induction of GluA2 expression by (-) epicatechin 
(Schroeter et al., 2007) suggests it has the potential to regulate synaptic function. 
Through alteration of signalling pathways involved in maintaining the balance 
between pro- and anti-amyloidogenic APP processing at the synapse, (-) epicatechin 
may be able to indirectly modulate BACE1 activity. (-) Epicatechin improves spatial 
memory and promotes basal synaptic transmission and LTP, suggesting it can 
increase synaptic strength and thus levels of synaptic activity, which would lead to a 
shift in APP processing away from Aβ production (van Praag et al., 2007, Wang et 
al., 2012).  
Flavonoids are proposed to have multi-modal activities (Maher et al., 2006) and so 
up-regulation of antioxidant enzymes and modulation of synaptic activity could be 
two complementary mechanisms acting to reduce Aβ levels following (-) 
epicatechin treatment. Without further evidence discounting one or both of these 
mechanisms they remain interesting hypotheses for future investigations. 
180 
 
In summary, (-) epicatechin-mediated reductions of βγ-secretase-mediated APP 
processing and Aβ levels have been shown to be independent of activity at the non-
amyloidogenic pathway of APP processing. Investigation of (-) epicatechin mediated 
effects on amyloidogenic processing revealed an indirect inhibition of BACE1 
activity that was not correlated with changes in BACE1 expression. Due to the 
strong spatial regulation of BACE1 activity, it is suggested that (-) epicatechin may 
exert its effect through modulation of cellular pathways involved in BACE1 
trafficking and cellular localisation such as oxidative stress associated pathways and 







6. Flavonoids differentially 





6.1.  Introduction 
 
6.1.1. ERK-mediated APP metabolism 
 
In the brain, the ERK cascade plays a crucial role in synaptic plasticity and memory 
formation. High ERK activity in the hippocampus is associated with the best capacity 
for long-term memory formation (Eckel-Mahan et al., 2008). Inhibition of ERK 
activity causes memory deficits, specifically in memory retention (Hebert and Dash, 
2002, Kelly et al., 2003). As well as the canonical role of ERK in activation of gene 
transcription through nuclear translocation and targeting of CREB and Elk to initiate 
gene transcription of genes such as zif268 and Arc (Adams et al., 2000, Ying et al., 
2002, Davis and Laroche, 2006), it also plays a crucial role at distal sites of the 
neuron. Here it regulates protein activity and localisation to dendritic and synaptic 
compartments. ERK-dependent cellular mechanisms modulate local protein 
synthesis at dendritic spines, such as modulation of calcium/calmodulin dependent 
kinase II (CaMKII) translation, a process required for LTP (Giovannini et al., 2001, 
Miller et al., 2002). They also regulate trafficking of extrasynaptic pools of AMPAR 
subunits to the synapse (Zhu et al., 2002, Kim et al., 2005b), and formation and 
stabilisation of dendritic spines (Goldin and Segal, 2003), essential structural 
changes associated with memory formation. ERK signalling is intimately linked with 
synaptic activity. Therefore the loss of synaptic function in AD, points to a potential 
link between ERK regulation of synaptic activity and APP processing. 
APP processing and the production of Aβ can be regulated by the ERK-dependent 
mitogen-activated protein kinase (MAPK) signalling pathway in neurons (Hoey et 
al., 2009). Levels of activated ERK are elevated in the cerebral spinal fluid (CSF) and 
brains of AD patients (Perry et al., 1999, Klafki et al., 2009), possibly as a response 
to AD-related changes such as oxidative stress. This suggests that ERK signalling 
may be implicit in pathological changes associated with AD and therefore could act 
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as a novel therapeutic target. ERK regulation of synaptic activity highlights this as a 
potential mechanism of ERK involvement in AD. 
Synaptic activity regulates Aβ generation (Kamenetz et al., 2003). Conflicting studies 
suggest synaptic activity can either increase or decrease neuronal Aβ production 
(Lesne et al., 2005, Hoey et al., 2009) although under physiological conditions 
activity-dependent suppression of A is most likely to occur. NMDAR induced 
reduction of Aβ production is ERK dependent, suggesting ERK activity plays a key 
role in inhibition of Aβ levels both in vitro and in vivo (Kim et al., 2005b, Hoey et al., 
2009, Verges et al., 2011, Kaufman et al., 2012, Wan et al., 2012). AMPAR activation 
also causes a reduction in Aβ production independent of NMDAR activity, which is 
at least partially ERK activity dependent (Hoey et al., 2013). Administration of MEK 
inhibitors, which lies upstream of ERK, increases Aβ interstitial fluid (ISF) levels 
suggesting that there is a physiological suppression of amyloidogenic processing by 
ERK signalling in vivo (Verges et al., 2011).  
The ERK dependent suppression of amyloidogenic processing is not unique to 
glutamate-dependent stimulation of the pathway. Treatment of primary neurons 
with brain derived neurotrophic factor (BDNF) decreased Aβ1-40 levels by 
approximately 40%, this was shown to be blocked by the MEK inhibitor UO126 
(Rohe et al., 2009). Following activation, ERK is observed in both dendritic and 
somatic regions of neurons (Thomas and Huganir, 2004). In non-neuronal cells, 
translocation of activation ERK from the cytoplasm to the nucleus is a well-
characterised phenomenon. However, in neurons nuclear translocation and 
transcriptional activation is unlikely to be the only functional outcome of ERK 
activation following stimulation at the synapse, which often causes ERK activity in 
subcellular compartments additional to the nucleus.. For short-term plasticity 
changes and rapid regulation of APP processing it is perhaps more likely that ERK 
acts on cytoplasmic target proteins, closer to synapses where activation of ERK was 




6.1.2. Flavonoids as regulators of ERK activation 
 
Accumulating evidence suggests that flavonoids interact selectively with MAPK 
signalling cascades. As already discussed, ERK activity is associated with cellular 
pathways thought to be responsible for learning and memory. Specific flavonoids 
including (-) epicatechin, fisetin and nobiletin and a flavonoid-rich pomegranate 
juice improve performance in behavioural tests of memory in mice (Hartman et al., 
2006, Maher et al., 2006, Onozuka et al., 2008, Wang et al., 2012), with ERK 
signalling providing a probable mechanistic link. 
A growing body of evidence suggests that flavonoids are able to modulate ERK 
activation in neurons. (-) Epicatechin and fisetin have been shown to enhance ERK-
dependent activation of CREB, a pathway associated with LTP (Maher et al., 2006, 
Schroeter et al., 2007). Anti-apoptotic properties of some flavanones are mediated 
by ERK activation (Vauzour et al., 2007) and the flavone apigenin sustains EGF-
stimulated ERK activation, correlating with downstream p90 ribosomal S6 kinase 
activation (Llorens et al., 2002). In contrast the flavonol quercetin potently inhibited 
ERK activation, leading to neuronal cell death. However, this effect was 
concentration dependent, with lower quercetin concentrations inducing increased 
CREB phosphorylation (Spencer et al., 2003). These differential signalling actions of 
flavonoids at varying concentrations are commonly observed, with low nanomolar 
concentrations typically stimulating ERK phosphorylation (Schroeter et al., 2007, 
Rainey-Smith et al., 2008). Collectively, these studies suggest that modulation of 
ERK activity is a property conserved across the flavonoid subfamilies and given that 
ERK regulates APP processing this represents a potential locus through which 
flavonoids might modulate Aβ production. 
The aim of this chapter was to determine whether the lead flavonoids identified in 
the initial APP-Gal4 gene reporter assay, were modulators of ERK activity. Two 
approaches were adopted: biochemical analysis of active ERK using 
phosphorylation state-specific antibodies and a viral Egr1-luciferase reporter assay 





In Chapter 4 select flavonoids were found to decrease βγ-secretase mediated APP 
processing as measured by an APP-Gal4 luciferase gene reporter assay. It was also 
shown that treatment with (-) epicatechin and epigallocatechin, two of the 
flavonoids identified as inhibitory in the reporter assay, led to an indirect inhibition 
of BACE1 activity, independent of BACE1 expression levels. Under physiological 
conditions, ERK signalling has an inhibitory effect on amyloidogenic APP processing 
(Hoey et al., 2009, Verges et al., 2011). It was therefore investigated whether 
flavonoids identified as inhibitors of βγ-mediated APP processing were also 
modulators of the ERK signalling cascade. 
6.2.1. (-) Epicatechin treatment causes a trend towards 
an increased pERK levels 
 
Activation of ERK requires dual phosphorylation on tyrosine and threonine residues 
within the TEY motif of the catalytic domain (Seger et al., 1992, Roskoski, 2012). To 
investigate the effects of five lead flavonoids on ERK signalling the levels of active 
ERK were measured using a phosphorylation state specific antibody by western blot 
analysis. Flavonoid treatments (fisetin, pelargonidin chloride, sinensetin, (-) 
epicatechin or epigallocatechin) of 100 nM were again chosen as a physiologically 
relevant concentration achievable in the brain; 10 μM was investigated due to the 
biphasic activity of flavonoids reported at other targets. A short, 15 min stimulation 
was chosen based on previous reports of the kinetics of pERK activation in neurons.  
(-) Epicatechin induced the largest increase in ERK activation at 100 nM, resulting in 
an average increase of ~75% but with a high level of variance between experiments 
due to changes in basal levels of phosphorylated ERK(Figure 6.1). (-) Epicatechin 
was also the most effective flavonoid at 10 μM, causing a ~50% mean increase in  




Figure 6.1: Trend towards acute activation of ERK in primary neurons by 100 
nM (-) epicatechin 
(A) 7 DIV primary cortical neurons were treated with vehicle (C), fisetin, 
pelargonidin, sinensetin, (-) epicatechin or epigallocatechin (100 nM) for 15 min 
followed by immunoblotting with p42/44 (pERK), ERK2 (tERK) and β tubulin 
antibodies. (B) pERK and tERK levels were analysed by ECL protein band 
densitometry using VilberLourmat imaging software. Levels of pERK expressed 
relative to tERK and transformed as a % of control. Each column represents the 




Figure 6.2: Trend towards acute activation of ERK in primary neurons by 10 
μM (-) epicatechin  
(A) 7 DIV primary cortical neurons were treated with vehicle (C), fisetin, 
pelargonidin, sinensetin, (-) epicatechin or epigallocatechin (10 μM) for 15 
min followed by immunoblotting with p42/44 (pERK), ERK2 (tERK) and β 
tubulin antibodies. (B) pERK and tERK levels were analysed by ECL protein 
band densitometry using VilberLourmat imaging software. Levels of pERK 
expressed relative to tERK and transformed as a % of control. Each column 
represents the mean ± S.E.M. from 4 independent experiments. 
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following (-) epicatechin treatment, these did not reach statistical significance. The 
consistency in the level of pERK at both concentrations was seen for all 5 
flavonoids, ranking (-) epicatechin > sinensetin > fisetin > pelargonidin > 
epigallocatechin at both concentrations (Figure 6.1 and 6.2). 
6.2.2. BDNF stimulates MEK-dependent Egr-1 
promoter-driven luciferase expression 
 
The levels of pERK are known to correlate well with ERK activity but they do not 
indicate whether activity is spatially restricted within the dendrites or whether 
activated ERK possesses the potential to recruit transcription. In addition the 
kinetics of ERK activation and phosphatase-driven deactivation creates some 
hurdles to using this approach for flavonoid screening. Due to the levels of 
variability seen with this standard biochemical approach and a relative lack of 
sensitivity using immunoblotting, a different methodology was adopted utilising 
viral transduction of an Egr1-luciferase reporter to measure ERK dependent 
transcription. Primary neurons were transduced with the Ad5-Egr-1-luciferase 
reporter and then treated with BDNF (50 ng/mL) over 24h. BDNF evoked a maximal 
5-fold induction of early growth response gene-1 product (Egr-1) mediated 
luciferase expression at 6h which was maintained up to 24h (Figure 6.3). This 
induction was completely blocked by co-treatment with two different MEK1/2 
inhibitors, UO126 and PD184352 at all the time points tested (Figure 6.3).  
6.2.3. NMDAR- and AMPAR-activation induce Egr-1 
promoter-dependent luciferase expression  
 
Glutamate receptors stimulate ERK activation, as measured by phosphorylated ERK 
levels (Sweatt, 2004). However, what is much less clear is whether this activation 
results in transcriptional activity at ERK target genes. To address this, primary 




Figure 6.3: BDNF stimulates ERK dependent transcriptional activity in 
primary neurons 
6 DIV primary cortical neurons were transduced with 5x105 pfu/mL Ad5-
Egr-1-luciferase and treated with vehicle, BDNF (50 ng/mL), BDNF and 
UO126 (10 μM) or BDNF and PD184352 (2 μM) over 24h.  Luciferase 
activity assays were performed 24h post treatment for quantification of 
luciferase expression. Each point is mean ± S.E.M. of 3 independent 
experiments (n=3; **** p<0.0001 compared to vehicle, two way ANOVA 
with Bonferroni post-test). 
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with NMDA or AMPA over 24h. NMDA and AMPA both induced time-dependent 
increases in Egr-1 mediated luciferase expression compared to control  
The NMDA and AMPA effects were of similar magnitude and timecourse. NMDA 
reached a maximal induction of 291% compared to control at 6h whilst AMPA 
reached maximal induction of 209 % compared to control at 6h (Figure 6.4(A)). 
6.2.4. NMDA-evoked Egr-1 promoter-driven luciferase 
expression is MEK dependent 
 
Next it was necessary to determine whether the glutamate receptor agonist 
promotion of Egr-1 promoter-driven luciferase expression was mediated by MEK-
dependent activation of ERK. Primary neurons transduced with the Ad5-Egr1-
luciferase reporter were treated with NMDA in the presence or absence of UO126 
or PD184352. The time-dependent stimulation of Egr-1 promoter driven luciferase 
expression by NMDA was blocked by both UO126 and PD184352 (Figure 6.4(B)). 
Furthermore, by 24h both MEK inhibitors has caused a substantial reduction in the 
levels of Egr-1 mediated luciferase expression compared with control, with maximal 
reduction of 19% (UO126) and 18% (PD184352) of control (Figure 6.4(B)).  
6.2.5. Quercetin co-treatment suggests a flavonol-
dependent reduction in NMDA-induction of Egr-1 
promoter-driven luciferase expression  
 
The flavonol quercetin formed the structural basis of a potent lipid kinase inhibitor 
LY294002, inhibiting PI3K with an IC50 of 1.4 μM (Vlahos et al., 1994). Due to its 
known kinase inhibitor properties it was tested for modulatory effects on Egr-1-
promoter dependent luciferase expression. Treatment with NMDA for 6h increased 
average Egr-1 promoter dependent luciferase expression by 50% compared to 




Figure 6.4: NMDA and AMPA stimulated ERK dependent transcriptional 
activity in primary neurons 
6 DIV primary cortical neurons were transduced with 5x105 pfu/mL Ad5-Egr-1-
luciferase and treated with (A) vehicle (Control), NMDA (50 μM) or AMPA (50 
μM) and (B) NMDA (50 μM), NMDA and UO126 (10 μM) or NMDA and 
PD184352 (2 μm) over 24h. Luciferase activity assays were performed 24h 
post treatment for quantification of luciferase expression. Each point is mean 
± S.E.M. of 3 independent experiments (n=3) (A) NMDA** p< 0.01 **** 
p<0.0001, AMPA ## P<0.01 ### P< 0.001 compared to control, two way 
ANOVA with Bonferroni post-test). (B) NMDA + UO126 ** P< 0.01 **** P< 
0.0001, NMDA +PD184352 ## p<0.01 #### p<0.0001 compared to NMDA, two 




Figure 6.5: Co-treatment with quercetin suggested that NMDA-mediated 
stimulation of ERK-dependent transcriptional activity is reduced by the 
flavonol in primary neurons 
6 DIV primary cortical neurons were transduced with 5x105 pfu/mL Ad5-Egr-1-
luciferase and subsequently treated with vehicle (Control), NMDA (50 μM), 
NMDA and quercetin (10 μM) or NMDA and quercetin (30 μM) for 6h. Luciferase 
activity assays were performed 24h post transduction for quantification of 
luciferase expression. Each point is mean ± S.E.M. of 2 independent experiments. 
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repeats. Co-treatment of transduced primary neurons with NMDA and quercetin 
(10 and 30 μM) for 6h showed a trend towards reduced luciferase expression to 
117 and 108% of control respectively (Figure 6.5) suggesting inhibitory activity 
within the ERK cascade. 
6.2.6. Fisetin treatment shows trend towards reduced 
basal Egr-1 promoter-induced luciferase expression 
levels  
 
Due to positive indications from the biochemical analysis of lead flavonoid-
mediated induction of ERK phosphorylation and the modulatory effects of 
quercetin in the Egr-1 luciferase assay, transduced primary neurons were treated 
with 10 and 30 μM of each flavonoid for 6h. No flavonoid showed potentiation of 
Egr-1 dependent luciferase expression. Contrary to the western analysis of 
phosphorylation ERK levels, fisetin showed a concentration dependent trend 
towards inhibition of Egr-1 dependent luciferase expression causing maximal 
inhibition of 43% of control, although this inhibitory trend was not significant 
(Figure 6.6). 
6.2.7. Fisetin and (-) epicatechin show inhibitory and 
potentiating trends respectively on NMDA mediated 
Egr-1 promoter-driven luciferase expression  
 
It has been demonstrated that NMDA mediated ERK activation leads to changes in 
APP processing, resulting in reduced Aβ levels. To investigate whether the lead 
flavonoids could modulate this NMDA-mediated ERK activation, each flavonoid in 
combination with NMDA was added to primary neurons. Levels of Egr-1-dependent 
luciferase expression were measured 6h later. In agreement with the effect of 
fisetin on basal Egr-1 promoter-dependent luciferase expression (Figure 6.6), fisetin 
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showed an inhibitory trend towards reducing NMDA-stimulated Egr-1 promoter 
driven luciferase expression.(Figure 6.7). In contrast to the basal Egr-1 luciferase 
expression where (-) epicatechin did not evoke any change, (-) epicatechin when co-
treated with NMDA showed a modest trend towards a concentration dependent 
potentiation of Egr-1 promoter driven luciferase expression. (-) Epicatechin 
enhanced Egr-1 promoter dependent luciferase expression by 209% (30 μM) 
compared to NMDA stimulation alone, however due to low power, this trend was 





Figure 6.6: Flavonol fisetin reduced basal ERK dependent transcriptional 
activity in primary neurons 
6 DIV primary cortical neurons were transduced with 5x105 pfu/mL Ad5-
Egr-1-luciferase and subsequently treated with vehicle, fisetin, 
pelargonidin, sinensetin, (-) epicatechin or epigallocatechin (10 and 30 μM) 
for 6h. Luciferase activity assays were performed 24h post transduction for 





Figure 6.7: Fisetin and (-) epicatechin showed inhibitory and potentiating 
trends towards NMDA-mediated stimulation of ERK transcriptional 
activity  
 6 DIV primary cortical neurons were transduced with 5x105 pfu/mL Ad5-
Egr-1-luciferase and subsequently treated with  NMDA (50 μM), or NMDA in 
combination with fisetin, pelargonidin, sinensetin, (-) epicatechin or 
epigallocatechin (10 and 30 μM) for 6h. Luciferase activity assays were 
performed 24h post transduction for quantification of luciferase expression. 





Up to this point, the focus of this thesis has been on flavonoid-mediated effects of 
APP processing and mechanisms through which they could be having a direct 
impact upon it. Failure to identify a direct mechanism for flavonoid regulation of 
APP processing, focussed attention on signalling pathways through which 
flavonoids may be able to exert their inhibitory actions on amyloidogenic 
processing. Flavonoid modulation of the MAPK signalling cascade, in particular ERK 
signalling has been reported previously and therefore an investigation into the 
activation of ERK activity by flavonoids identified in the APP-Gal4 screen was 
conducted. Measurement of activated ERK following acute treatment with lead 
flavonoids identified (-) epicatechin as a potent activator of ERK activity. (-) 
Epicatechin also potentiated NMDA-mediated up-regulation of ERK transcriptional 
activity, suggesting (-) epicatechin treatment leads to transcriptional regulation of 
targets. Further analysis showed the flavonol fisetin to be an inhibitor of ERK-
dependent transcriptional activity, although the precise mechanism remains 
unclear as no change in active ERK1/2 was observed.  
6.3.1. pERK blots suggest (-) epicatechin may up-
regulate ERK signalling in primary neurons 
 
Comparison of fisetin, pelargonidin, sinensetin, (-) epicatechin and epigallocatechin- 
mediated modulation of ERK activation, did not identify any significant changes in 
pERK levels however showed differences in trends of activity of the flavonoids. (-) 
Epicatechin treatment exhibited a clear trend towards increased pERK levels at both 
concentrations tested. It is likely that variability in control levels of ERK 
phosphorylation in the primary cortical cultures altered the effect size of (-) 
epicatechin treatment across experiments. Sinensetin and fisetin also displayed 
trends towards increased ERK activation, however these were not as strong as that 
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of (-) epicatechin. Pelargonidin and epigallocatechin had no effect on ERK activity at 
either concentration. (-) Epicatechin mediated- activation of ERK has been 
demonstrated previously in primary neurons (Schroeter et al., 2007), supporting 
this observation. 
6.3.2. Egr-1 luciferase assay is a measure of ERK 
transcriptional activity in primary neurons 
 
To investigate whether the lead flavonoids mediated ERK-dependent transcriptional 
activation, an Egr-1 luciferase viral assay was utilised. Activation of ERK and its 
translocation from the cytoplasm to the nucleus is necessary for the expression of 
many immediate early gene products, including Egr-1. A viral construct with a 
luciferase gene under the control of the Egr-1 promoter therefore can be utilised as 
a sensitive transcriptional readout for ERK activation (Caunt et al., 2008).  
Biochemical and regulatory properties of post-mitotic CNS neurons are distinct 
from PNS neurons and non-neuronal cell types. As the Egr-1 luciferase assay had 
previously only been used in non-neuronal cell types, it was crucial to validate Egr-1 
luciferase assay as a valid method for measurement of ERK-dependent 
transcriptional activity in primary neurons. BDNF is the most widely distributed 
neurotrophin in the brain and via its receptor TrkB has been shown to promote 
neuronal cell survival (Lu and Martinowich, 2008). These survival-promoting 
properties are elicited by activation of the ERK intracellular pathway both in vitro 
and in vivo and can be blocked with specific ERK inhibitors (Hetman et al., 1999, 
Han and Holtzman, 2000). As a well characterised activator of ERK in neuronal cells, 
BDNF stimulation of Egr-1 dependent luciferase expression was measured over a 
time course of 24h and showed a significant induction of ERK dependent 
transcriptional activity from 6h which was maintained to 24h. This effect was 
completely blocked by two structurally distinct MEK inhibitors UO126 and 
PD184352. This confirmed that the Egr-1 luciferase assay was a measure of ERK 
transcriptional activity in primary neurons.  
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6.3.3. NMDA- and AMPA-induced glutamatergic 
signalling causes ERK-dependent transcriptional 
activation in primary neurons 
 
Following confirmation that the assay was sensitive to BDNF, the effects of 
ionotropic glutamate receptor agonists NMDA and AMPA were investigated. Under 
physiological conditions, glutamate binding to post-synaptic AMPAR leads to 
depolarisation of the post-synaptic membrane, this allows activation of NMDAR and 
an influx of Ca2+ into the post-synaptic cell. This increase in intracellular Ca2+ 
concentration triggers a series of intracellular signalling cascades (Bloodgood and 
Sabatini, 2007). Excitatory glutamatergic signalling has been demonstrated to 
activate ERK as part of a mechanism heavily implicated in LTP and synaptic plasticity 
(Thomas and Huganir, 2004). Of particular interest to this project, NMDA-mediated 
regulation of APP processing has also been shown to be ERK dependent and results 
also suggest a role for ERK activation in AMPA-mediated regulation of APP (Hoey et 
al., 2009, Verges et al., 2011, Hoey et al., 2013). Despite activation of ERK being 
conclusively demonstrated downstream of glutamatergic signalling, it remains 
unclear whether this is through ERK activity that mediated activation of 
transcription or through ERK modulation of cytoplasmic targets, or perhaps most 
interesting-both. NMDA treatment of transduced neurons resulted in a time 
dependent increase in ERK dependent transcriptional activity, reaching maximal 
activity at 6h, which was maintained to 24h. AMPA treatment of transduced 
neurons also resulted in a time dependent increase in ERK dependent transcription 
activity, reaching maximal activity at 3h and maintained over 24h.  This provides 
direct evidence for ERK-driven transcriptional activity following glutamate receptor 
stimulation and supports previous evidence showing activation of nuclear 
transcription factors such as CREB (Impey et al., 1998, Roberson et al., 1999) and 
expression of immediate early genes such as zif268 following glutamate receptor 
stimulation (Ying et al., 2002). 
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Blockade of ERK activation by MEK inhibitors UO126 and PD184352 blocked NMDA-
mediated ERK-driven transcriptional activity, confirming that the NMDA mediated 
effects on Egr-1 dependent luciferase expression were ERK signalling dependent.  
Chronic inhibition by both UO126 and PD184352 caused ERK transcriptional activity 
to drop to 20% of control. This could be an indication of reduced cell viability 
following chronic ERK inhibition coupled with NMDA activation or that basal ERK 
activity was high in these cultures.  
6.3.4. Fisetin treatment shows inhibitory trend on ERK-
dependent transcriptional activity  
 
It was next investigated whether transcriptional up-regulation of ERK could be a 
potential mechanism of action by flavonoids identified as inhibitors in the initial 
APP-Gal4 screen. Nanomolar concentrations of all flavonoids were ineffective at 
inducing ERK-driven transcriptional activity, however following micromolar 
flavonoid treatment over 24h, results suggested that the flavonol fisetin may down-
regulate ERK transcriptional activity in a concentration dependent manner. Fisetin 
has previously been demonstrated to have activity at ERK, promoting 
differentiation of PC12 cells via activation of the ERK cascade (Sagara et al., 2004) 
and inducing ERK dependent CREB phosphorylation in primary rat hippocampal 
slices (Maher et al., 2006). Inhibition of ERK-driven transcriptional activity is difficult 
to correlate with these studies; however ERK signalling pathways are regulated 
differently in neuronal cell types compared to non-neuronal cell types which may 
explain these opposing roles for fisetin. Induction of CREB phosphorylation is highly 
correlated with transcriptional activation of ERK-related genes; however regulation 
of CREB as the rate-limiting molecular switch of transcription remains unclear. It 
therefore may be possible that the two observations of fisetin-mediated ERK-
dependent CREB activation and suspected ERK transcriptional down-regulation are 
not mutually exclusive.  
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It must also be considered that fisetin may be neurotoxic to primary neurons and 
this, rather than a specific inhibition of ERK-driven transcriptional activity is causing 
the inhibitory trend Egr-1 promoter-dependent luciferase expression. However, 
fisetin has previously been shown to possess neuroprotective properties at 
micromolar concentrations in an in vitro model of stroke, and following H2O2 
administration (Dajas et al., 2003, Maher et al., 2007). These reports question the 
probability of fisetin acting as a neurotoxic agent in primary neurons, thus 
supporting a more specific activity for fisetin at the level of the ERK signalling 
pathway. 
No modulation of ERK phosphorylation was observed following fisetin treatment of 
primary neurons, however a strong trend towards ERK dependent transcriptional 
activity down-regulation following fisetin treatment was observed. Flavonoid-
mediated changes in levels of ERK phosphorylation were measured at 100 nM and 
10 μM whilst ERK transcriptional activity changes by fisetin were measured at 10 -
30 μM with no effect observed at 100 nM. This concentration-dependent paradox 
could be due to, or the cause of the biphasic activity seen for fisetin in the APP-Gal4 
reporter assay. It would therefore be interesting to investigate the ERK dependence 
of the concentration dependent, biphasic activity of fisetin in primary neurons as it 
may elucidate a mechanistic explanation for the concentration-dependent activity 
of this flavonol. 
6.3.5. Fisetin and (-) epicatechin show opposing trends 
on NMDA-mediated ERK transcriptional activity in 
primary neurons. 
 
Select flavonoids, as shown in Chapter 3, can reduce levels of amyloidogenic 
processing and excitatory glutamatergic signalling also leads to ERK dependent 
reductions in Aβ levels in vitro and in vivo (Hoey et al., 2009, Verges et al., 2011). 
Investigation of flavonoid modulation of NMDA-mediated ERK-driven 
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transcriptional activation identified fisetin and (-) epicatechin as flavanols with 
potential activity at NMDA mediated ERK transcriptional activity.  
Fisetin showed a similar inhibitory trend on NMDA-mediated ERK driven 
transcriptional activity as that seen on basal ERK activity, suggesting a target 
common to both mechanisms. Classical neuronal stimulation of ERK is caused by 
increased Ras-GTP levels in response to extracellular stimuli such as neurotrophins. 
Neuronal activation by membrane depolarisation and subsequent excitatory 
glutamatergic signalling requires increased intracellular Ca2+ concentrations for 
activation of Ras-GTP (Fiore et al., 1993, Rosen et al., 1994) (Figure 6.8). These 
divergent initial mechanisms of activation suggest that potential cellular targets of 
fisetin may lie downstream of Ras in the ERK pathway or a modulator of one of the 
downstream effectors. 
(-) Epicatechin caused a concentration dependent potentiation trend in ERK driven 
transcriptional activation when co-administered with NMDA. As (-) epicatechin 
exhibited no stimulatory effect when delivered alone, this suggests that (-) 
epicatechin may act to potentiate the NMDA-mediated increase in ERK activation. 
Further experiments to confirm the potentiating action of (-) epicatechin and 
studying the effect of this in combination with NMDA antagonists such as MK801 
would allow further elucidation of this potential mechanism.  
This trend towards (-) epicatechin potentiation of NMDA-mediated ERK driven 
transcriptional activity supports findings that (-) epicatechin enhances learning and 
memory in mice (van Praag et al., 2007). Synaptic plasticity is thought to underlie 
complex behaviours such as learning and memory. LTP is one of the best-
characterised forms of synaptic plasticity and is therefore one of the most 
promising candidates for the cellular mechanism behind the behaviours. NMDAR-
mediated-ERK activation is required for cortical LTP, therefore (-) epicatechin 
potentiation of this pathway is likely to enhance LTP and subsequent pathways 
leading to improvement in learning and memory described (van Praag et al., 2007, 




   
Figure 6.8: Activation of ERK signalling in neuronal cells 
Classical activation of the ERK pathway by neurotrophins through receptor 
tyrosine kinases, activation of adaptor proteins and increased activity of guanyl 
nucleotide exchange factors (GEFs) triggers increased levels of Ras-GTP. ERK 
activation in response to glutamatergic signalling is different in that activation of 
Ras is intracellular Ca2+ concentration dependent, where Ca2+ influx through 
NMDAR triggers Ras-GTP levels to increase. Downstream of Ras activation both 
pathways converge, with Ras activating Raf, mitogen activated protein kinase 
(MAPK)/ERK kinase (MEK) and ERK. Following its activation ERK can 
phosphorylate both cytoplasmic and nuclear targets. 
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In summary, flavonoid-mediated effects on ERK activation were concentration 
dependent and different flavonoids had contrasting effects at the same 
concentrations. This suggests that, at least at the level of flavonoid modulation of 
ERK activity, there is not a common mechanism across the flavonoid families and as 
these clear trends did not reach significance that ERK activation by flavonoids is 
possibly modulatory. (-) Epicatechin has been the only flavonoid to consistently 
show activity across all measures of ERK activity. Whether these effects are in 
addition to or are associated with the inhibition of amyloidogenic processing and 
BACE1 activity down-regulation is not clear. It has been proposed that flavonoids 
are capable of modulating multiple pathways associated with maintenance of brain 
function. Thus searching for a single mechanism that is responsible for all flavonoid 
mediated effects may not be the ideal approach for the study of these 
















This thesis set out to address whether flavonoids were modulators of APP 
processing in primary neurons. An APP-Gal4 gene reporter assay was characterised 
and manipulated to provide a tractable system for the identification of novel 
modulators of APP processing in primary neurons. Using this system, five flavonoids 
were identified that inhibited amyloidogenic processing: fisetin, pelargonidin, 
sinensetin, (-) epicatechin and epigallocatechin. Investigations into (-) epicatechin-
mediated inhibition of APP supported indirect inhibition of BACE1 activity as the 
mechanism of action. Interestingly, study of the lead flavonoids’ effects on ERK 
signalling showed that (-) epicatechin may enhance ERK activation and activity-
dependent ERK-driven transcriptional activity in primary neurons. In contrast, 
another lead flavonoid, fisetin, showed a trend towards suppression of ERK-
dependent transcriptional activity. These data suggest that individual flavonoids do 
indeed modulate APP processing, and that they may regulate the ERK signalling 
cascade, likely through multiple cellular targets. 
Through modification of the APP-Gal4 luciferase gene reporter assay, a highly 
sensitive, tractable assay system has been established which allows novel 
compounds to be tested for activity at APP processing. This can be conducted under 
physiological, as well as environmental and genetically-induced AD-associated 
conditions. The APP-Gal4 assay allows assessment of compounds of interest prior to 
appearance of AD pathology, allowing preventative compounds to be evaluated. 
The assay has been characterised as a measure of βγ-secretase mediated 
processing, greatly enhancing its utility, however the underlying cellular mechanism 
for this preference is unclear. It is therefore not possible to draw mechanistic 
conclusions about modulatory compounds identified. This is a significant limitation 
of the assay as mechanistic understanding of compound inhibition could provide 
critical new insight into regulation of APP processing. 
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Due to the post-mitotic nature of primary neurons, transfection efficiency is low 
compared to non-neuronal cell types. This meant that levels of the transfected APP 
protein were too low to be detected by traditional biochemical techniques. This 
meant that direct corroboration of assay hits, through APP metabolite 
measurements for example, could not be conducted. Generation of viral vectors for 
expression of APP-Gal4 would enhance the power of this assay as the number of 
cells expressing the exogenous APP-Gal4 would be greatly increased. Parallel 
measurements of APP processing modulation could then be performed, gaining 
mechanistic insight into the changes observed in the assay. 
APP metabolism is central to the pathogenesis of AD. Rare mutations, either in the 
APP gene surrounding the secretase cleavage sites, or in the PS genes affecting γ-
secretase cleavage of APP, cause autosomal dominant inheritance of AD (Larner, 
2013, Tanzi, 2013). A major pathological hallmark of the disease is the presence of 
extracellular amyloid plaques, whose main constituent is Aβ, the proteolytic 
product of amyloidogenic processing of APP (Selkoe and Podlisny, 2002). Despite 
continuing controversy, soluble Aβ oligomers present as the strongest candidates 
for the neurotoxic species that initiates AD pathogenesis (Walsh et al., 2002, Lesné 
et al., 2006, Li et al., 2009). In contrast, a product of non-amyloidogenic processing, 
sAPPα, is neuroprotective and is suggested to be crucial for LTP (Gralle and Ferreira, 
2007, Taylor et al., 2008). Inverse coupling of α- and β-secretase activities generates 
equilibrium between cellular levels of amyloidogenic and non-amyloidogenic APP 
processing in neuronal cells (Postina et al., 2004, Kuhn et al., 2010, Colombo et al., 
2012). This dynamic interaction between the alternative pathways of APP 
processing provides an increased number of cellular targets for the treatment of AD 
through modulation of APP processing. Up-regulation of the non-amyloidogenic 
pathway as well as down-regulation of the amyloidogenic pathway represents two 
viable targets for development of novel therapeutics. 
Epidemiological studies suggest that consumption of flavonoid rich foods is 
associated with prevention or delay of onset of AD. The Kame, Paquid, and Three 
City cohort longitudinal studies of aged subjects all found reduced AD incidence in 
populations with higher flavonoid intake (Commenges et al., 2000, Dai et al., 2006, 
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Barberger-Gateau et al., 2007, Letenneur et al., 2007). In vivo studies, consistently 
report flavonoid-mediated inhibition of Aβ levels associated with improvements in 
behavioural tests of memory (Hartman et al., 2006, Rezai-Zadeh et al., 2008, Mori 
et al., 2012, Wang et al., 2012). These results suggest that flavonoid-mediated 
reductions in Aβ are capable of impacting on behavioural symptoms of AD, at least 
in rodent models of the disease. In vivo studies allow the phenotypic effects of 
flavonoid molecules to be elucidated; however they have not provided mechanistic 
insight into the actions of flavonoids on specific cell types or cellular pathways.  
In vitro studies, such as those conducted in this thesis, have allowed the effects of 
flavonoids on neuronal cells to be studied and have shown that select flavonoids 
are able to reduce amyloidogenic APP processing (Chapter 4) and (Obregon et al., 
2006, Wang et al., 2006, Rezai-Zadeh et al., 2009, Ho et al., 2013)) (Figure 7.1(A)). It 
appears that flavonoids have multiple actions on APP processing depending on the 
concentrations involved. In this study the flavanols (-) epicatechin and 
epigallocatechin indirectly inhibited BACE1 activity at low concentrations (Figure 
7.1(B)). In independent studies, another catechin, EGCG, and a catechin-rich 
Cabernet Sauvignon extract have been shown to promote α-secretase-mediated 
APP processing at high concentrations, increasing levels of sAPPα (Rezai-Zadeh, 
2005, Wang et al., 2006) (Figure 7.1(C)).  
Concentration dependence is also crucial for actions of flavonoids at other cellular 
targets. Low concentrations of (-) epicatechin activate ERK activity, with maximal 
effect at 100 nM (Chapter 6) and (Schroeter et al., 2007)) (Figure 7.1(D)), however it 
appears that only mid-micromolar concentrations may potentiate NMDA-mediated 
ERK dependent transcriptional activity (Chapter 6) (Figure 7.1(E)). This suggests that 
at physiological concentrations achievable in the brain, (-) epicatechin modulation 
of ERK activity is likely at a cytoplasmic target rather than through translocation to 
the nucleus and gene transcription. Fisetin was also suggested to be a regulator of 
ERK-dependent transcriptional activity at micromolar concentrations however, in 
contrast to (-) epicatechin, showing a trend towards reducing ERK-dependent 






Figure 7.1: Model of flavonoid modulation of APP processing and ERK 
activity in primary neurons 
The cellular effects of flavonoids are strongly dependent on concentration. 
The multimodal activities of flavonoids lead to inhibition of Aβ production 
(A) via a number of different mechanisms. Low concentrations of 
flavonoids modulate BACE1 activity (B) and activity of ERK (D). High 
concentrations of flavonoids modulate ADAM10 expression and sAPPα 
levels (C) as well as NMDA mediated ERK driven gene transcription (D and 




to previous work identifying fisetin as an activator of the ERK pathway (Maher et al., 
2006), it is supported by data from another flavonol, quercetin, identified as a 
potent inhibitor of another kinase - PI3K, through binding to its ATP binding domain 
(Vlahos et al., 1994). These contrasting results could be as a result of concentration-
dependent activities. It is tempting to propose that these potential differential 
activities at ERK are linked to the biphasic activity of fisetin seen at APP processing 
(Chapter 4) as inhibition of ERK signalling can lead to increased amyloidogenic 
processing (Rohe et al., 2009, Gil-Bea et al., 2012). This further underlines how 
imperative it is consider concentration when comparing flavonoid-mediated effects 
between studies. 
 It is unclear whether the BACE1 inhibition and the suggested potentiation of ERK 
activity by (-) epicatechin are part of the same mechanism, with activation of ERK 
upstream of BACE1 inhibition. Epigallocatechin was also an indirect inhibitor of 
BACE1 activity, however it did not affect ERK activity at any concentration, 
suggesting the two mechanisms are independent. However, neuronal activity- 
dependent ERK activation has been shown to down-regulate amyloidogenic 
processing (Hoey et al., 2009, Verges et al., 2011). This could be taken as evidence 
for a potential link between the two activities. However, these studies showed ERK 
activation led to increased levels of sAPPα, which was not altered by (-) epicatechin 
in this study (Chapter 5). (-) Epicatechin has been shown to exert multiple cellular 
effects, which may act synergistically to decrease amyloidogenic processing in 
primary neurons.  
Although (-) epicatechin was the focus of this thesis, the four flavonoids identified in 
the original screen are also potentially interesting molecules as inhibitors of 
amyloidogenic APP processing. (-) Epicatechin was the focus of this study due to its 
high potency, known blood-brain barrier permeability and good oral bioavailability 
properties. Fisetin has poor bioavailability due to poor water solubility, forming a 
significant barrier to development as an effective in vivo inhibitor. However, 
attempts to design liposomal formulations of fisetin have had success, increasing 
bioavailability 47-fold whilst maintaining efficacy (Mignet et al., 2012, Seguin et al., 
2013), suggesting packaging of flavonoids is a viable approach to overcome their 
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poor solubility properties. Bioavailability of pelargonidin in humans has not been 
fully assessed, although presence of the pelargonidin aglycone in plasma following 
ingestion of strawberries has been demonstrated (Azzini et al., 2010). No human 
bioavailability data is available for sinensetin, however an oral delivery study in rat 
suggests it is very poorly absorbed (Loon et al., 2005). Sinensetin remains an 
interesting molecule however as it was the only flavonoid to inhibit amyloidogenic 
processing at both concentrations tested (chapter 4). Sinensetin was the only 
flavonoid tested with methoxy- substitutions on its central structure. Flavonoids 
with methoxy- substitutions have been shown to have increased metabolic stability 
compared to hydroxylated compounds. Metabolism of active flavonoids to inactive 
metabolites in the small intestine and liver significantly affects activity of many 
bioavailable flavonoids (Spencer et al., 2001, Abd El Mohsen et al., 2002, El Mohsen 
et al., 2006), therefore the relative stability of sinensetin could make it a better drug 
candidate. Epigallocatechin, despite its extremely similar structure to (-) 
epicatechin, has greatly reduced bioavailability in comparison, although levels are 
still detectable in human plasma following oral ingestion (Renouf et al., 2013). The 
biphasic activity at APP processing of epigallocatechin, as well as fisetin, also raises 
an important consideration for future flavonoid activity studies, as flavonoid 
concentration may need to be strictly controlled to avoid off-target negative side 
effects (Chapter 4). 
Treatments currently available for AD patients are symptomatics and therefore do 
not alter the underlying pathophysiology of the disease. AChEIs were the first class 
of agents to be approved for the treatment of AD, acting to increase the availability 
of ACh at cholinergic synapses. Currently three are widely licenced for treatment of 
mild to moderate AD: donepezil, rivastigmine and galantamine (Wilcock et al., 2000, 
Seltzer et al., 2004, Cummings et al., 2007). These small molecule drugs aim to 
maintain neuronal activity in affected brain areas, which has been shown to reduce 
the rate of cognitive decline compared to placebo (Rogers and Friedhoff, 1996, 
Rosler et al., 1999, Raskind et al., 2000). Another small molecule that has been FDA 
approved is memantine, which is a non-competitive antagonist of NMDAR and acts 
to attenuate NMDAR function, aiming to slow neuronal loss in medium to late stage 
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dementia (Winblad and Poritis, 1999). Although popular, like all drugs currently 
available to AD sufferers, memantine is not a disease-modifying drug and can only 
alleviate symptoms (Herrmann et al., 2011). 
Currently there are 60 therapeutics in active clinical trials for the treatment of AD 
(Alzheimer’s Research Forum accessed 27/02/2014). Due to the central role of Aβ in 
AD pathogenesis, it has become the main drug target for the development of 
disease modifying treatments. There are two principal therapeutic strategies: small 
molecule inhibitors of Aβ production or Aβ vaccinations to promote clearance of 
aggregated Aβ from the brain (Schenk et al., 2012).  
Inhibition of Aβ production has focussed on BACE1 and the γ-secretase complex as 
the obvious drug targets. The largest hurdle to overcome in the development of -
secretase inhibitors are the side effects due to other -secretase substrates, most 
notably notch. Semagacestat, the most advanced non-selective inhibitor, was 
halted during Phase III human testing due to a high occurrence of adverse events 
reported associated with notch inhibition and no observed improvement in 
cognitive (Doody et al., 2013). This led to the development of two new classes of γ-
secretase inhibitor: γ-secretase modulators (GSM) based on NSAIDs and notch 
sparing/APP selective γ-secretase inhibitors (GSI). Both of these however have also 
suffered from disappointing results. GSMs such as R-flurbuprofen have been 
discontinued to due lack of efficacy and notch sparing GSIs such as BMS-299897 
have also shown disappointing efficacy. These have also caused unacceptable side 
effects such as ELND006 which showed dose-limiting liver toxicity (Schenk et al., 
2012).  
Targeting BACE has also proved difficult due to its extended substrate binding 
groove and multiple substrates. Selectivity over other aspartyl proteases has also 
been an issue. Development of CNS permeable, selective molecules has been slow, 
with few compounds making it to clinical development; only two trials are currently 
active. MK-8931, the furthest through development is a BACE1 and BACE2 inhibitor 
currently in Phase III trials following good tolerability and dose-dependent 
reductions of Aβ results from Phase II.  
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The second area of drug development that has received much attention is A 
immunotherapy, following a seminal paper in PDAPP transgenic mice 
demonstrating IP injection of Aβ once a month for a year led to reduced plaque 
burden, reduced neuritic dystrophy and associated inflammatory changes (Schenk 
et al., 1999). The first A immunisation trial developed by Elan and Wyeth, AN1792, 
reduced Aβ levels in plasma and CSF but failed in Phase II as 6% of patients 
developed ameningoencephalitis and leukoencephalopathy (Orgogozo et al., 2003). 
This was an active immunisation using full length Aβ1-42 and caused the field to shift 
towards passive immunisation with humanised antibodies rather than the full 
length Aβ peptide. These have proven to be safer, with less adverse events reported 
(Lemere and Masliah, 2010). Solanezumab by Eli Lilly reached Phase III trials for mild 
to moderate AD, however failed due to no improvement in cognition or functional 
ability at the end of the study (Doody et al., 2014). Further analysis of the data, 
however showed a small benefit in a subset of mild AD patients and Eli Lilly have 
announced a new Phase III trial in patients with mild AD (www.clinicaltrials.gov). 
The positive effect of Solanezumab in mild AD patients has prompted Genentech to 
conduct the first trial of passive immunotherapy in a prevention paradigm: 
Crenezumab will be given to preclinical carriers of the PSEN E280A autosomal 
dominant mutation in a Colombian cohort of patients (www.clinicaltrials.gov). This 
study is still in its recruitment stage, however will be crucial in determining the 
potential of APP-targeting drugs in the treatment of AD and a stern test of the 
amyloid cascade hypothesis of AD. Immunisation has potential as a viable 
therapeutic approach for those at high risk of FAD however, due to the current lack 
of accurate biomarkers and good diagnostic tools for AD, immunisation is a 
treatment that most AD patients would currently miss out on as LOAD is often not 
diagnosed until pathology and symptoms are well established.  
 The current failure rate of AD drugs has driven research interests towards 
alternative AD therapy approaches. An emerging consensus that treatment of AD is 
required much earlier in the disease process emphasises the needed for safer 
treatments. This thesis has provided further evidence that select flavonoids reduce 
amyloidogenic processing in primary neuronal cells through multimodal activities.  
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(-) Epicatechin and its metabolites show good bioavailability both in rodents and in 
humans and reach quantifiable concentrations in the brain (Richelle et al., 1999, 
Abd El Mohsen et al., 2002, van Praag et al., 2007, Wang et al., 2012, Renouf et al., 
2013). As a dietary molecule it is well tolerated with no toxic effects reported. Its 
inhibitory action at APP is independent of notch, a significant hurdle in the AD 
therapy field (Chapter 5). (-) Epicatechin is a potent inhibitor of amyloidogenic APP 
processing at physiologically relevant, nanomolar concentrations, causing a 20% 
reduction in processing in WT primary neurons (Chapter 4). In collaborative work 
this in vitro activity was confirmed in preliminary in vivo work in the TASTPM 
transgenic mouse model of AD, whereby oral (-) epicatechin treatment led to 
decreased amyloid pathology (Cox et al., under review). Oral delivery of (-) 
epicatechin in two independent studies has led to cognitive improvements, one in a 
mouse model of AD (van Praag et al., 2007, Wang et al., 2012), indicating the (-) 
epicatechin-mediated effects are having a positive impact on cognition and 
function, at least in rodents. It remains to be seen whether the (-) epicatechin 
mediated improvements observed in rodent models can translate to cognitive 
benefits in man and furthermore whether these benefits would be sufficient for (-) 
epicatechin to be an effective prophylactic for the prevention of AD.  
These questions are extremely important given the scarcity of effective therapies 
and when no disease modifying drugs are available. Shifts in focus to earlier 
intervention means conventional drug therapy will have to be safer, thus more 
difficult to develop and further from entering the clinic. Development of effective 
preventative treatments would provide the growing economic and social burden of 
potential AD patients with a line of proven defence against this disease. For this 
reason, clinical trials of flavonoids must be tightly controlled and strictly regulated 
so that previous inconsistencies in flavonoid studies can be avoided and a clear 





This study confirmed that select flavonoids are able to reduce amyloidogenic 
processing in primary cortical neurons. Investigation into the mechanism of 
inhibition by (-) epicatechin suggests that the mechanism is likely through indirect 
BACE1 inhibition. The study of ERK-regulation activities by the lead flavonoids 
suggested (-) epicatechin can also activate ERK activity and that fisetin may inhibit 
ERK-dependent transcriptional activity. This study supports the hypothesis that 
flavonoids are modulators of APP processing, achieved through multi-modal 
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